Synthesis and Therapeutic activity of some new piperazine Derivatives by Savaliya, Mahendra D.
          Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 
     (CGPA 2.93) 
 
 
 
 
Savaliya, Mahendra D., 2010, “Synthesis and Therapeutic activity of some new 
piperazine Derivatives”,  thesis PhD, Saurashtra University 
  
http://etheses.saurashtrauniversity.edu/id/eprint/458 
  
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given.  
 
 
 
 
 
 
 
 
 
Saurashtra University Theses Service 
http://etheses.saurashtrauniversity.edu 
repository@sauuni.ernet.in 
 
© The Author 
 “SYNTHESIS AND THERAPEUTIC  
ACTIVITY OF SOME NEW 
PIPERAZINE DERIVATIVES” 
A THESIS 
SUBMITTED TO THE 
SAURASHTRA UNIVERSITY  
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
IN  
THE FACULTY OF SCIENCE (CHEMISTRY) 
BY 
MAHENDRA  D. SAVALIYA 
 
UNDER THE GUIDANCE  
OF 
Dr. D. M. PUROHIT 
 
SHREE M. & N. VIRANI SCIENCE COLLEGE, 
DEPARTMENT OF CHEMISTRY, 
KALAWAD ROAD, 
RAJKOT – 360 005. 
 INDIA 
2010 
           
           
           
           
           
           
  
          
 
                                                                                                            Date: 26/ 04 /2010 
 
 
Dr. D. M. Purohit             Residence: 
M. Sc. Ph. D.,         Dr. D. M. Purohit 
Lecturer,             B-149,"shandilya"                   
Shree M. & N. Virani Science College              Shastrinagar, 
Department of chemistry,  Nana Mova Road, 
Kalawad Road  Rajkot – 360 005  
Rajkot – 360 005       Gujarat (India) . 
           
 
 
 
Statement under O. Ph. D. 7 of Saurashtra University 
 
The work  included  in  the  thesis  is  my  own  work  under  the  supervision   
of Dr. D. M. Purohit and leads to some contribution in Chemistry subsidised by a 
number of references. 
 
Date: 26 / 04 / 2010 
 
Place : Rajkot.       (Mahendra D. Savaliya) 
 
 
This is to certify that the present work submitted for the Ph. D. Degree of 
Saurashtra University by Mahendra D. Savaliya is his own work and leads to 
advancement in the knowledge of chemistry. The thesis has been prepared under my 
supervision. 
 
Date: 26 / 04 / 2010 
 
Place: Rajkot. 
(Dr. D. M. Purohit) 
Lecturer,  
Shree M. & N. Virani Science College 
Department of Chemistry 
 Kalawad Road.  
Rajkot – 360 005. 
Gujarat (India). 
           
 
 
 
 
 
 
 
Dedicated 
     To 
     My Family 
ACKNOWLEDGEMENTS 
 
 “ JAY  GIRNARI ” 
 Hats off to the Omnipresent, Omniscient and Almighty God, the glorious 
fountain and continuous source of inspirations! I offer salutations to him and my 
head bows with rapturous dedication from within my heart, to the Omnipotent Lord   
“ JAY  GURUDATT ”  and my ideal  “ SWAMI  VIVEKANANDA ” 
 An endeavour such as a Ph.D. is impossible to accomplish without the 
generous help and support of my family, friends and colleagues. I would like to take 
this opportunity to thank those whom I was fortunate to know, work, and form 
friendship with over the past three years. 
 First, I wish like to express my deep appreciation and gratitude to my co-
traveler and guide Dr. D. M. Purohit Lecturer, Chemistry Department, shree M.& 
N. Virani science college, Rajkot. His dedication to science, unwavering demand for 
excellence from him self has set up a high standard for his students to look up to and 
to follow. I appreciated the freedom he allowed, which permitted me to develop 
scientific thoughts and experimental skills independently, lofty research methodology 
and the motivation as well as them highly punctual affectionate encouragement and 
occasional constructive criticism when needed, towards the goal of my academic 
journey.  
 I also owe to, from the deepest corner of heart, deepest sense of gratitude and 
indebtedness to Dr. V. N. Patolia, Head, Chemistry Department, Kamani science 
college, Amreli, as I have been constantly benefited with them. 
 Who is in this world can not entirely and adequately thank the parents who 
have given us everything that we possess in this life ? The life itself is their gift to 
us, so I am at loss of words in which I express myself to my most esteemed father 
Shri Dhirubhai and my loving mother Smt. Prabhaben, who had always wished that 
I scale many more heights of success in the field of research. I pay my humble 
respects to my grand father Bavabapa and grand mother Hemba. Through the stress 
and strain of this study, I can never forget to express my special gratitude to my 
beloved younger brother Sanjay and younger sister Manisha, whose unstopping flow 
of love and encouraged me to reach my destination. I wish to thank my uncle, my 
aunty and all other family members. 
 I am deeply indebted to my best friend Dr. Jitendra G. Dobaria and Mr. 
Jagdish Makwana for his help, suggestions, encouragement and kindness that made 
my research work success. 
 I feel great pleasur to acknowledge my deepest sense of indebtedness to Mr. 
Mahendra G. Dobaria and Mr. Kalpesh Vadadoriya for her invaluable inspiration 
and moral support throught the course of my research work.  
  I wish to thank Dr. Jayesh V. Guna, Dr. Vipul V. Bhuva and Paresh 
Kathiriya for his most willing co-operation and comprehensive exchange of ideas 
during the course of my research work. 
I offer my heart full gratitude to Dr. Hitin Hirpara, Dr. Viral Parekh,  
Dr. Snehal Dhol, Dr. Harshad Sangani, Dr. Ranjanben, Dr. Ashok Patel, Dr. Vijay 
Lunagariya, Dr. Dinesh Paghdar, Dr. Sajid, Dr. Dinesh Bhoot, Dr. Kanji Bhimani, 
Dr. Ramesh Kanparia and Dr. Chirag Bhuva  for their support and much fruitful 
discussion at various stages. I am most thankful to all my juniors for their valuable 
co-operation and help during the course of my research work.  
I feel lucky and very proud to have intimate friends like Pravinbhai(PSP), 
Majidbhai, Bhaveshbhai, Rajubhai, Vivek, Prashant, Jasmin, Rajni, Suresh, 
Hitendra, Arvind, Chinal, Safi, Ashwin, Ujjwal, Reena, Priya, Vinita, Jignesh, 
Daxesh, Lalitbhai, Lalji, Amit, Rohit, Yogesh and Mukesh, who have been always 
participated with my problems, encouraged and rebuilt my confidence at appropriate 
stages. 
As with the completion of this task, I find myself in difficult position on 
attempting to express my deep indebtedness to Dr. Hitesh T. Kubavat and Mr. 
Manish G. Gondaliya for their kind support during the course of my research work.  
  
  
 I wish to thank of all teaching staff members and non teaching staff 
members of Shree M. &  N. Virani Science College, Rajkot for their valuable 
cooperation and help during the course of my research work. 
 
I gratefully acknowledge the most willing help and co-operation shown by 
Department of chemistry, Saurastra university, Rajkot. CSMCRI Bhavnagar, CIL 
Chandigadh  for spectral studies . 
 
Finally, I am thankful to Principal and Management of Shree M. &  N. 
Virani Science College, Rajkot for their kind support and provided me the excellent 
chemical research laboratory facility and glass wares on time his co-operation in 
magnifying the presentation of my work in the form of thesis. 
                   
                  Mahendra D. Savaliya 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
 
SYNOPSIS   . .   . .  . .    1                  
                
SYNTHESIS AND THERAPEUTIC ACTIVITY OF SOME NEW 
PIPERAZINE DERIVATIVES 
 
General Introduction  . .    . .   . .   12  
Subject  Introduction  . .    . .   . .   16  
 
PART - I     :  STUDIES ON ARYLAMIDE 
 
Introduction    . .    . .   . .                   29                   
 
Section - I  :   Synthesis and biological Screening of 1-aroyl-4-[(4',4"-difluoro  
  diphenyl)-methyl]-piperazines. 
Introduction and Spectral studies ...   . .   . .                   33        
Experimental    . .    . .   . .               39             
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .          44                  
 
Section - II  :   Synthesis and biological Screening of 1-N-aroylamino-4-[(4',4"-
   difluorodiphenyl)-methyl]-piperazines. 
Introduction and Spectral studies ...   . .   . .                   46        
Experimental    . .    . .   . .               52             
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .          55                  
 
PART - II   :   STUDIES ON SULPHONEMIDES 
 
Introduction    . .    . .   . .                      57                        
                
Section - I  :  Synthesis and biological Screening of 1-arylsulpho-4-[(4',4"- 
           difluorodiphenyl)-methyl]-piperazines. 
Introduction and Spectral studies ...     . .   . .           62             
Experimental    . .    . .   . .                68 
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .   70 
                
Section - II :   Synthesis and biological Screening of 1-N-arylsulphonamido-4- 
  [(4',4"-difluorodiphenyl)-methyl]-piperazines. 
Introduction and Spectral studies ...    . .   . .                       72  
Experimental    . .    . .   . .                78 
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .           80 
 
PART - III  :  STUDIES ON MANNICH BASES 
 
Introduction   . .    . .   . .                              82            
 
Section - I  :  Synthesis and biological Screening of 1-arylaminomethyl-4-[(4',4"-
difluorodiphenyl)-methyl]-piperazines.   
Introduction and Spectral studies ...     . .   . .           88               
Experimental   . .    . .   . .                                  94              
Graphical data of  In Vitro Evaluation of Antimicrobial screening                . .          96            
 
Section - II  :  Synthesis and biological Screening of 1-N-(arylaminomethyl 
amino)-4-[(4',4"-difluorodiphenyl)-methyl]-piperazines. 
Introduction and Spectral studies ...     . .   . .           98               
Experimental   . .    . .   . .                                 104              
Graphical data of  In Vitro Evaluation of Antimicrobial screening               . .         106            
 
PART - IV  :  STUDIES ON SCHIFF’S BASES 
 
Introduction   . .    . .   . .                            108 
 
Section - I  :  Synthesis and biological Screening of 1-N-arylideneamino-4-[(4',4"-
           difluorodiphenyl)-methyl]-piperazines. 
Introduction and Spectral studies ...     . .   . .         114                 
Experimental   . .    . .   . .                  120 
Graphical data of  In Vitro Evaluation of Antimicrobial screening              . .           122          
Section - II  :   Synthesis and biological Screening of 1-N-arylmethylamino-4- 
   [(4',4"-difluorodiphenyl)-methyl]-piperazines. 
Introduction and Spectral studies ...     . .   . .         124                  
Experimental   . .    . .   . .                           130                
Graphical data of  In Vitro Evaluation of Antimicrobial screening  . .         132 
 
PART - V  :  STUDIES ON 4-THIAZOLIDINONES 
 
Introduction  . .    . .   . .                            134                         
 
Section - I :  Synthesis and biological Screening of 2-aryl-3-N-{4'-[(4",4'''-
difluorodiphenyl)-methyl]-piperazine-1'-yl}-5-H-4-thiazolidinones.   
Introduction and Spectral studies ...     . .   . .         142         
Experimental     . .   . .   . .                         148                 
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .        150                        
 
Section - II : Synthesis and biological Screening of 2-aryl-3-N-{4'-[(4'',4"'-       
difluorodiphenyl)-methyl]-piperazine-1'-yl}-5-methyl-4-
thiazolidinones.   
Introduction and Spectral studies ...                           . .                                  . .         152    
Experimental   . .   . .   . .                                 158             
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .   160                 
 
Section - III : Synthesis and biological Screening of 2-aryl-3-N-{4'-[(4",4'''- 
  difluorodiphenyl)-methyl]-piperazine-1'-yl}-5-carboxymethyl-4-
  thiazolidinones.   
Introduction and Spectral studies ...                           . .                                  . .      162                         
Experimental   . .   . .   . .   . .        168               
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .  170                       
 
PART - VI   :  STUDIES ON  2-AZETIDINONES 
 
Introduction   . .   . .   . .   . .                    172            
 
Section - I  :  Synthesis and biological screening of 1-N-{4'-[(4",4'''-difluoro 
diphenyl)-methyl]-piperazine-1'-yl}-4-aryl-3-chloro-2-azetidinones.   
Introduction and Spectral studies ...                           . .                                  . .        178                    
Experimental                  . .           . .           . .   . .        184        
Graphical data of In Vitro Evaluation of Antimicrobial screening              . . 186 
 
PART- VII :  STUDIES ON  5-OXO-IMIDAZOLINES 
 
Introduction  . .   . .   . .   . .                    188 
 
Section - I :  Synthesis and biological Screening of 1-N-{4'-[(4",4'''-difluoro  
 diphenyl)-methyl]-piperazine-1'-yl}-4-arylidene-2-phenyl-5-oxo-
 imidazolines.  
Introduction and Spectral studies ...     . .   . .         196         
Experimental    . .       . .       . .                             . .        202                 
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .        204                        
 
Section - II : Synthesis and biological Screening of 1-N-{4'-[(4",4'''-difluoro  
 diphenyl)-methyl]-piperazine-1'-yl}-4-arylidene-2-(4""-methoxy 
 phenyl)-5-oxo-imidazolines.  
Introduction and Spectral studies ...     . .   . .         206         
Experimental    . .       . .       . .                             . .        212                 
Graphical data of  In Vitro Evaluation of Antimicrobial screening   . .        214                        
 
  
REFERENCES  . .       . .       . .                             . .         216              
                    
LIST OF PAPER PUBLICATIONS        . .            . .                   . .    247
                         
 
              
   
 
 
 
                                                                                                                                                Synopsis 
                                                                                                                                      1 
“SYNTHESIS AND THERAPEUTIC ACTIVITY OF               
SOME NEW PIPERAZINE DERIVATIVES” 
 
               The research work incorporated in the thesis entitled “SYNTHESIS AND 
THERAPEUTIC ACTIVITY OF SOME NEW PIPERAZINE DERIVATIVES” 
has been described as under. 
 
 The aim of research is to develop new bioactive entities, especially with 
antimicrobial activities bearing a different piperazine derivatives nucleus. Numerous 
piperazine derivatives like aryl amide, sulphonamides, Mannich bases, Schiff's bases, 
thiazolidinones, azetidinones, imidazolinones have been prepared. Above piperazine 
derivatives containing a wide spectrum of biological activities viz. anti-inflammatory, 
antibacterial, antimalarial, anticonvulsant, antipyretic, antitumor, anthelmintics,       
analgesic, antidepressant, antifungal, antitubercular, anticancer, antidiabetic etc. 
Taking in view of the applicability and chemical diversity in the molecular frame 
work in order to interest synthesis, spectral studies and therapeutic activity of some 
new piperazine derivatives.     
 
   Some new synthesized piperazine derivatives which have been described as 
under. 
 
 
PART – I :  STUDIES ON ARYLAMIDE. 
    Arylamide derivatives showed different biological activity such as 
antihistamine, anti-inflammatory, anticonvulsant, antitubercular, antipyretic, 
analgesic, antiseptic, etc. With a view of getting better therapeutic agent and to 
evaluate its pharmacological  profile. Some new aryl amide derivatives have been 
synthesized. Which have been described as under. 
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SECTION-I : Synthesis   and   biological   screening  of  1-aroyl-4-[(4',4"-difluoro 
diphenyl)-methyl]-piperazines. 
                       
                                                                                                                                      2 
 
 
    
    
    
               
                           
  
F
N N
F
O
R
 
Type-I                                  R= Aryl 
 
               Aryl amide of Type-(I) have been synthesized by the condensation of 1-(H)- 
4 -[(4',4"-difluoro diphenyl)-methyl]-piperazine with aroyl chloride. 
 
SECTION-II : Synthesis  and  biological  screening  of  1-N-aroylamino-4-[(4',4"-                         
difluorodiphenyl)-methyl]-piperazines. 
              
F
N N
F
NH
O
R
 
Type-II                                  R= Aryl 
 
 
 
 
 
 
 
 
 
 
              Arylamide of Type-(II) have been synthesized by the condensation of 1-
amino -4-[(4',4"- difluorodiphenyl)-methyl]-piperazine with aroyl chloride. 
  
 
                                                                                                                                                Synopsis 
PART – II :  STUDIES ON SULPHONAMIDES.    
 Sulphonamide derivatives have been found to be associated with various 
pharmacological activities such as anti-inflammatory, antibacterial, tuberculosis, 
antimalarial, antiviral, anticonvulsant etc. These finding encouraged us to synthesized 
some new sulphonamide derivatives are as under. 
 
SECTION-I : Synthesis  and  biological  screening  of  1 - arylsulpho - 4 - [(4', 4"-
             difluorodiphenyl)-methyl]-piperazines.    
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 Type-III                                  R= Aryl 
 
         Sulphonamides of Type-(III) have been synthesized by the condensation 
of 1 - (H) - 4 - [(4', 4"- difluorodiphenyl) - methyl]- piperazine  with  arylsulphonyl 
chloride. 
SECTION-II : Synthesis  and  biological  screening  of  1 -N - arylsulphonamido -              
4-[(4',4"-diflurodiphenyl)-methyl]-piperazines.     
    
    
    
N N
F
F
NH
S
O
R
O
 
 Type-IV                                  R= Aryl 
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                  Sulphonamides of Type-(IV) have been synthesized by the condensation 
of 1-amino- 4 -[(4',4"-difluorodiphenyl)-methyl]-piperazine with arylsulphonyl 
chloride. 
 
PART – III :  STUDIES ON MANNICH BASES. 
                     Mannich bases containing bridge N-atom exhibit diverse 
pharmacological activities like anti-inflammatory, anthelmintics, antibacterial, 
antimalarial, antineoplastic, analgesic, anticonvulsant etc. Mannich bases are also 
found as intermediate in organic synthesis and good chelating agent hence it is 
pertinent to synthesized new Mannich base. which have been described as under. 
 
SECTION-I : Synthesis and biological screening of 1-arylaminomethyl-4- [(4',4"-
difluorodiphenyl)-methyl] -piperazines.   
 
 
    
    
    
    
    
    
    
   
F
N N
F
NH R
 
Type-V                                  R= Aryl 
  
   
      Mannich bases of Type-(V) have been synthesized by the condensation of 
1-(H)-4-[(4',4"-difluoro diphenyl)-methyl]-piperazine with aryl amine, formaldehyde 
in presence of hydrochloric acid. 
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                                                                                                                                                Synopsis 
SECTION-II :   Synthesis  and  biological  screening  of  1-N-( arylaminomethyl 
amino ) - 4 -[(4',4"-difluorodiphenyl)-methyl] -piperazines. 
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F
NH
NH
R
 
 
 
 
 
   
 
   
Type-VI                                  R= Aryl 
   
   
  Mannich bases of Type-(VI) have been synthesized by the condensation of 1-  
amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine with  aryl  amine, formaldehyde 
in presence of hydrochloric acid. 
 
 
 
PART – IV :   STUDIES ON SCHIFF’S BASES. 
  Schiff’s base derivatives represent one of the modest class of biological   
active agent which have been deeply studies during search on new potential agent. 
These have been reported to be active as antimicrobial, antitubercular, anticancer, 
anthelmintics etc. In view of these valid observation to synthesized some new  schiff’s 
base derivatives possessing wide biological  activities which have been described as 
under.  
 
 
                                                                                                                                                Synopsis 
 
SECTION-I : Synthesis  and  biological  screening  of 1 - N - arylideneamino - 4 -            
 [(4',4" -difluorodiphenyl)-methyl] -piperazines. 
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F
N N N
R
 
 
Type-VII                                  R= Aryl 
 
  
      Schiff’s base of Type-(VII) have been synthesized by the condensation of 
1- amino - 4 - [(4', 4"- difluorodiphenyl)- methyl]- piperazine  with different aromatic 
aldehydes.   
 
SECTION-II : Synthesis and biological screening of 1 - N - arylmethylamino - 4 -  
[(4',4"-difluorodiphenyl)-methyl] -piperazines.           
                    
 
    
  
    
    
    
   
F
F
N N NH
R
 
Type-VIII                                  R= Aryl 
 
 
  
                                                                                                                                                Synopsis 
             The compounds of Type-(VIII) have been synthesized by the reduction of 1-
N-arylideneamino-4-[(4', 4"- difluorodiphenyl)- methyl]- piperazines  of  Type-(VII) 
with NaBH4.
PART-V :  STUDIES ON 4-THIAZOLIDINONES. 
       4-Thiazolidinones  have  been  found  to  be  associated  with  various  
biological activities such as antitubercular, anticonvulsant,  antifungal, hypnotic, 
sedative,analgesic, antibacterial  etc.  In  view  of getting  better  therapeutic  agent, 
we have synthesized some new 4-thiazolidinones derivatives which have been 
described as under. 
 
SECTION-I : Synthesis and biological screening of 2-aryl-3-N-{4'-[(4",4"'-
difluorodiphenyl)-methyl]-piperazine-1'-yl}-5-H-4-
thiazolidinones. 
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F
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 Type-IX                                    R= Aryl 
                 
                     
  4-Thiazolidinone derivatives of Type-(IX) have been synthesized by the 
heterocyclization of Schiff’s bases of Type-(VII) with thioglycolic acid.     
 
 
SECTION-II: Synthesis and biological screening of 2-aryl -3 - N- { 4'-[( 4",4"'-    
difluorodiphenyl)-methyl]-piperazine-1'-yl}-5-methyl-4-
thiazolidinones. 
                                                                                                                                                Synopsis 
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 Type-X                                  R= Aryl 
 
 
                4-Thiazolidinone derivatives of Type-(X) have been synthesized by the 
heterocyclization of Schiff’s bases of Type-(VII) with thiolactic acid.    
     
 
SECTION-III:   Synthesis  and  biological  screening  of  2-aryl-3-N-{ 4'-[( 4",4"'-
 difluorodiphenyl )- methyl]- piperazine-1'-yl }-5- carboxymethyl- 
  4-thiazolidinones. 
                        
 
      
      
      
      
      
   
N
F
F
N N
S
O
R
COOH
   Type-XI                                   R= Aryl 
   
 
 
 
                                                                                                                                                Synopsis 
      4-Thiazolidinone derivatives of Type-(XI) have been synthesized by the 
heterocyclization of Schiff’s bases of Type-(VII) with thiomalic acid.    
 
PART – VI :  STUDIES ON 2-AZETIDINONES. 
  2-Azetidinones derivatives represent one of the most active classes of 
compounds possessing a wide spectrum of biological activities such as antibiotic, 
antidepressant, sedative, hypnotic, anticonvulsant, antiviral etc, with a view to get 
better therapeutic agents, we have synthesized different types of 2-azetidinone 
derivatives which have been described as under.     
  
SECTION-I:  Synthesis  and  biological  screening  of  1 - N - { 4' - [(4",4"'- difluoro 
   diphenyl)-methyl]-piperazine-1'-yl}-4-aryl-3-chloro-2-azetidinones.    
    
 
    
    
    
    
    
    
    
    
   
N
F
F
N N
O
Cl
R
 
Type-XII                                R= Aryl 
 
 
                 2-Azetidinones of Type-(XII) have been synthesized by the chemo 
selective cyclization of Schiff’s bases of Type-(VII)  with chloroacetyl chloride in the 
presence of triethyl amine as a basic catalyst.       
 
PART-VII :  STUDIES ON 5-OXO-IMIDAZOLINES. 
 5-Oxo- imidazoline derivatives have been reported to be active as 
anticonvulsant, potent CNS depressant, anti-inflammatory, anticancer, sedatives, 
hypnotics and as mono amino oxidase (MAO) inhibitors etc. In view of obtaining 
                                                                                                                                      9 
                                                                                                                                                Synopsis 
better  therapeutic  agents, we have synthesized some new 5-oxo-imidazoline 
derivatives which have been described as under. 
 
SECTION-I: Synthesis  and  biological  screening   of  1 - N - {4' -[(4", 4"'- difluoro       
                       diphenyl)- methyl]- piperazine-1'-yl} -4- arylidene-2- phenyl-5-oxo - 
                         imidazolines. 
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Type-XIII                                R= Aryl 
 
 
       5-Oxo-imidazolines of Type-(XIII) have been synthesized by the 
condensation  of  1 - amino - 4 - [(4', 4"- difluorodiphenyl) - methyl]- piperazine  with 
different  oxazolones. 
 
SECTION-II: Synthesis and biological  screening  of 1 - N - {4'- [(4", 4"'- difluoro       
                       diphenyl)- methyl]- piperazine-1'-yl}-4- arylidene-2-(4""- methoxy  
                         phenyl)-5-oxo-imidazolines. 
                 
                                                                                                                                                Synopsis 
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Type-XIV                                R= Aryl  
 
       5-Oxo-imidazolines of Type-(XIV) have been synthesized by the 
condensation  of  1 - amino - 4 - [(4', 4"- difluorodiphenyl)- methyl]- piperazine  with 
different  oxazolones. 
 
 
CHARACTERIZATIONS:        
  The constitution of the synthesized products for structure elucidation 
have been characterized using elemental analysis, IR, 1H NMR spectroscopy and 
further supported by mass spectrometry. Purity of the compounds have been checked 
by thin layer chromatography. 
 
 
STUDIES ON BIOLOGICAL ACTIVITIES :     
  All the compounds have been also evaluated for their antibacterial 
activity towards Gram positive and Gram negative bacterial strains and antifungal 
activity towards Aspergillus niger at a concentration of 50 µg/ml. The biological 
activities of the synthesized compounds have been compared with known standard 
drugs. 
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                                                                                                               General Introduction 
 INTRODUCTION  
Research programs for the discovery of new drugs and for improving the 
evolution criteria are under way in many laboratories. In addition knowledge of 
specific constituents of the mycobacterium cell and their biochemical roles has 
advanced considerably in the recent years and may permit a more rational 
approach to the design of new drug action on specific targets. Also, recent 
improvements in the knowledge of the mechanism of action of available drugs and 
the biochemical mechanism of resistance to them may be used as a basis for design 
new and better drugs to care the mycobacterial diseases. 
The current environment for discovery and development of new 
pharmaceuticals agents could hardly be ware challenging. Public policies and 
attitudes are requiring reduction in health care expenditures and increase efficiencies, 
resulting in major health care reform in the United States. At the sometime, major 
diseases remain untreated and paradoxically, scientific progress continues with ever 
increasing acceleration. 
The last few decades have witnessed massive advances in biochemistry, 
physiology, pharmacology and genetics. This has to a better understanding of 
working the body at the molecular level. This in turn has resulted a much better 
understanding of the structure and function of important drug targets e.g. enzymes 
and receptors and that how drugs can be designed for these targets. 
Advances in genetics engineering have been used to produce human 
proteins and enzymes in fast growing microbial cells, allowing these molecules to 
be obtained in far greater yields than if they were extracted from human tissue. 
This makes it easier to study these micro molecules and to design drugs that will 
interact with them. Mapping of human DNA through human genome project has 
immense implications for medicinal chemistry. 
Advances in chemistry have made possible the synthesis of complexes 
molecules. Enantiometry is an important process in medicinal chemistry since life is 
inherently chiral and the drug targets within the body are chiral. As such, they can 
distinguish between the enantiomers of a chiral drug, so the use of recemic drug is 
                                                                                                                                      12 
 
                                                                                                               General Introduction 
inherently wasteful, since only one enantiomer is ideally designed to interact 
with its target. Moreover, the existences of the “wrong” enantiomer could create 
problems if it interacted with a different receptor, resulting inside effects. 
The focus of drug design has switched from structure oriented to target 
oriented research, e.g. development of the antiulcer agent cimetidine. Histamine 
was the lead compound for the project and various strategies were used to find an 
analog that would prevent it fitting its receptor. Once an antagonist was 
developed, a theory was proposed on how it might interact with the histamine 
receptor at a molecular level. Further analogs were then synthesized to test theory 
and the theory was continusally modified as required. 
In the nineteenth century, chemistry developed as a science, both in terms of 
experimental procedures and scientific theory. Scientist isolated and purified single 
compounds from natural extracts. Method of organic synthesis were developed 
that helped chemists altering structures in a predictable way. 
The chemists started separating out the various components of ancient 
positions to discover whether a single compound was responsible for the medicinal 
effect known as the active principle. 
Drugs are chemicals of low molecular weight (~100-500) which interact with 
macromolecular targets to produce a biological response. The biological response 
may be therapeutically useful in the case of medicines or harmful in the case of 
poisons. Most drugs used in medicine are potential poisons if taken in higher 
doses than recommended. 
Drugs are classified by their chemical structures. Drugs classified in this way 
share a common structural feature and often share similar pharmacological 
activity. For example, all penicillin’s contain a β-lactum ring and kill bacteria by the 
same mechanism, as a result, this classification can sometimes be useful in 
medicinal chemistry. However, it is not foolproof. Sulfonamides have a similar 
structure and are mostly antibacterial. However some sulfonamides are useful in 
the treatment of diabetes. Similarly all steroids have a tetracyclic structure, but the 
pharmacological effect of different steroids can be quite different e.g. Testosterone 
is a sex hormone and Spironolactone is a diuretic. 
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Finally classifying drugs according to their molecular target is the most useful 
classification as far as medicinal chemist is concerned, since it allows a rational      
comparison of the structure involved. 
Such compounds either in extract form or in pure form become a part of 
pharmacopoeia. For intanse, though the chinese drug, Mauhany was in use for over 
5000 years for the treatment of various types of fever and respiratory ailments,its 
active principle ephidrine was isolated in 1887. In 1925 chemical investigations 
followed by pharmacological evaluation led this compound into the modern medicine. 
Similarly during this period, urea stibamine was introduced as the first drug in 1920 
for the treatment of Kala azar, in 1930 De Raywolfia preparation were first employed 
for sedative and hypotensive properties. 
A drug is a substances having abnormal effect on certain body functions 
estrichnine stimulates the action of heart and aspirin still it action since both of them 
effects abnormally the two substances are known as drugs chemical sciences 
contributed extensively new discoveries leading to useful drug after 1930. 
The modern concept of drug discovery supported in 1933 by Gerhand 
Domayk with his finding of "Prontosil Red" a compound responsible for the 
antibacterial activity. The advert of sulphonamides draw attention to the different 
acitvity of various chemicals for bacterial and human cells, this important factor 
prompted the Florey and chain in 1939 to investigate penicillins which was 
discovered ten years earlier by Aexander Fleming. 
A large number of important drugs have been introduced during the period of 
1940 to 1960. This perod is knowns as 'Golden Period' of new drug discovery.Thus 
starting from 1933-the first antibacterial drug prontosil leading various sulpha drugs; 
1940-penicillin; 1945-chloroquine (antimalarial); 1950-methyldopa (antidiabetic); 
1957-chlorothiaido (diuretic); 1958-adrenergic (beta blockers coronary vasodilatory); 
1960-semi synthetic penicillin (antibiotics); 1965-trimethoprim (antimicrobial); 1967-
disodium chromoglycate (antiallergic); 1972-cimetidine (H2-antagonist); 1975-
verampril (calcium antagonist); 1981-captopril (antihypertensive) etc. There are some 
specific examples representing new therapeutics. 
The spectacular chemotherapeutical properties of penicillin and its dramatic 
time was development for the treatment of wound made penicillin, a most commonly 
used inexpensive drug.  
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The word ‘drug’ is derived from the French word ‘drogue’ which means a dry 
herb. According to “WHO” a drug may be defined as “any substance or product 
which is used or intended to be used for modifying or exploring physiological   
system or pathological status for the benefit of recipient”. 
The ultimate product of a successful drug design effort. Our goal for this is to 
begin to deconvolute this information in order to apply it to design of new drugs. 
Taking in view of the applicability of heterocyclic compounds, we have undertaken 
the preparation of piperazine derivatives nucleus.  The placement of a wide variety of 
substituents of these nuclei has been designed in order to evaluate the synthesized 
products for their pharmacological profile against several strains of bacteria and fungi. 
 
AIMS AND OBJECTIVES 
 In the pharmaceutical field, there is a need for new and novel chemical 
inhibitors of biological functions. Our efforts are focused on the introduction of 
chemical diversity in the molecular frame work in order to synthesizing 
pharmacologically interesting  piperazine derivatives of widely different composition. 
During the course of research work looking to the applications of piperazine 
derivatives, several entities have been designed, generated and characterized using 
spectral studies. The aims and objectives of the work carried out are as under. 
 
1.  To synthesize pharmacologically active entities like arylamide, 
sulphonamides, Mannichbases, Schiff’s bases, thiazolidinones, 2-azetidinones,  
5-Oxo-imidazolines etc. 
 2.  To characterise these products for structural elucidation using spectroscopic 
 techniques like IR, 1H NMR and Mass spectral studies. 
 3.  To check the purity of all compounds using thin layer chromatography. 
 4.  To evaluate these new products for better drug potential against different 
 strains of bacteria and fungi. 
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 INTRODUCTION OF PIPERAZINE DERIVATIVES    
INTRODUCTION 
Piperazine was used early in the 20th century for the treatment of gout. 
Giround discovered the anthelmintic activity of piperazine, synthesized by Cloez in 
1853, fortuitously in 1942; the same effect was observed by Biosmare in 1948 and 
conformed by Bayared in 1949. Structural modification of this molecule in the search 
for effective filaricidal resulted in diethyl carbamazine synthesized by Kishner et al in 
1946 and studied pharmacologically by Hewitt et al in 1947. Clinical studies have 
shown that the drug is highly effective against both ascaris lumbricoides and 
enterobius (oxyuris) vermicularis. 
 
CHEMISTRY 
Piperazine is a six member cyclic secondary diamine with the nitrogen in the 
1, 4 - position. It can also be called diethelenediamine for convenience its molecular 
formula can be written C4H10N2, and structural formula shown as under (I). 
N
H
N
H ( I )
 
PHYSICAL PROPERTIES 
  Piperazine is soluble in water and ethanol, but insoluble in ether. An aqueous 
solution reacts strongly alkaline, the Pka being 9.8.It occurs in the form of hygroscopic 
plates M.P. 1040C and B.P. 1400C. It is available as the hexahydrate which contains 
about 44% of base and in addition, as various salt such as citrate C24H46N6O14, M.P. 
1820-1870C, adipate C10H20N2O4, M.P. 2560-2570C, phosphate, calcium acetate and 
tartrate. 
ECONOMIC ASPECTS 
Total production of piperazine is about 3 million lb/yr. Most of this is 
converted to one of the salts since these are widely used as animal anthelmintics and 
are more easily administrated in this form. 
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STORAGE & HANDLING 
Anhydrous piperazine should be stored in a dry, airconditioned building at a 
temperature below 600F. On contacting oxygen, piperazine will darken in colour to a 
deep yellow after a long period of time. When anhydrous piperazine is exposed to the 
atmosphere, it will pick up moisture and will tend to cake and darken in warm 
whether. 
HEALTH & SAFETY 
Anhydrous piperazine itself has a low acute oral toxicity. However the 
investigation of large amounts should be avoided and in case where large amounts 
have been swallowed, vomiting should be induced and medical attention obtained 
promptly. Piperazine exhibits a sensitizing potential so that pronged exposure to small 
quantities or a short exposure to a single massive quantity should be avoided. 
Because of its alkalinity, piperazine can cause serious eye damage. When 
piperazine has accidentally been introduced into the eye flushing for 15 minute with 
running water is recommended as the first-aid measure. Piperazine exhibits a high 
vapours pressure and should be handled in well-ventilated areas only. 
PHARMACOLOGICAL EFFECT 
The effects of piperazine on ascaris have been investigated intensively. The 
gross effect is a paralysis of muscle that results in expulsions of the worm by 
peristalsis. Affected worms recover if incubated in a saline medium at 370C. Further 
studies have shown that piperazine blocks the response of ascaris muscle to 
acetylchloline, an action that is much weaker in skeletal muscle preparations. It has 
been proposed that piperazine acts on ascaris muscle by altering the permeability of 
the cell membrane to ions that are responsible for the maintenance of the resting 
potential. Piperazine also inhibits production of succinate by Ascaris at concentrations 
that resulting paralysis and bioclade of the stimulatory effects of acetylcholine. 
Orally administrated piperazine is almost devoid of pharmacological activity. 
Intravenous administration results in a transient fall in blood pressure. Lethal doses 
cause convulsions and respiratory depression. A large number of substituted 
piperazine derivatives exhibit anthelmintic activities. 
Various derivatives have found actual or potential use as antihistamines, 
hypertension, anesthetic, analgesic epilepsy, anticonvulsant, antispasmodic, burn 
shock and hemorrhagic shock. Other application of piperazine and its derivatives 
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except medicine was rubber antioxidants, corrosion inhibitors, additives, wetting 
emulsifying, cosmetic, dyeing industry, resin, polymers, synthetic fibers and 
analytical reagent. 
SYNTHETIC ASPECT 
Preparation of piperazine at atmospheric pressure; diethylene triamine was 
heated with Raney nickel under various experimental conditions. The results of these 
experiments are tabulated below. In all cases ammonia was evolved and piperazine 
formed according to the reaction. A temperature at about 150°C or somewhat higher 
was found to be most suitable for the reaction (II). 
+ NH3
H2 H2
H2H2
C C
NH
CC
HN
Ni
NH2
NH2
CH2
CH2
CH2
CH2
H N
( II )
 
Autoclave method of piperazine; The autoclave was charged with 150 gm of 
N-(2-hydroxy ethyl)-ethylene diamine in 200 ml of dioxane 5-30 gm of catalyst was 
added, and reaction was carried out for three hours at a temperature in the range 200-
300°C. The reaction mixture filtered from catalyst was distilled; dioxane-water 
azeotrope distilled at 87°C, then dioxane at 100-103°C, and finally piperazine at 140-
150°C. Raney nickel appeared the catalyst at choice; copper chromium oxide, 
activated alumina, silica gel, cupric oxide and iron, were intermediate in 
effectiveness.1-9                                                                                      
THERAPEUTIC IMPORTANCE 
R. Rastogi et al10 prepared N-(2-substituted-ethyl)-N’-aryl piperazine (III) as 
potential antihookworm agents. 
 
OCH2CH2 NN
R1
R
( III )
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  N. Serradji at eal11 have been synthesized a variety of analogues 1-[4-
methoxy-3,5-dimethyl benzyl]-4-[3-(ethyl amino)-2-pyridyl]piperazine hydrochloride 
(IV) and evaluated for their anti HIV activity. 
 
N N
N .HCl
NHCH 2CH3
CH3
H3CO
H3C
( IV )
 
 
L-Romero et al12 and S. Ali et al13 have been synthesized various piperazines 
derivatives and evaluated its antiviral activity. 
R. B. Petigara et al14 synthesized various N1-N4-disubstituted piperazine 
derivatives in which the N1 substitutents are 3,4,5-trimethoxy benzoyl alkyl (V) and 
screened for CNS activity, majority of the compounds produced CNS depressant 
effects as shown by gross observation of intact animals and confirmed by motor 
activity studies  in some conditional avoidance behavior. 
 
AH3CO
H3CO
H3CO
NN HAH3CO
H3CO
H3CO
NN H
( V )
 
 
 S. K. Saxena et al15 synthesized piperazine derivatives (VI) and B. M. 
Khadilkar et al16 (VII) showed best CNS depressant, anti-inflammatory, diuretic 
activities.  
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AH3CO
H3CO
H3CO
NN H
Cl
NH2
O (CH2)3
H3CO
NN
( VI )
 
 
H3CO
CO
Cl
N
CH3 R
O(CH2)3 NN
3
l
3
( 2)3
( VII )
 
R. C. Tripathi et al17 have been synthesized piperazine derivatives and 
evaluated its hypotensive and CNS depressant activities. 
Pyrazole derivatives (VIII) and (IX) containing substituted piperazine nucleus 
possess antitumor activity evaluated by A. Ejima and S. Ohsuki.18  
N
N N
N
C=C
H
H CH2
Cl
NN
Me
N
N N
N
C=C
H
H CH2
Cl
NN
Me
( VIII )
 
 
N
N N
N
C=C
H
H CH2
Cl
NN
Me
N
N
N CO(CH 2)2 N N
Cl
F
Cl
( IX )
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The effect of (X) hydrochloride on blood pressure of cat was studied by B. M. 
Khadilkar et al19 for intracerebroventricular administration at the dose of 50-µg/kg 
weights. The fall in B.P. was so rapid that cat died within 15 minutes.  
R
N
O
O
OH
NN
R
N
O
O
OH
NN
( X )
 
 
S. K. Agrawal et al20 prepared 1-(3-carboxyphenoxy)-3-(N1-N4-
phenypiperazinyl) -propane (XI), some of these compounds show potent CNS 
depressant, hypotensive and α-adrenoceptor blocking activities. 
HOOC
O(CH2)3 NN
( XI )
 
U. V. Kargaonkar et al21 have prepared ethyl-8-[4-(3-chlorophenyl)-1-
piperazinyl methyl]-2-oxocoumarin-4-acetate (XII) as most effective anti-
inflammatory agents. Analgesic and anti-inflammatory activities of piperazines 
reported by several research workers.22-27 
O O
COOC2H5
Cl
N N
O O
COOC2H5
Cl
N N
( XII )  
  
Preparation and activity against plasmodium berghei of compound 1-(4-
methoxycinnamoyl)- 4 - [5-(4-chloro/bromo)phenyl-4-oxo-2-oxazin-2-yl] - piperazine 
(XIII) were described by Herrin and his co-workers.28 Some nitrogen containing 
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heterocycles found to posses high antimalarial activity, which was described by F. S. 
Mikhalitsym et al.29 
 
 
 
O
N
O
Br/Cl
N
N
O
OCH3
(XIII)
 
 
L. C. Meurer and his coworkers30 synthesized alkyl & halo substituted 8-(1-
piperazinyl)imidazol [1,2-α]pyrazine and studied their hypoglycemic activity. In these 
derivatives some compounds showed potent hypoglycemic activity. Varieties of 
hypoglycemic agents contained with piperazine moiety were also assessed by several 
investigators.31,32
    Some piperazine derivatives are showed a useful activities like as brain 
protectant33, diagnosis of schizophrenia34, neurokinine35,36, serration antagonist 
receptors37-39, heart muscle receptor40, and cholesterol reducing agents41, HIV-I 
inhibitors42,43, dopamine transporter44-46, sorbitol dehydrogenase inhibitor47-49, 
spermicidal agent50. Besides the anathematic application of piperazine51-53, 
anesthetic54, antiparkinson55, anticonvulsant56-58, antidepressant agents59, 
antipshycotic60-61, antiallergic62-64, antiulcer65, insecticide66, antiparasitics67, and 
normolipemic hypoglycemic & hypotriglyceridemic activity.68
  5-{[4- [4- (Fluorophenyl) -1- piperazinyl] - butyryl] amino}-5H-dibenzo[a,d] 
cyclohepene] (XIV) selectively for cardiac tissue over vascular tissue, thereby 
conferring antianginal activity without an effect on blood pressure by M. Kurokawa 
et. al.69 
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FNNNHCO(CH2)3 FNNNHCO(CH2)3
(XIV)
 
 
     G. R. Brown70 synthesized 1 - (Arylsulfonyl) - 4 - {[1-(4-
pyridyl)piperazine-1-yl] carbonyl}piperazines and analogs (XV) are useful as oxido-
sqelene cyclase inhibitors. 2-Piperazine-1-acetic acid derivatives are used as platelet 
aggregation inhibitors and antithrombotics71, piperazinyl ethyl indazoles as 
calmodulin inhibitors72 and tryptase inhibiting alkynediol piperazine carboxylic 
esters.73 
NNN NN S
O
O
BrC
O
(XV)  
 
S. Paris et.al.74 synthesized pyrrolo[3,2,1-i,j]quinoline (XVI) and documented 
as potential therapeutic application in asthma. 
N
R CH2CH2 N N
N
Me
R'
Me
2 2
e
'
e
(XVI)
 
 
[(Piperazine)alkylthio]pyridine (XVII) was recommended for the control 
helicobacter pybri bacteria by G. Hanauer and his co-workers.75 
N
N
N N S N N
NH
Me S
N
N
N N S N N
NH
e S(XVII)  
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S. Seshadri et. al.76 prepared dimeric products (XVIII) and (XIX) of 
dithioacetals with piperazine showed moderate to significant activity. These 
compounds also show better activity against gram negative bacteria as compared to 
gram positive bacteria. 
 
SO2N NC C
SCH3 SCH3
N NSO2H3C CO HN NHCOCH3
SO2N NC C
SCH3 SCH3
N NSO2H3C CO HN NHCOCH3
(XVIII)  
 
SO2N NC C
SCH3 SCH3
N NSO2H2N NH22
3 3
22 2
(XIX)
 
 
S. J. Brickner et. al.77 prepared potent, synthetic oxazolidinones (XX) which is 
currently in clinical development for the gram positive bacterial infections caused by 
strains of Staphylococci, Streptococci & Enterococci. The in vitro and in vivo 
activities of above compound, against representative strains are similar to these of 
vancomycin. These compounds demonstrate potent in vitro activity against 
mycobacterium tuberculosis. 
 
N
N
N O
O CH
N C
C
H
H3
O
O
H
F
(XX)
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Some quinazolinone derivatives containing substituted piperazines (XXI) 
found to posses strong antibacterial activity.78-84 Substituted piperazinyl-phenyl-
oxazolidione derivatives used as antibacterial agents, which showed MIC of 0.5 µg/ml 
against S. auresas by G. D. Cung et. al.85 
 
NN
N
O
COOH
R
R'
R1
NN
N
O
COOH
R
R'
R1
(XXI)  
 
7-[(4- Substituted phenylpierazine-1-yl) - alkoxyl]- 4 -methylchromene-2-ones 
(XXII) as potential atypical antipsychotics synthesized and evaluated by S. H. 
Bhosale and his co-workers.86 
R3
R2R1
N N(CH2)nOO
CH3
O R3
R2R1
N N(CH2)nOO
CH3
O
(XXII)  
 
N1 - (2- Substituted-4-nitrophenyl)-N4-(2,3 - disubstitutedpropyl) - piperazines 
(XXIII) as useful antifungal agent prepared and characterized by G. L. Talesara et. 
al.87 
 
N NO2N CH2CHCH2   
X
R
R'
(XXIII)
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Preparation and biological evaluation of (5-methyl-1H-indol-2-yl)-4-methyl-
piperazine-1-yl)-methanone (XXIV) as potent human histamine H4 antagonists by J. 
D. Venable and his co-workers.88 
 
N
H
CH3
C NN C 3H
O
(XXIV)  
 
 
N-{4-[4-(2,3-Dichlorophenyl)-piperazine-1-yl]trans-but-2-enyl}-4-pyridine-2-
yl-benzamide (XXV) as selective probes with high affinity for the dopamine D3 
receptor has been prepared by P. Grundt et. al.89 
 
ClCl
N NNH
OC
N
ClCl
N NNH
OC
N
(XXV)
 
 
          N-(2- Chloro-6-methylphenyl)- 2 -(6-(4-(2- hydroxyethyl)- piperazine-1-yl - 2 –
methyl pyrimidine-4-ylamino)thiazole-5-carboxamide (XXVI), a dual Src/Abl kinase 
inhibitors with potent antitumor activity in preclinical assays has been synthesized 
and discovered by L. J. Lombardo et al.90 
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OH
CH3
N N
N
N
H
N
O
S
N
H
N
Cl
CH3
OH
CH3
N N
N
N
H
N
O
S
N
H
N
Cl
CH3
(XXVI)
 
   Several investigators synthesized varieties of new compounds with 
piperazine moiety and found their antimicrobial activities such as antifungal and 
antibacterial.91-101 
 Flunarizine (brand name sibelium) {1-cinnamyl-4-[(4',4"-diflurodiphenyl)-
methyl]-piperazine}(XXVII) was discovered at Janssen Pharmaceutical in 1967. 
Flunarizine is a drug classified as a calcium channel blocker. Flunarizine is a selective 
calcium entry blocker with calmodulin binding properties and histamine H1 blocking 
activity by W. K. Amery.102 It is effective in the prophylaxis of migraine, occlusive 
peripheral vascular disease, vertigo of central and peripheral origin, and as an 
adjuvant in the therapy of epilepsy. It may help to reduce the severity and duration of 
attacks of paralysis associated with the more serious form of alternating hemiplegia.            
Potent visodilater improve cerebral blood flow reduce duration and incidences of 
migraine attack by J. M. Van Nueten.103      
       
 
F
F
NN
(XXVII)
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          Lomerizine{1-(2''',3''',4'''-trimethoxybenzyl)-4-[(4',4"-diflurodiphenyl)-Methyl]-
piperazine}(XXVIII) is a calcium channel blocker with antimigraine properties.104-108 
 
 
 
 
F
F
NN
H3CO
H3CO OCH3(XXVIII)
 
Thus the important role displayed by piperazine derivatives for various 
therapeutic and biological activities prompted us to synthesize some arylamide, 
sulphonamides, Mannichbases, Schiff’s bases, 4-thiazolidinones, 2-azetidinones, 5-
oxo-imidazolines etc. bearing  piperazine moiety in order to active compounds having 
better biological activities as described in the following parts. 
 
 
STUDIES ON PIPERAZINE DERIVATIVES 
 
PART – I        : STUDIES ON ARYLAMIDE  
PART-   II      : STUDIES ON SULPHONAMIDES 
PART -  III     : STUDIES ON MANNICH BASES 
PART-   IV     : STUDIES ON SCHIFF’S BASES 
PART-   V       : STUDIES ON 4-THIAZOLIDINONES 
PART-   VI     : STUDIES ON 2-AZETIDINONES 
PART-   VII    : STUDIES ON 5-OXO-IMIDAZOLINES 
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STUDIES ON ARYLAMIDE  
INTRODUCTION 
The characteristic group present in the simple carboxylic amide is CONH2. 
They are the acyl substitution products of ammonia. Many natural products are 
amides (-CO-NH-), urea (-NH-CO-NH-), and diamides (-CO-NH-CO-NH) 
derivatives of carbonic acid. The peptides and proteins are linear structure of cyclic 
polyamides. The alkaloids of pepper, piperidine and chavicine are N-substituted 
amides of unsaturated acid. N-isobutyl amides of certain highly unsaturated aliphatic 
acids occur in plants, shows insecticidal activity.109 Amides derived from 
polyacetylenic acid have been isolated from certain fungi.110      
SYNTHETIC ASPECT:              
 Various methods for the synthesis of aryl amides are described in  
literature.111-117 Marayama, Tatsuya, Suzuki Onda118 have synthesized arylamide (I) as 
under. 
NH2
NH
OH
Ph
Cl
N
N
Cl
O
N N
NH
Cl
O
NH
OH
Ph
+
Pyridine
( I )
 
MECHANISM 
 
R N+
H
H
O
R'
R1
Cl
O
R NH2
..
+
R N+
H
H
O-
R
Cl + Cl-
R N
H O
R'
-H+
+ B.HCl
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THERAPEUTIC IMPORTANCE 
 Amides, aryl amides, heterocyclic aryl amides showed widely useful as 
pharmacologically activities. The biological activities of aryl amide derivatives have 
been reported as under.   
1. Anticonvulsant119
2. Herbicidal120
3. Cardiotonic121          
4. Antimicrobial122, 123
5. Analgesic124
6. Antiulcer125
7. MAO inhibitor126
8. Anticancer127,128 
9. Antiinflammatory129
10. Anti-HIV130
11. Sodium channel blockers131, 132      
A. K. Mallams133 has reported arylamide derivatives as antitumor agent. More 
over S. J. Laulloo et al134 and J. Hazarika135 have prepared some new biologically 
active arylamide derivatives and reported them as antimicrobial agents. Dhanak 
Dushyant et al.136 have synthesized arylamide (II) useful as urotensin-II antagonist. 
Cl
Cl
O NH
N
S
O
O
O
N
H
( II )
Cl
Cl
NH O
NH NH
( III )
 
E. J. Sanderson Philip et al137 (III) have synthesized aryl amides and studied 
their biological activity. M. B. Anthony et al.138 have reported aryl amide derivatives 
as antiulcer agents. J. E. Foster et al.139 have synthesized some new amide derivatives 
as potent anticonvulsant. A. R. Mulik et al.140 have studied some aryl amides shows 
antibiotic activity. G. Bridge et al.141 have screened arylamides as anti-HIV agent. L. 
Bettineti and co-workers142 have prepared arylamides as antibacterial agents. D. W. 
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Hobbs et al.143 have designed some amides and reported them as MCH-receptor 
antagonist.  
S. Tabuchi et al.144 have screened arylamide derivatives as novel potent 
antagonist of human neuropeptide YY5 receptor. J. H. Chan145 have recorded 
substituted benzophenone arylamide derivatives as inhibitor reverse transcriptase. L. 
Pieters et al.146 have synthesized new diazene carboxamides (IV) as anticancer. N. J. 
Anthony and co-workers147 have investigated amides as anti-HIV. G. Chen et al.148 
have reported aryl amides (V) as antitumor agents. 
NH
N
O
N
F F
F
FF
N
NH
O
CF3
N
CH3
CH3
NH
F
( IV )
( V )
 
CONTRIBUTION FROM OUR LABORATORY 
Some new arylamide derivatives bearing benzimidazol (VI) moiety were 
assessed by H. H. Parekh et al.149 and evaluated its antimicrobial activity. A. R. Parikh 
et al.150-153 have synthesized new arylamide derivatives of (VII), (VIII) and reported 
them as antimicrobial agents. 
 
N
N
H O
NH NH
R
O
N
N
S
N
NH R
NH2O
N
N
R
O
NH2
OH( VI ) ( VII ) ( VIII )
  
V. H. Shah et al.154 (IX) have synthesized some new aryl amide and evaluated 
its antimicrobial activity. V. N. Patoliya et al.155-158 (X-XI) have synthesized and 
evaluated its antimicrobial activity. 
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 D. M. Purohit et al.159 have reported new aryl amides in Piperazine molecules 
as a antimicrobial agent (XII).   
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(IX)
(X)
(XI)
(XII)
(XI)
In the past years, considerable evidence has been accumulated to demonstrate 
the pharmacodynamic and chemotherapeutic activities of amide derivatives. To 
further assess the potential of such type of compounds, the synthesis have been 
carried out which have been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 1-AROYL-4-
  [(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
 
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-AROYL 
  AMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL] - 
  PIPERAZINES. 
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SECTION - I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-AROYL - 4 - [(4', 4"-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
 
Aryl amide represents one of the important classes of compounds, with an 
intension of preparing the compounds possessing better therapeutic activity such as 
antimalarial, anthalmintics, anticonvulsant, antihistamine, anti-inflammatory etc. In 
view of getting 1-aroyl-4-[(4',4"-difluorodiphenyl)-methyl]- piperazines of Type (I) 
have been synthesized by the condensation of 1-(H)-4-[(4',4"-difluorodiphenyl)-
methyl]-Piperazine with aroyl chloride. 
 
Type-I R=Aryl
F
N N
F
R
O
 
           
 The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no-A. 
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IR   SPECTRAL   STUDY   OF   1 - (4"'- METHOXYBENZOYL) - 4 - [(4', 4" - 
DIFLUORODIPHENYL) - METHYL] - PIPERAZINE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
Frequency in cm-1Type Vibration 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2964 2990-2850 474 
C-H str. (sym.) 2860 2880-2860 " 
C-H def. (asym.) 1462 1470-1435 " Alkane 
C-H def. (sym.) 1369 1390-1370 " 
C-H  str. 3057 3090-3030 " 
C=C str 1500 1600-1450 " Aromatic 
C-H i.p. (def.) 1278 1300-1100 " 
Piperazine C-N str. 1319 1360-1310 475 
Halide C-F str. 711 800-600 " 
Ether C-O-C 1219 1260-1200 " 
C-N str. 1155 1220-1020 " Arylamide 
C=O str. 1637 1700-1630 " 
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Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
 
 
NMR  SPECTRAL  STUDY OF  1 - (4"'- METHOXYBENZOYL) - 4 - [(4', 4" - 
DIFLUORODIPHENYL) - METHYL] - PIPERAZINE. 
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.20-2.35 4H doublet C-H (ee’) 
2 3.31-3.65 4H doublet  C-H (dd’) 
3 4.15 3H singlet Ar-OCH3 (a) 
4 5.23-5.27 1H singlet C-H (f) 
5 6.90-6.92 4H singlet Ar-H (gg’, jj’) 
6 7.28-7.29 8H singlet Ar-H 
(hh’, ii’, bb’, cc’) 
F
F
N
N
O
O
CH3
a
b
b'
c
c'
d
d'
e
e'f
g
g'
h
h'
ii'
jj'
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MASS  SPECTRAL STUDY OF 1 - (4"'- METHOXYBENZOYL) - 4 - [(4', 4" - DIFLUORODIPHENYL) - METHYL] -PIPERAZINE. 
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MASS FRAGEMENT STUDY OF 1-(4"'-METHOXYBENZOYL)-4-[(4', 4" -DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
O
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REACTION SCHEME 
 
  
F
OH
F
F
Cl
F
F
N NH
F
O
R Cl
Toluene
SOCl2
Reflux
Piperazine
Toluene
Reflux
F
N N
O
R
F
Pyridine
 
                 
 Type - I                R = Aryl 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-AROYL - 4 - [(4',4"-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
 [A] Synthesis of 1-chloro-1-[(4',4"-difluorodiphenyl)-methane: 
A mixture of 1-(4',4"-difluorodiphenyl)methanol (2.20 gm,0.01M) in Toluene 
(25 ml) with thionyl chloride (1.3 gm, 0.011M) was stirring with at room temp. for 2 
hrs, than after the reaction mixcture refluxed 110-112oC for 8 hrs. Toluene is distilled 
out completely and remained product is oil form. B.P.321°C; Yield: 82.86 %. 
(C13H9ClF2: Required: C: 65.42; H: 3.80; Cl: 14.89; Found: C: 65.40; H: 3.77; Cl: 
14.88 %) 
[B] Synthesis of 1 -[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
A mixture of 1-chloro-1-[(4',4"-difluorodiphenyl)-methane(2.38gm,0.01M), 
anhydrous piperazine (3.44gm, 0.04M), Toluene (25 ml) was heated under reflux in a 
oil bath for 8-10 hours. The reaction mixture is cool at room temp. Filter it and filtrate 
wash with water (25 ml) and separate layers. Take toluene layer and add water (25 
ml) than acidify with Con. HCl about 2.0 pH. and separate layers. Take aqueous layer 
and basify with caustic lye about 13.0 pH. Filter the product and wash with water 
dried and crystallized from methanol. M.P.92°C; yield 85.72%. (C17H18F2N2 : 
Required: C: 70.83; H: 6.25; N: 9.72; Found: C: 70.79; H: 6.23; N: 9.70 %). 
[C]  Synthesis of 1-(4"'-methoxybenzoyl)-4-[(4',4"-difluorodiphenyl)-methyl]-
piperazine(1e):  
A mixture of 1-(H)-[(4',4"-difluorodiphenyl)-methyl]-piperazine (2.88 gm, 
0.01M) and 4-methoxybenzoyl chloride (1.70gm, 0.01M), pyridine(10 ml) was heated 
on an oil bath at 1200c for 5-6 hours. The reaction mixture was cooled and poured in 
to crushed ice, neutralized with diluted hydrochloric acid, filter it and washed with 
water. The isolated product was crystallized from methanol. M.P. 129°C; yield 
63.71%.( C25H24O2N2F2: Requried: C:71.08; H:5.68; N:6.63; Found: C:71.04; H:5.60; 
N:6.61%). 
 Similarly, other aryl amides were synthesized. The physical data are recorded 
in Table no-1.  
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[D] Biological Screening of 1 - aroyl - 4 - [(4',4"-difluorodiphenyl) -methyl] -
 piperazines. 
 All the compounds have been evaluated for their biological screening 
represented in Graphical chart no-1. 
(a) Biological screening: 
It was carried out by cup-plate diffusion method476 which has been described 
as under. 
(I) Antibacterial Screening476
 The purified products were screened for their antibacterial activity using cup-
plate agar diffusion method.  The nutrient agar broth prepared by the usual method 
was inoculated aseptically with 0.5 ml of 24 hr. old subcultures of Bacillus subtillis, 
Bacillus cerus, Escherichia coli, Enterobacter aerogen in separate conical flasks at 
40-50 oC and mixed well by gentle shaking. About 25 ml content of the flask was 
poured and evenly spreaded in a petridish (13 cm diameter) and allowed to set for 2 
hrs. The cups (10 mm diameter) were formed by the help of borer in agar medium and 
filled with 0.05ml (50μg) solution of sample in DMF. 
The plates were incubated at 37 oC for 24 hrs. and the control was also 
maintained with 0.05ml of DMF in a similar manner and the zone of inhibition of the 
bacterial growth were measured in millimeter and recorded in Part-I, section-I, page 
no-42, Table No- A.  
(II)Antifungal Screening476
 Aspergillus niger was employed for testing antifungal activity using cup-plate 
agar diffusion method. The culture was maintained on sabourauds agar slants 
sterilized sabourauds agar medium was inoculated with 72 hrs. old 0.5ml suspension 
of fungal spores in a separate flask.  
About 25 ml of the inoculated medium was evenly spreaded in a Petri dish 
(13cm diameter) and allowed to set for 2 hrs, the cups (10mm diameter) were 
punched. The plates were incubated at 30oC for 48 hrs.  
After the completion of incubation period, the zone of inhibition of growth in 
the form of diameter in mm was measure. Along the test solution in each Petri dish 
one cup was filled up with solvent, which acts as control. The zones of inhibition of 
test solution are recorded in Part-I, section-I, page no-42, Table No- A.
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 The biological screening was compared with standard drug viz Ampicillin, 
Chloramphenicol, Norfloxacin, and antifungal activity was compared with viz 
Greseofulvin. The inhibition zones were measured in mm. The zones of inhibition that 
displayed by standard drugs are recorded in part-I, section-I, page no-42, Table no-A. 
        Greseofulvin. 
Fungi    :  Aspergillus niger  
 Concentration   :  50µg/ml 
 
 
 
 
              Chloramphenicol    
Standard drugs :  Ampicillin 
Solvent   :  Dimethyl formamide 
       
                                                                        Enterobacter aerogen 
Gram negative bacteria :  Escherichia coli 
      Bacillus cerus 
Gram positive bacteria :  Bacillus subtillis 
Method   :  Cup-Plate476
BIOLOGICAL SCREENING 
Norfloxacin 
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TABLE NO - A :  ANTIMICROBIAL  ACTIVITY  ZONE  OF  INHIBITION OF  STANDARD DRUGS. 
 
 
 
                                                                                              Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.  
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                        
                                                                                                                                        
Ampicillin            (50 µg/ml)                 23                         22                              21                          19                                   -- 
 
Chloramphenicol(50 µg/ml)                 22                         23                              21                          20                                   -- 
 
Norfloxacin         (50 µg/ml)                  24                         21                              23                          22                                   --                    
 
Greseofulvin       (50 µg/ml)                  --                           --                               --                           --                                    23 
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TABLE NO-1: PHYSICAL CONSTANTS OF  1-AROYL - 4 - [(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
1a C6H5 - C24H22ON2F2 392 184 88.72 7.14 7.10 
1b 2-CH3-C6H4 - C25H24ON2F2 406 122 74.52 6.89 6.85 
1c 4-CH3-C6H4 - C25H24ON2F2 406 211 74.26 6.89 6.80 
1d 2-OCH3-C6H4 - C25H24O2N2F2 422 121 63.87 6.63 6.60 
1e 4-OCH3-C6H4 - C25H24O2N2F2 422 129 63.71 6.63 6.61 
1f 2-Cl-C6H4  - C24H21ON2F2Cl 426 134 73.52 6.56 6.52 
1g 2-NO2-C6H4 - C24H21O3N3F2 437 172 60.11 9.61 9.57 
1h 3-NO2-C6H4 - C24H21O3N3F2 437 152 59.09 9.61 9.55 
1i 4-NO2-C6H4 - C24H21O3N3F2 437 192 60.99 9.61 9.50 
1j 3,4-(OCH3)2-C6H3 - C26H26O3N2F2 412 187 79.55 6.19 6.15 
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GRAPHICAL CHART NO-1:  BIOLOGICAL SCREENING OF  1 - AROYL - 4 - [(4', 4"- DIFLUORODIPHENYL) - METHYL] -  
          PIPERAZINES. 
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                                                                                              Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                       A. niger 
                                                                                                                                                                                        
                                                        1c-(22)                  1b-(23)                     1a-(20)                 1a-(19) 1a-(21) 
  1e-(24) 1c-(20)                      1d-(23) 1c-(21) 1d-(23) 
  1g-(23) 1e-(22)                      1f-(21) 1f-(19) 1e-(22) 
  1j-(23) 1h-(21) 1j-(20) 1h-(18) 1f-(21) 
 1j-(22) 
 
 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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PART-I 
 
SECTION – I :  BIOLOGICAL SCREENING STUDY OF  1-AROYL - 4 - [(4',4"-DIFLUORODIPHENYL)-METHYL]-  
      PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS. 
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SECTION – II 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-AROYLAMINO-4-       
[(4',4"-DIFLUORODIPHENYL)-METHYL] -PIPERAZINES. 
Aryl  amide  represents  one  of  the  important  classes of compounds, with an 
intension  of  preparing  the  compounds  possessing  better  therapeutic  activity  such 
as antihistamine, anti-inflammatory, anticonvulsant, antipyretic, analgesic etc. In view 
of  getting  1-N-aroylamino-4-[(4',4"-difluorodiphenyl)-methyl]- piperazines  of  Type 
(II)  have been synthesized  by  the  condensation  of  1-amino-4-[(4',4"-difluoro 
diphenyl)-methyl]-Piperazine with aroyl chloride. 
 
F
N N
+
F
Type-II R=Aryl
O
R
NH
F
N N
F
 
           
 The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no-A.  
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IR  SPECTRAL  STUDY OF  1 - N -[(4"'-METHOXYBENZOYL)-AMINO] - 4 -
[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
 
 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
 
Frequency in cm-1Type Vibration 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2989 2990-2850 474 
C-H str. (sym.) 2894 2880-2860 " 
C-H def. (asym.) 1456 1470-1435 " Alkane 
C-H def. (sym.) 1384 1390-1370 " 
C-H  str. 3066 3090-3030 " 
C=C str 1490 1600-1450 " Aromatic 
C-H i.p. (def.) 1213 1300-1100 " 
Halide C-F str. 703 800-600 475 
Piperazine C-N str. 1315 1360-1310 " 
Ether C-O-C str. 1276 1260-1200 " 
C-N str. 1083 1220-1020 " Arylamide 
C=O str. 1677 1700-1630 " 
Sec. amine N-H str. 3359 3500-3100 " 
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NMR  SPECTRAL  STUDY OF  1 - N -[(4"'-METHOXYBENZOYL)-AMINO] - 
4 -[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.40-2.46 4H doublet C-H (ff’) 
2 2.64-2.67 4H doublet C-H (ee’) 
3 3.80 3H singlet Ar-OCH3 (a) 
4 5.30 1H singlet C-H (g) 
5 6.93-6.96 4H triplet Ar-H (hh’, kk’) 
6 7.18-7.27 2H triplet Ar-H (bb’) 
7 7.39-7.48 4H doublet Ar-H (ii’, jj’) 
8 7.81-7.83 2H doublet Ar-H (cc’) 
9 8.27 1H singlet N-H (d) 
 
 
F
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O
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MASS  SPECTRAL  STUDY OF  1 - N - [(4"'-METHOXYBENZOYL) - AMINO] - 4 - [(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
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MASS  FRAGEMENT  STUDY OF  1 - N - [(4"'-METHOXYBENZOYL) - AMINO] - 4 - [(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
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REACTION SCHEME 
 
 
Type - II                                                                                 R = Aryl
F
N NH
F
NaNO2 
F
N N N
F
O
LiAlH4
F
N N NH2
F
O
R Cl
N N NH
O
R
F
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-AROYLAMINO-4-       
[(4',4"-DIFLUORODIPHENYL)-METHYL] -PIPERAZINES. 
 
 [A]      Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
A mixture of 1-[(4',4"-difluorodiphenyl)-methyl]-piperazine (8.6 gm, 0.03M) 
in 50 ml of ice cold water containing 24 ml of diluted HCl is nitrosated with 2.1 gm 
NaNO2 in 10 ml water. The reaction mix is made alkaline by the addition of NaOH 
Solution and an oily layer forms. The oily product is separated and crystallized from a 
mix of 5 ml ethyl acetate - 70 ml n-heptane. The resultant solid is recystallized from a 
mixture of 2-propanol and hexane, to give 1-nitroso-4-[(4',4"-difluorodiphenyl)-
methyl]-piperazine. M.P.153-155°C; Yield: 80.56 %. (C17H17N3F2O; Required: C: 
64.34; H: 5.40; N:13.24;  Found: C: 64.30; H: 5.37; N: 13.22 %). 
 
 [B] Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
A mixture of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine (10 gm, 
0.03 M) in 140 ml of anhy. ether and 5 ml of benzene is added drop wise to a 
suspension of 1.9 gm of Lithium aluminium hydride in 140 ml of ether. The reaction 
mixture is stirred for 1 hrs at room temperature and then refluxed and stirred for 2 hrs. 
The reaction mixture is cooled in an ice bath and excess Lithium aluminum hydride is 
decomposed by the addition of ethyl acetate. The reaction mixture is hydrolyzed by 
drop wise addition of 2 ml of water, 2ml of 20 % NaOH solution. The inorganic salts 
are filtered and washed with ether. The filtrate is dried over sodium sulphate. The 
solvent is evaporated, the residue is dissolved in benzene and the solvent is 
evaporated once again to give 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-
piperazine. M.P.126-129°C; Yield: 57.72%. (C17H19F2N3; Required: C: 67.31; H: 
6.31; N: 13.85; Found: C: 67.27; H: 6.29; N: 13.83 %).  
 
[C] Synthesis of 1 - N - [(4"'-methoxybenzoyl)-amino] - 4 - [(4',4"-difluoro 
 diphenyl)-methyl]-piperazine(2e): 
A mixture of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine (3.03gm, 
0.01M) and 4-methoxybenzoyl chloride (1.70gm, 0.01M), pyridine(20 ml) was heated 
on an oil bath at 120°C for 5-6 hours. The reaction mixture was cooled and poured in 
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to crushed ice, neutralized with diluted hydrochloric acid, filter it and washed with 
water. The isolated product was crystallized from ethanol. M.P. 169°C; yield 68.71%. 
(C25H25O2N3F2 ; Requried: C: 68.64; H: 5.76; N: 9.60; Found: C: 68.61; H: 5.74; 
N:9.58 %).   
 Similarly, other aryl amides were synthesized. The physical data are 
recorded in Table no-2.  
[E] Biological screening of 1-N-aroylamino-4-[(4',4"-difluorophenyl)-methyl]-
 piperazines: 
Biological screening was carried out as described in Part-I, Section-I, page no. 
40. The zones of inhibition of test solutions are recorded in Graphical Chart no-2. 
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TABLE NO-2: PHYSICAL CONSTANTS OF  1-N-AROYLAMINO - 4 - [(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
2a C6H5 - C24H23ON3F2 407 172 85.72 10.31 10.29 
2b 2-CH3-C6H4 - C25H25ON3F2 421 157 76.52 9.97 9.96 
2c 4-CH3-C6H4 - C25H25ON3F2 421 192 74.56 9.97 9.96 
2d 2-OCH3-C6H4 - C25H25O2N3F2 437 182 63.67 9.60 9.58 
2e 4-OCH3-C6H4 - C25H25O2N3F2 437 169 68.71 9.60 9.58 
2f 2-Cl-C6H4  - C24H22ON3F2Cl 441 148 77.53 9.51 9.50 
2g 2-NO2-C6H4 - C24H22O3N4F2 452 176 65.19 12.38 12.36 
2h 3-NO2-C6H4 - C24H22O3N4F2 452 198 57.59 12.38 12.36 
2i 4-NO2-C6H4 - C24H22O3N4F2 452 183 64.54 12.38 12.36 
2j 3,4-(OCH3)2-C6H3 - C26H27O3N3F2 467 202 78.35 8.99 8.97 
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GRAPHICAL CHART NO- 2: BIOLOGICAL SCREENING OF 1-N-AROYLAMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL] - 
                                                      PIPERAZINES. 
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PART-I 
 
SECTION - II :  BIOLOGICAL SCREENING STUDY OF  1-N-AROYLAMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL] -        
        PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS. 
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
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     Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                         
                                                        2a-(22)                 2a-(20)                       2b-(21)                 2b-(22)                        2b-(22)  
  2d-(23) 2c-(21)  2d-(20)  2d-(20)                        2d-(21)  
  2f-(21) 2e-(20) 2g-(23)  2e-(22)                         2g-(22) 
  2i-(22) 2f-(22) 2i-(20)  2g-(21) 2j-(23) 
  2j-(24) 2h-(23)  2j-(21)  2j-(22) 
 2i-(22) 
 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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STUDIES ON SULPHONAMIDES  
INTRODUCTION 
The discovery of sulphonamides as drugs is considered to be the beginning of 
chemotherapeutic era by making possible a direct attack on microbial infection. 
 Sulphonamide was first prepared by Glemo in 1908. Gerhald Domagk in 1935 
tested prontosil towards infection by hemolytic streptococci and found it very 
effective antibacterial which lead to the synthesis of newer molecules by 
incorporating different nucleus. Sulphonamides have the general structure R-SO2- N-
R′, R″, where R=organic radical, R′,R″=hydrogen or organic radical. They are 
classified as aliphatic, aromatic and heterocyclic which is depending upon the nature 
of R. Aromatic and heterocyclic sulphonamides have achieved greater commercial 
significance. Their application on chemotherapy is so well known that the name, 
‘sulpha drug’ is widely used as a general name for sulphonamide derivatives as 
therapeutic agent. 
 
THERAPEUTIC IMPORTANCE AND SYNTHETIC ASPECT  
    It has been now well established that sulphonamides possess valuable 
biological properties including, 
1. Hypoglycemic160 
2. Antimalarial161
3. Antiinflammatory162
4. Herbicidal163
5. Anticoagulant164
6. Anti-HIV165
7. Antitumer166
8. Antihypertension and antiglaucoma167
9. Antimicrobial168
10. Antidiabetic169
11. Anticancer and antibacterial170
12. Herbicidal171
13. Potassium channel inhibitor172
14. Antibacterial173
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 Sulphonamides showed good biological activities. Due to these many sulpho 
namide derivatives are recently in clinical use some of them are shown below. 
N
NCH3
SO2
NH2
NH
O
CH3
Methazolamide
(CA inhibitor)
N
S
SO2
NH2
O
H5C2
Ethoxzolamide 
(CA inhibitor)
O
NH SO2 CH3
NO2
O
NH SO2 CH3
O
F
F
NS-398
(COX-inhibitor)
Flosulide
(COX-inhibitor)
SO2-NH2
SO2-NH2
Cl
Chlorphenaide
(diuretic)
NH2
SO2-NH2
Sulphanilamide
(antibacterial)
NH2
SO2-C6H4-NH2
Dapsone
(antileprotic)
N
NH3CO
H3CO
NH SO2 NH2
Sulphodoxine
(antimalarial)
Cl
SO2 NH CO NH
N
CH3 CH3
Glyparamide 
(antidiabetic)
 
Sulphonamides continue to be used as antibacterial as they are effective, 
inexpensive and free of super infection of problems caused by antibiotics. Extensive 
research has been carried out to enhance the activity and reduced toxicity of sulpha 
drugs. 
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Recently two isoenzymes of cyclooxy genase have been identified: COX-1 
and COX-2 selective inhibition of COX-2 or dual inhibition of COX-1 and COX-2 is 
under discussion as a promising principle in the treatment of inflammatory diseases. 
For several reasons, including increased cardiovascular risk, the important role of 
COX-2 produced prostaglandins in the response of the mucosa to irritants and in 
healing and other critical aspects the accuracy of selective COX-2 inhibition as the 
principle tent is under debate. 
A number of substituted sulphonamides are known as antiinflammatory agent. 
The substances were diflumidone and nimesulide which was lead NS-348 and 
flosulide. 
Diarylmethanoes such as ketoprofen, tiaprofenic acid, tolmetine and ketorolac 
are used in the therapy of inflammation. 
The objective of this study was to correlate the structural parameters with the 
inhibitory potency and the enzyme selectivity i.e. to evaluate the significance of 
sulphonamides as latest biologically active compounds. 
 Moreover G. Dannhardt et.al174 have described the synthesis and COX-
1/COX-2 inhibitory activity of some sulphonamides. 
  
O
CH3
NH
SO2
CH3
NH
SO2
CH3Cox-1 and Cox-2 inhibitors
 
 
C. T. Supuran et. al.175 have documented some CA inhibitors. CA is 
concerning to von-Hippel-Lindau tumors. Progressive polycystic kidney disease, 
carcinomas of the pancreas of Autoimmune/idiopathic chronic pancreatities, it 
appeared of great interest to further explore the connections between CAs and tumors. 
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SO2 NH OCH3
X
F
F
F F
Carbonic Anhydrase (CA) isozyme inhibitors
 
 
P. P. Stein et.al.176 have reported arylsulphonaidopiperidones and also tested 
biological activity such as inhibitors of Factor Xa. 
D. Dushyant et.al.177 synthesized some sulphonamides as antagonist of  
urotensin- II.  
SO2 NHH3CO
H3CO
Cl
O
N
CH3
O CH3
Antagonist of urotensin-II
 
 
CONTRIBUTION FROM OUR LABORATORY  
A. R. Parikh and Co-workers178 (I) have evaluated several sulphonamide 
derivatives having the general formula R-SO2-NH-R′, where R= phenyl, substituted 
phenyl, α and β-napthyl and R′= 2, 4-distributed s-triazine.179
V. H. Shah and Coworkers180-185 (II) have synthesized new sulphonamide 
derivatives and evaluated its antimicrobial screening. 
D. M. Purohit et. al.186 (III) have synthesized new piperazine sulphonamide 
derivatives and evaluated its antimicrobial activity. 
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N
N
N
CH3
SO2-PhNH
R
N
N
N
CH3
SO2-PhSO2
Ph
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NHSO2R
N
N
O
R'
SO2R
Cl
Cl
OCH2COOH
RSO2NHNHSO2
N
N
RNHSO2
CH3
O
NH
COCH2NHR'
N
CH2CH2NHNHSO2R
CH2CH2CH3
F3C
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NO2
NN
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SO2
OCH2COOH
Cl
Cl
NN
Cl
NH
S
O
O
R
( I ) ( I ) ( II )
( II ) ( II )
( II )
( II ) ( II )
( III )
R=R'= Aryl
 
 
B. R. John et. al.187 has prepared some sulphonamide derivatives as potent 
antidiabetic agent. More recently A. R. Mishra et. al.188 and O. A. Fathalla189 have 
reported some novel sulphonamides as antifungal, pesticidal and anticancer agent. 
With a view to get better therapeutic agent, it was contemplated to synthesize 
sulphonamide derivatives to enhance the overall activity of resulting compounds 
which have been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ARYL   
  SULPHO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]- 
  PIPERAZINES. 
 
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYL 
  SULPHONAMIDO-4-[(4',4"-DIFLUORODIPHENYL)- 
  METHYL] -PIPERAZINES. 
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SECTION – I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1 - ARYLSULPHO - 4 -
[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
With an aim to getting better therapeutic agent of sulphonamides 
derivatives and considering the association of various biological activity such 
as antibacterial, antifungal, anticonvulsant, antimalarial, tuberculosis, 
antiviral etc. of piperazine nuclei, the synthesis of 1 - arylsulpho - 4 - [(4', 4"- 
difluorodiphenyl) - methyl] - piperazines  of Type (III) have been undertaken by 
the condensation of 1 - (H)- 4 - [(4',4" -difluorodiphenyl)-methyl]-Piperazine with   
arylsulphonyl chloride in presence of pyridine. 
 
F
N N
H
F
Type-III R=Aryl
F
N N
F
S R
O
O
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no-A. 
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IR SPECTRAL STUDY OF 1-[(4"'-METHYLPHENYL)-SULPHO]-4-[(4', 4"-
DIFLUORODIPHENYL)-METHYL]- PIPERAZINE. 
 
F
F
N N S
O
O
CH3
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
 
Frequency in cm-1Type Vibration 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2989 2990-2850 474 
C-H str. (sym.) 2891 2880-2860 " 
C-H def.(asym.) 1444 1470-1435 " Alkane 
C-H def. (sym.) 1375 1390-1370 " 
C-H  str. 3091 3090-3030 " 
C=C str 1502 1600-1450 " Aromatic 
C-H i.p. (def.) 1172 1300-1100 " 
Halide C-F str. 732 800-600 475 
Piperazine C-N str. 1329 1360-1310 " 
S=O str. (asym.) 1329 1380-1300 " 
S=O str. (sym.) 1126 1180-1140 " Sulphonamide
C-S str. 732 750-600 " 
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NMR SPECTRAL STUDY OF  1 - [(4"'- METHYLPHENYL) - SULPHO] - 4 -
[(4',4" -DIFLUORODIPHENYL)-METHYL]- PIPERAZINE. 
 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
 
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity 
Inference 
1 2.36-2.38       2.41 
4H 
3H 
doublet 
singlet 
    C-H (ee’) 
    Ar-CH3 (a) 
2 2.53-2.91 4H doublet     C- H (dd’) 
3 6.18 1H singlet     C-H (f) 
4 8.88-8.91 4H doublet     Ar-H (gg’, jj’) 
5 9.22-9.40 6H ddoublet Ar-H (hh’, ii’, bb’) 
7 9.55-9.57 2H doublet     Ar-H (cc') 
 
F
F
N N S
O
O
CH3
a
b
b'
c
c'
d
d'
e
e'
f
g
g' h
h'
i
i'j
j'
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MASS SPECTRAL STUDY OF 1-[(4"'-METHYLPHENYL)-SULPHO]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
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MASS FRAGEMENT STUDY OF 1 - [(4"' - METHYLPHENYL) - SULPHO] - 4 - [(4', 4"- DIFLUORODIPHENYL) - METHYL] -
PIPERAZINE. 
                                                                                                                                                           Studies on Sulphonamides 
C H 3
S
N H 2O
O
N
NH
F
F
NH 2
F
F
CH 3
NC3
F
F
 
H
+
o +
o
+
o
+
o
+
o
+
o
+
o
+
o
C H 3
CH 3
S
O
N
CH 3
O
F
F
N
N
S
O
C H 3
O
CH 3
S
O
NN
F
O
N
N
F
F
S +
O
O
C H 3
F
+
o
+
o
NH
N H
+
o
F
F
o
CH 3
S
O
N HN
O
+
m/z = 92
m/z = 96
m/z = 171
m/z = 275
m/z = 86
m/z = 240
m/z = 204
m/z = 442
m/z = 227
m/z = 351
m/z = 219
m/z = 348
m/z = 288
 
    
 
 
                                                                
 
 
                                                                                                                   Studies on Sulphonamides 
REACTION SCHEME 
 
 F
OH
F
F
Cl
F
F
N NH
F
SR Cl
O
O
Toluene
SOCl2
Reflux
Piperazine
Toluene
Reflux
F
N N S
F
O
O
  
 
R
Pyridine
             Type - III                    R = Aryl 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1 - ARYLSULPHO - 4  -
[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
 [A]      Synthesis of  1-chloro-1-[(4',4"-difluorodiphenyl)-methane: 
See, Part-I, Section-I (A), on page no-39 
[B] Synthesis of 1 -[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-I (B), on page no-39 
[C] Synthesis of  1-[(4"'-methylphenyl)-sulpho]- 4 -[(4',4"-difluorodiphenyl)-
 methyl]- piperazine(3j): 
A mixture of 1-(H)-[(4',4"-difluorodiphenyl)-methyl]-piperazine (2.88gm. 
0.01M), 4-methylbenzenesulphonyl chloride (1.90g, 0.01M),pyridine(10 ml) was 
heated in a oil bath at 120°C for 5-6 hours. The reaction mixture was cooled and 
poured into crushed ice, neutralized with diluted hydrochloric acid.  The product is 
filtered, washed with water and crystallized from isopropyl alcohol. M.P. 189°C,  
yield: 75%.  
(C24H24O2N2F2S: Required: C:65.15; H:5.42; N:6.33; Found: C:65.10; H:5.41; 
N:6.30 %).  
Similarly, other sulphonamides were synthesized. The physical data are 
recorded in Table no -3.    
[D]     Biological Screening of 1-arylsulpho-4-[(4',4"-difluorodiphenyl)-methyl]-     
 piperazines. 
Biological screening were carried out as described in Part-I, Section-I, page 
no-40. The zones of inhibition of test solutions are recorded in Graphical Chart no-3. 
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TABLE NO- 3: PHYSICAL COSTANTS OF 1 - ARYLSULPHO - 4 -[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
3a 3-COOH-C6H4 - C24H22O4N2F2S 472 150 71.10 5.93 5.90 
3b 5-COOH-2-CH3-C6H3 - C25H24O4N2F2S 486 202 66.71 5.76 5.71 
3c 3-COOH-4-CH3-C6H3 - C25H24O4N2F2S 486 123 61.62 5.76 5.70 
3d 5-COOH-2-OCH3-C6H3- C25H24O5N2F2S 502 200 79.81 5.57 5.52 
3e 3-COOH-4-OCH3-C6H3- C25H24O5N2F2S 502 227 65.50 5.57 5.50 
3f 5-COOH-2-Cl-C6H3  - C24H21O4N2F2ClS 506 120 66.60 5.53 5.47 
3g 3-COOH-4-NO2-C6H3 - C24H21O6N3F2S 517 159 76.52 8.12 8.00 
3h 3-COOH-5-NO2-C6H3 - C24H21O6N3F2S 517 180 62.76 8.12 8.08 
3i 5-COOH-2-NO2-C6H3 - C24H21O6N2F2S 517 197 74.40 8.12 8.04 
3j 4-CH3-C6H4 - C24H24O2N2F2S 442 189 75.00 6.33 6.30 
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GRAPHICAL CHART NO- 3 : BIOLOGICAL SCREENING OF 1 - ARYLSULPHO - 4 -[(4',4"-DIFLUORODIPHENYL)-METHYL]-
                       PIPERAZINES. 
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PART-II 
 
SECTION – I: BIOLOGICAL SCREENING STUDY OF   1 - ARYLSULPHO - 4 - [(4', 4"- DIFLUORODIPHENYL) - METHYL] -                         
PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS. 
 
 
                                                                                              Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                        
                                                        3b-(22)                 3b-(22)                      3a-(20)                  3a-(18) 3a-(21) 
 3d-(21) 3d-(21) 3c-(21) 3b-(20) 3b-(22) 
 3e-(23) 3f-(23) 3f-(21) 3c-(19) 3d-(21) 
 3g-(24) 3h-(20) 3j-(23) 3d-(21) 3g-(23) 
 3i(21) 3g-(19) 3j-(22) 
 3j-(22) 3h-(22) 
 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYLSULPHO 
NAMIDO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES.  
Sulphonamides derivatives shows  better therapeutic  activity such as 
antiviral, anti-inflammatory, antibacterial, antifungal, antimalarial etc. of  
piperazine nuclei. In view of getting to synthesis 1-N-arylsulphonamido-4-
[(4',4"-difluorodiphenyl)-methyl]-piperazines of Type (IV) have been undertaken 
by the condensation of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-Piperazine with   
arylsulphonyl chloride in presence of pyridine. 
 
Type-IV R=Aryl
F
N N
F
NH
S
R
O
O
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no- A. 
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IR SPECTRAL STUDY OF 1 - N - [(4"' - METHYLPHENYL) - SULPHO 
NAMIDO] - 4 - [(4', 4"- DIFLUORODIPHENYL) - METHYL] - PIPERAZINE. 
 
 
F
F
N
N
NH
S
O
O
CH3
 
 Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:            
4000-400 cm-1(KBr disc). 
 
Frequency in cm-1Type Vibration 
Mode Observed Reported 
Ref. 
C-H str.(asym.) 2923 2990-2850 474 
C-H str. (sym.) 2873 2880-2860 " 
C-H def. (asym.) 1402 1470-1435 " Alkane 
C-H def. (sym.) 1373 1390-1370 " 
C-H  str. 3031 3090-3030 " 
C=C str 1573 1600-1450 " Aromatic 
C-H i.p. (def.) 1170 1300-1100 " 
Halide C-F str. 808 800-600 475 
Piperazine C-N str. 1326 1360-1310 " 
C-S str. 703 750-600 " 
S=O str. (asym.) 1326 1300-1380 " Sulphonamide 
S=O str. (sym.) 1151 1180-1140 " 
Sec. amide N-H str. 3240 3500-3100 " 
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NMR SPECTRAL STUDY OF 1 - N - [(4"'- METHYLPHENYL) - SULPHO 
NAMIDO] - 4 - [(4',4"- DIFLUORODIPHENYL) - METHYL] - PIPERAZINE. 
 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
 
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.35-2.40 4H 3H 
doublet 
singlet 
    C-H (ff’) 
    Ar-CH3 (a) 
2 2.53-2.59 4H doublet     C-H (ee’) 
3 5.20 1H singlet     C-H (g) 
4 6.93-7.02 4H triplet     Ar-H (hh’, kk’) 
5 7.12-7.19 4H triplet     Ar-H (ii’, jj’) 
6 7.37-7.43 2H doublet     Ar-H (bb’') 
7 7.76 1H singlet     N-H (d) 
8 7.99-8.01 2H doublet     Ar-H (cc') 
 
F
F
N
N
NH
S
O
O
CH3a
b
b'
c
c'
de
e'
f
f'g
h
h'
i
i'
j j'
k k'
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MASS SPECTRAL STUDY OF 1-N-[(4"'-METHYLPHENYL)-SULPHONAMIDO]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]- 
PIPERAZINE. 
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MASS FRAGEMENT STUDY OF 1-N-[(4"'-METHYLPHENYL)-SULPHONAMIDO]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]- 
PIPERAZINE. 
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REACTION SCHEME 
 
 
F
N NH
F
NaNO2 
F
N N N
F
O
LiAlH4
F
N N NH2
F
S
O
R Cl
O
F
N N NH
F
S
O
R
O
0-5 0C
+ HCl
Pyridine
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYLSULPHO 
NAMIDO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
[A] Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (A), on page no-52 
[B]       Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (B), on page no-52 
[C]  Synthesis of 1 - N - [(4"'- methylphenyl)-sulphonamido] - 4 - [(4',4" -   
 difluorodiphenyl)-methyl]-piperazine(4j): 
      A mixture of 1- amino - 4 - [(4',4"-difluorodiphenyl)-methyl] - piperazine 
(3.03gm, 0.01M), 4-methylbenzenesulphonyl chloride(1.90g, 0.01M), pyridine(20 ml) 
was heated in a oil bath at 120°C for 8 hours. The reaction mixture was cooled and   
poured into crushed ice, neutralized with diluted hydrochloric acid. The product is 
filtered, washed with water and crystallized from isopropyl alcohol. M.P. 172°C, 
yield: 72.00 %. (C24H25O2N3F2S; Required: C:63.00; H:5.51; N:9.18; Found: C:62.97; 
H:5.49; N:9.15 %).  
Similarly, other sulphonamides were synthesized. The physical data are 
recorded in Table no - 4.  
[D] Biological screening of 1 - N - arylsulphonamido - 4 - [(4',4"-difluoro  
diphenyl)-methyl]-piperazines.  
Biological screening were carried out as described in Part-I, Section-I, page 
no-40. The zones of inhibition of test solutions are recorded in Graphical Chart no- 4. 
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TABLE NO - 4:  PHYSICAL CONSTANTS OF 1-N-ARYLSULPHONAMIDO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-             
PIPERAZINES. 
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
4a 3-COOH-C6H4 - C24H23O4N3F2S 487 171 73.14 8.62 8.61 
4b 5-COOH-2-CH3-C6H3 - C25H25O4N3F2S 501 194 67.74 8.38 8.36 
4c 3-COOH-4-CH3-C6H3 - C25H25O4N3F2S 501 154 66.52 8.38 8.36 
4d 5-COOH-2-OCH3-C6H3- C25H25O5N3F2S 517 217 75.41 8.12 8.09 
4e 3-COOH-4-OCH3-C6H3- C25H25O5N3F2S 517 202 67.56 8.12 8.09 
4f 5-COOH-2-Cl-C6H3  - C24H22O4N3F2ClS 521 168 63.69 8.05 8.03 
4g 3-COOH-4-NO2-C6H3 - C24H22O6N4F2S 532 178 77.54 10.52 10.50 
4h 3-COOH-5-NO2-C6H3 - C24H22O6N4F2S 532 194 64.70 10.52 10.50 
4i 5-COOH-2-NO2-C6H3 - C24H22O6N4F2S 532 209 78.45 10.52 10.50 
4j 4-CH3-C6H4 - C24H25O2N3F2S 457 172 72.00 9.18 9.15 
 
                                                                                                                                                                                                                                    79                         
 
 
 
 
                                                                                                                                                                                                                              Studies on Sulphonamides            
 
GRAPHICAL CHART NO- 4 : BIOLOGICAL SCREENING OF 1 - N - ARYLSULPHONAMIDO - 4 - [(4',4"- DIFLUORO  
                                      DIPHENYL)-METHYL]-PIPERAZINE. 
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PART-II 
 
SECTION–II:  BIOLOGICAL  SCREENING  STUDY  OF  1-N-ARYLSULPHONAMIDO-4-[(4',4"-DIFLUORODIPHENYL) - 
 METHYL]-PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS. 
 
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                    
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger  
                                                                                                                                                                                        
                                                        4e-(21)                 4b-(21)                      4a-(20)                  4a-(18)  4b-(22) 
 4h-(22) 4d-(22) 4e-(22) 4b-(20)  4e-(21) 
 4i-(24) 4e-(23) 4f-(20) 4d-(19)  4g-(23) 
 4j-(22) 4g-(20) 4i-(23) 4g-(20)  4j-(22) 
 4j-21) 4j-(20) 4i-(22) 
 4j-(21) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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STUDIES ON MANNICH BASES  
 
 
INTRODUCTION 
 
Mannich reaction consists of the condensation of ammonia or 
primary/secondary amine, usually as the hydrochloride, with formaldehyde or other 
aldehyde, and a compound containing atleast one hydrogen atom of pronounced 
reactivity. 
 
In 1912, Carl Mannich has investigated this reaction. Today, due to its 
wide range of biological activities, much interest has been focused on this reaction. 
Mostly, they are found to be antineoplastic, analgesic and antibiotic agents. 
Mannich bases are also employed as an intermediate in industrial chemical 
synthesis. 
 
Mannich bases containing bridged N-atom exhibit pronounced biological 
activities. The study of mannich reaction attracted a great deal of attention to the 
chemists because it plays a vital role owing to their wide range of pharmacological 
and industrial applications. Mannich bases are also employed as intermediate in 
chemical synthesis.190-192 Mannich base derivatives with bridge N-atom have been 
found to be potent drug in medicinal science and possess wide range of biological 
activities like antibacterial, antimalarial, analgesic, anti-inflammatory, anticonvulsant, 
anthelmintics, etc. Mannich bases have gained important because of their 
technological applications in polymer chemistry193, especially as paints and surface. 
active agents and exhibits complexation characteristic with many transition metal 
ions. Over the years there has been much contraversy about the mechanism of the 
Mannich reaction. Studies of the reaction kinetics have led to the following 
mechanistic proposals. 
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SYNTHETIC ASPECT 
Different methods have cited in literature to synthesize Mannich bases by 
several workers194,195 using various interesting substractes. 
1.  P. G. Venkatesha and  D. Vanappayya 196  have  synthesized  aminobenzylated       
     Mannich bases by the condensation reaction between heterocyclic secondary    
     amines and benzaldehyde. 
2.  Seshaiah Krishnan et. al.197 have synthesized Mannich bases from the schiff 
 bases of isatin in presence of formaldehyde and diphenyl amine. 
 
N
H
R
N
O
R1
N
R
N
O
R1
R2
HCHO
NH
C6H5
C6H5
R=H,Cl,Br
R1=-C6H4Br,-C6H4CH3
R2=-N(C6H5)2
N
H
R
N
O
R1
N
R
N
O
R1
R2
HCHO
NH
C6H5
C6H5
R=H,Cl,Br
R1=-C6H4Br,-C6H4CH3
R2=-N(C6H5)2
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3.  Yung-son Hon et. al.198 have  prepared Mannich base from the reaction of 
 phenolic compounds with a preheated mixture of dibromomethane and 
 diethylamine. 
 
[CH2Br2,NH(Et)2]
OH
N
OH
CH3
CH3
[CH2Br2,NH(Et)2]
 
 
4.  S. N. Pandeya   and D. Sriram Dave199   have   synthesized Mannich   bases  
 by the condensation of the acidic group of isatin with formaldehyde and 
 secondary amines. 
5.  K. W.  Chi   and co-workers200   have synthesized   Mannich   base   using  
     1,4,10,13-tetraoxa-7,16  diazacyclooctadecane,   formaldehyde   and  phenolic  
    derivatives in benzene. 
6.  A. Christos Kontogiorgis et. al.201 have synthesized Mannich base of 
 coumarine. 
 
THERAPEUTIC IMPORTANCE 
Mannich bases are associated with a wide variety of biological activities and 
therapeutic applications such as, 
1. Anti-inflammatory202-204
2. Antifungal205
3. Antitumor206
4. Analgesic207
5. Cytotoxic and anticancer208
6. Antibacterial209
7. Antipsychotic210
8. Tranquilizer211,212
9. Antileishmanial213
10. Antimalarial214
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T. Lorand and B Kocsis215 have synthesized some new Mannich bases and 
reported their antibacterial activity. D. D. Erol, A. Rosen et. al.216 have synthesized 
some new Mannich base derivatives from 6-acyl-3-(3,5-dimethylpiperidinomethyl)- 
2(3H)-benzoxazolones and reported their biological activities. H. M. Hassan et. al.217 
have synthesized some new Mannich bases containing 1,8-napthyridine moiety and 
reported their antimicrobial activity. 
M. Movrin and D. Maysinger218 have synthesized Mannich bases from 
nitroxoline and reported them as biologically active agents. T. Ojanen and 
coworkers219 have reported antifungal activity of some mono, bis and quaternary 
Mannich bases derived from acetophenone. Y. Li, Z. S. Yang et. al.220 have 
synthesized some Mannich base derivatives and reported their antimalarial activity. 
B. Shivarama Holla et. al.221 have  prepared Mannich  bases  and tested them 
for anthelmintic activity (I) and all the newly synthesized compounds (II) were tested 
for their antibacterial and antifungal activity. 
 
NN
N
S
R
NN CH3
N O
OCH3
O2N
NN
N
S
R
ON
N O
OCH3
O2N
( I ) ( II )  
 
Amodiaquine,222,223 Mannich base derivatives (III) which shown an 
antimalarial activity superior than chloroquine in areas of high chloroquine resistance. 
M. L. Edwards et. al.224 have prepared the Mannich base of 4-phenyl-3-buten-2-one as 
an antiherps agent. K. Malcolm Scott and co-workers225 have prepared the pyrrole 
mannich base (IV) as a potent antipsychotic agent. 
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N
NR1
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N
R3
(CH2)nN
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OH
NH
NCl
N
CH3
CH3
( III ) ( IV )
1
2
3
( 2)n
l
3
3
( III ) ( I  )  
 
J. Knoll et. al.226 have prepared the Mannich base (V) which was the most 
potent neuroleptic compound of a series of aryl substituted analogues. Molindone (VI) 
which has been reported to demostrate potent neuroleptic activity.227 Jan Balzarini and 
co-workers228 have prepared the Mannich bases of chalcone shows cytotoxic 
activities. 
 
CH3
CH3
O
N
N
H
CH3
CH3 O
O
N
( V ) ( VI )
 
 
H. I. Gul et. al.229,230 have documented antifungal activity of bis Mannich 
bases derived from acetophenones and some mono Mannich bases evaluated for their 
anticonvulsant activity. M. S. Shingare et. al.231 have described the synthesis and the 
antiviral activity of Mannich bases (VII). 
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N
N
S
N
S
NH
N
S
R
R
( VII )
R= H, 4-Me, 5-OMe, 5-Cl, 6-Br
 
 
S. vijayraghavan et al.232 have prepared 5-[2-(ethylthio)-1H-benzimidazol-1-
yl]-methyl-3-[(arylamino)-methyl]-1,3,4-oxadiazole-2-thiones (Mannich bases) and 
tested them for antibacterial activity (VIII). 
 
N
N
SCH2CH3
O
N N
S
CH2NR1R2
R1=H
R2=Phenyl, Substituted phenyl etc.
( VIII )
 
In view of the importance of Mannich bases as versatile synthetic 
intermediates and the availability of scanty literature on therapeutic properties, we 
have undertaken the preparation of Mannich bases in following sections.  
 
SECTION-I :  SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  1 -ARYL  
AMINOMETHYL-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]  
-PIPERAZINES.   
 
SECTION-II : SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  1 - N -      
(ARYLAMINOMETHYLAMINO) - 4 - [(4',4"- DIFLUORO 
DIPHENYL) - METHYL] -PIPERAZINES. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1 - ARYLAMINO 
METHYL -4-[(4',4"-DIFLUORODIPHENYL)-METHYL]  -PIPERAZINES.   
Mannich bases reported in literature exhibit biodynamic activities like anti-
inflammatory, antifungal, antibacterial, analgesic, anticonvulsant etc., with a view of 
getting to synthesis 1 - arylaminomethyl - 4 - [(4',4"- difluorodiphenyl) - methyl] -
piperazines of Type (V) have been synthesized from 1-(H)-4-[(4',4"-difluoro 
diphenyl)-methyl]-piperazine with aryl amine, formaldehyde in presence of 
hydrochloric acid in methanol. 
Type-V R=Aryl
F
N N
F
NH R
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR SPECTRAL STUDY OF 1-[(4"'-METHOXYPHENYL)-AMINOMETHYL]-
4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
F
F
N N
NH O
CH3
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
 
Frequency in cm-1Type Vibration 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2958 2990-2850 474 
C-H str. (sym.) 2877 2880-2860 " 
C-H def. (asym.) 1467 1470-1435 " Alkane 
C-H def. (sym.) 1388 1390-1370 " 
Alkene -CH2 str. 2793 2850-1790 " 
C-H  str. 3047 3090-3030 475 
C=C str 1500 1600-1450 " Aromatic 
C-H i.p. (def.) 1282 1300-1100 " 
Halide C-F str. 786 800-600 " 
Piperazine C-N str. 1352 1360-1310 " 
Ether C-O-C str. 1232 1280-1200 " 
Mannich base C-N str. 1041 1220-1020 " 
Sec. amine N-H str. 3310 3500-3100 " 
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NMR  SPECTRAL  STUDY  OF  1 - [(4"' - METHOXYPHENYL) - AMINO 
METHYL]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.23-2.37 8H doublet     C-H (f) 
2 2.72-2.74 1H singlet     N-H (d) 
3 3.82 3H singlet     Ar-OCH3 (a) 
4 4.11 2H singlet     C-H (e) 
5 5.22-5.23 1H singlet     C-H (g) 
6 6.86-6.89 6H doublet Ar-H (cc’,hh’,kk’) 
7 7.24-7.27 6H doublet Ar-H (bb’, ii’, jj’) 
 
NN
F
F
NH O
CH
ab
b'
c
c'
d
e
ff
f f
g
h
h'
i
i'
j
j'k
k'
3
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MASS SPECTRAL STUDY OF 1-[(4"'-METHOXYPHENYL)-AMINOMETHYL]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
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MASS FRAGEMENT STUDY OF 1-[(4"'-METHOXYPHENYL)-AMINOMETHYL]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
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REACTION SCHEME 
 
 
 
 
F
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F
F
Cl
F
F
N NH
F
Toluene
SOCl2
Reflux
Piperazine
Toluene
Reflux
F
N N
F
NH R
HCHO
R-NH2
 
Type - V                                                                                 R = Aryl 
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EXPERIMENTAL 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  1 - ARYLAMINO 
METHYL-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]  -PIPERAZINES.   
 
[A]      Synthesis of  1-chloro-1-[(4',4"-difluorodiphenyl)-methane: 
See, Part-I, Section-I (A), on page no-39 
[B] Synthesis of 1 -[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-I (B), on page no-39 
[C] Synthesis of 1 - [(4"'-methoxyphenyl)-aminomethyl] - 4 - [(4',4"-difluoro 
 diphenyl)-methyl]-piperazine(5f): 
A mixture of 1-(H)-[(4',4"-difluorodiphenyl)-methyl]-piperazine.(2.88gm, 
0.01M), 4-methoxyaniline (1.23gm, 0.01M), formaldehyde (1ml), concentrated 
hydrochloric acid(0.5 ml) and methanol(25 ml) was refluxed for 6 hrs. The contents 
were cooled and poured into crushed ice, neutralized with 10% NaHSO3 solution. The 
isolated product was filtered washed with water. The product was crystallized from 
ethanol. M.P. 210°C, yield: 88.10%. (C25H27ON3F2: Required: C:70.92; H:6.38;  
N:9.92; Found: C: 70.88; H:6.30; N:9.85%). 
Similarly, other Mannich bases were synthesized. The physical data are 
recorded in Table no -5.  
 
[E] Biological screening of 1 - arylaminomethyl-4-[(4',4"-difluorodiphenyl)-                      
 methyl] -piperazines: 
Biological screening were carried out as described in Part-I, Section-I, page 
no-40. The zones of inhibition of test solutions are recorded in Graphical Chart no-5. 
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TABLE NO - 5 :    PHYSICAL  CONSTANTS  OF   1 - ARYLAMINOMETHYL - 4 - [(4', 4"- DIFLUORODIPHENYL) - METHYL]  -      
   PIPERAZINES. 
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
5a C6H5 - C24H25N3F2 393 158 70.91 10.68 10.65 
5b 2-CH3-C6H4- C25H27N3F2 407 170 78.19 10.31 10.25 
5c 3-CH3-C6H4 - C25H27N3F2 407 179 75.16 10.31 10.28 
5d 4-CH3-C6H4 - C25H27N3F2 407 180 58.81 10.31 10.32 
5e 2-OCH3-C6H4 - C25H27ON3F2 423 154 68.11 9.92 9.89 
5f 4-OCH3-C6H4 - C25H27ON3F2 423 210 88.10 9.92 9.85 
5g 2-Cl-C6H4  - C24H24N3F2Cl 427 176 72.82 9.82 9.79 
5h 2-NO2-C6H4 - C24H24O2N4F2 438 157 65.41 12.78 12.70 
5i 3-NO2-C6H4 - C24H24O2N4F2 438 130 89.16 12.78 12.75 
5j 4-NO2-C6H4 - C24H24O2N4F2 438 163 74.02 12.78 12.72 
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GRAPHICAL CHART NO- 5 :  BIOLOGICAL  SCREENING  OF  1 - ARYLAMINOMETHYL - 4 - [(4',4"-DIFLUORODIPHENYL)-
           METHYL]-PIPERAZINES.   
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PART-III 
 
SECTION - I :  BIOLOGICAL  SCREENING  STUDY OF 1-ARYLAMINOMETHYL-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-      
        PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS. 
 
 
 
 
 
 
 
                                                                                              Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                        
                                                        5b-(21)                  5a-(22)                     5b-(21)                  5a-(18) 5a-(22) 
 5c-(20)  5b-(20) 5c-(20) 5c-(20) 5c-(21) 
 5f-(24)  5e-(21) 5e-(23) 5e-(20) 5f-(22) 
 5h-(23)  5h-(22) 5g-(21) 5f-(21) 5h-(23) 
 5j-(22)  5j-(23) 5h-(20) 5i-(19) 5j-(21) 
 5j-(22) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                         
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-(ARYLAMINO 
METHYLAMINO)-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINES.   
Mannich bases showed pharmacological activities like anthelmintics, 
antibacterial, antifungal, antimalarial, anticonvulsant, analgesics etc. In view of 
getting  better  therapeutic  activity  to  synthesis 1 - N - (arylaminomethylamino) - 4 - 
[(4', 4"- difluorodiphenyl) - methyl] - piperazines of Type (VI) have been synthesized 
from 1 - amino - 4 - [(4',4" - difluorodiphenyl) - methyl] - piperazine with aryl amine, 
formaldehyde  in  presence  of  hydrochloric acid  in methanol. 
Type-VI R=Aryl
F
N N
F
NH
NH
R
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR SPECTRAL STUDY OF 1-N-[(4"'-METHOXYPHENYL)-AMINOMETHYL 
AMINO]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
N
F
F
N
H
N
H
N
O
CH3
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
 
Frequency in cm-1Type Vibration 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2958 2990-2850 474 
C-H str. (sym.) 2865 2880-2860 " 
C-H def. (asym.) 1452 1470-1435 " Alkane 
C-H def. (sym.) 1371 1390-1370 " 
Alkene -CH2 str. 2367 2850-1790 " 
C-H  str. 3047 3090-3030 475 
C=C str 1512 1600-1450 " Aromatic 
C-H i.p. (def.) 1280 1300-1100 " 
Halide C-F str. 773 800-600 " 
Piperazine C-N str. 1359 1360-1310 " 
Ether C-O-C str. 1255 1280-1200 " 
Mannich base C-N str. 1172 1220-1020 " 
Sec. amine N-H str. 3409 3500-3100 " 
Amine N-H str. 3367 3500-3100 " 
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NMR SPECTRAL STUDY OF 1-N-[(4"'-METHOXYPHENYL)-AMINO   
METHYLAMINO]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.19-2.39 4H doublet     C-H (hh’) 
2 2.56-2.72 4H doublet     C-H (gg’) 
3 3.78 3H singlet     Ar-OCH3 (a) 
4 4.0 2H singlet     C-H (e) 
5 6.13 1H singlet     C-H (i) 
6 6.95-6.99 4H doublet     Ar-H (jj’, mm’) 
7 7.10-7.12 1H singlet     N-H (f) 
8 7.21-7.29 2H doublet     Ar-H (bb’) 
9 7.35-7.46 4H doublet     Ar-H (kk’, ll’) 
10 7.60-7.63 2H 1H 
doublet 
singlet 
    Ar-H (cc’) 
    N-H (d) 
F
F
N
N
NH NH
O
CH3
a
b
b'
c
c'd
e
fg
g'
h
h'i
j
j'
k
k'
l l'
m m'
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MASS SPECTRAL STUDY OF 1-N-[(4"'-METHOXYPHENYL)-AMINOMETHYLAMINO]-4-[(4',4"-DIFLUORODIPHENYL)-
METHYL]-PIPERAZINE. 
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m/z = 332
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MASS FRAGEMENT STUDY OF 1-N-[(4"'-METHOXYPHENYL)-AMINOMETHYLAMINO]-4-[(4',4"-DIFLUORODIPHENYL)-
METHYL]-PIPERAZINE. 
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REACTION SCHEME 
 
F
N NH
F
NaNO2 
F
N N N
F
O
LiAlH4
F
N N NH2
F
F
N N NH
F
NH
R
0-5 0C
+ HCl
HCHO
R-NH2
 
Type - VI                                                                                 R = Aryl 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-(ARYLAMINO 
METHYLAMINO)-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINES.   
 
[A] Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (A), on page no-52 
 
[B]       Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (B), on page no-52 
 
[C]  Synthesis of 1-N-[(4"'-methoxyphenyl)-aminomethylamino]-4-[(4',4"-
 difluorodiphenyl)-methyl]-piperazine(6f):  
   A mixture of 1- amino- 4 -[(4',4"-difluorodiphenyl) - methyl] - piperazine 
(3.03gm, 0.01M),4-methoxyaniline(1.23gm,0.01M),formaldehyde(2 ml), concentrated 
hydrochloric acid(0.5 ml) and methanol(25 ml) was refluxed for 6 hrs. The contents 
were cooled and poured into crushed ice, neutralized with 10% NaHSO3 solution. The 
isolated product was filtered washed with water. The product was crystallized from 
ethanol. M.P. 182°C, yield: 85.10 %. (C25H28ON4F2; Required: C:68.47; H:6.44;  
N:12.78; Found: C: 68.45; H:6.43; N:12.75; %). 
Similarly, other Mannich bases were synthesized. The physical data are 
recorded in Table no -6.  
 
[E] Biological screening of 1-N-(arylaminomethylamino)-4-[(4',4"-difluoro 
 diphenyl)-methyl]-piperazines:  
     Biological screening were carried out as described in Part-I, Section-I. page 
no-40. The zones of inhibition of test solutions are recorded in Graphical Chart no-6. 
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TABLE NO-6: PHYSICAL CONSTANTS OF 1-N-(ARYLAMINOMETHYLAMINO)-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
     PIPERAZINES.   
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
6a C6H5 - C24H26N4F2 408 159 72.94 13.72 13.71 
6b 2-CH3-C6H4- C25H28N4F2 422 182 75.29 13.26 13.24 
6c 3-CH3-C6H4 - C25H28N4F2 422 169 69.36 13.26 13.24 
6d 4-CH3-C6H4 - C25H28N4F2 422 184 64.71 13.26 13.24 
6e 2-OCH3-C6H4 - C25H28ON4F2 438 190 67.54 12.78 12.75 
6f 4-OCH3-C6H4 - C25H28ON4F2 438 182 85.10 12.78 12.75 
6g 2-Cl-C6H4  - C24H25N4F2Cl 442 201 76.42 12.65 12.64 
6h 2-NO2-C6H4 - C24H25O2N5F2 453 218 67.32 15.44 15.42 
6i 3-NO2-C6H4 - C24H25O2N5F2 453 232 79.17 15.44 15.42 
6j 4-NO2-C6H4 - C24H25O2N5F2 453 195 76.85 15.44 15.42 
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GRAPHICAL CHART NO- 6 : BIOLOGICAL SCREENING OF 1-N-(ARYLAMINOMETHYLAMINO)-4-[(4',4"-DIFLUORO  
           DIPHENYL)-METHYL]-PIPERAZINES. 
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B.subtillis 19 20 21 18 19 23 17 22 20 24 23 22 24 0
B.cerus 21 17 16 22 23 19 14 21 18 22 22 23 21 0
E .coli 20 22 16 19 21 18 13 17 23 15 21 21 23 0
E .aerogen 17 20 16 21 15 19 15 22 20 19 19 20 22 0
A.niger 19 21 17 22 19 15 21 23 17 19 0 0 0 23
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PART-III 
 
SECTION-II : BIOLOGICAL SCREENING STUDY OF 1-N-(ARYLAMINOMETHYLAMINO)-4-[(4',4"-DIFLUORODIPHENYL)-
     METHYL]-PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS.  
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
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     Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
 
 
 
 
                                                                                                                                                                                        
                                                         6b-(20) 6a-(21) 6a-(20)  6b-(20) 6b-(21) 
 6c-(21) 6d-(22) 6b-(22)  6d-(21) 6d-(22) 
 6f-(23) 6e-(23) 6e-(21)  6f-(19) 6g-(21) 
 6h-(22) 6h-(21) 6i-(23)  6h-(22) 6h-(23) 
 6i-(20) 6j-(22)  6i-(20) 
 6j-(24)  6j-(19) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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STUDIES ON SCHIFF’S BASES  
INTRODUCTION  
The condensation of primary amines with carbonyl compounds was first 
reported by Schiff 233, and the condensation products are often referred to as Schiff 
bases. The general structure of these bases is 
 
R'
R''
N R
'
''
 
 
where R, R’ and R” are H, alkyl, cyclohexyl, aryl, or heterocyclic radicals, 
which may be variously substituted. This condensation reaction, along with the 
chemical and physical properties of Schiff bases have been reviewed.234-236 Schiff 
bases are also known as anils, imines, or azo methines. 
 Various studies have been shown that the >C=N- group has considerable 
biological importance, this can be substantiated by the fact that the possibility of 
having a lone pair of electrons in either a  π or an sp2 hybridized orbital on trigonally 
hybridized nitrogen in the >C=N- group; which is of fundamental chemical and 
biological importance, and together with the variability of angles of hybridization it 
makes possible the formation of nitrogen containing molecules with all the delicate 
differences in physicochemical properties necessary to produce the various 
phenomena of life. 
 In recent years, interest has also focused on aza-analogs such as Schiff’s bases 
derivatives which show a very similar pharmacological profile to classical. Over the 
past few years, several lead-compounds have been developed. Schiff’s bases are also 
known as schiff’s bases and they are well known intermediates for the preparation of 
azetidinones, thiazolidinone, formazan, arylacetamide and many other entities of 
pharamaceutical  potential.  These  are  the  compounds  containing  characteristic  
–HC=N– group. 
Schiff’s bases are obtained mainly by warming the aldehyde & aromatic 
amine together. However, it is more convenient to work in a solvent such as alcohol, 
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dilute acetic acid or glacial acetic acid. Some time the reaction is aided by trace of 
acid in other cases the hydrochloride of the amines can be used in the synthesis. In 
general Schiff’s bases do not react further with either of the reagents used in their 
preparation as do most of the other types of simple intermediates. Synthetic Schiff’s 
base derivatives contribute in huge libraries owing to their wide applicability in 
different fields. 
SYNTHETIC ASPECT 
 Different methods for the preparation of azomethine derivatives documented 
in literature are described as under. 
1.      A.  J.  Gallant et. al.237  have  prepared  schiff’s  bases  by  condensation  of 
 equimolar quantity of 3,6-diformyl catechol and substituted o-phenylene 
 diamine.  
+
O OH
OH
N
NH2
OR
OR
O OH
OH
O
NH2
NH2
OR
OR
 
2. General account of the summary of reaction of aldehydes with amine 
 (aromatic or aliphatic) has been reviewed by M. S. Murray.238
R-CHO R'-NH2 R-CH=N-R'+  
3. A new one pot procedure for the generation of azomethine has been 
 investigated by R. J. Anderson and co-workers.239
N
O
R2
O
CH3
O
R1 N+
O
R2
O
CH3
Cl
R1
COCl2
2
3
1 +
2
3
l
1
l2
 
4.   Strache240 and Van Alphen241 have prepared imine involves in two steps. 
a.  Add. of the amine to the aldehyde gives aldol, which are rarely capable of 
isolation. 
R-CHO R'-NH2+ R-CHOHNHR' 
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b.  The loss of water to give an imine (azomethine), this corresponds to the    
“crotonaldehyde stage” of the aldol condensation. 
R-CH=N-R' + H2OR-CHO + R'-NH2  
5. Oddo and Tognacchini242 have introduced the comparative rates of formation 
of Schiff‘s base from aniline & substituted aniline & aromatic aldehyde 
using a cryscopic method follow the course of reaction. 
 
 P. L. Beaulieu and co-workers243 have synthesized (E)-N-phenyl methylene 
glycine ethyl ester by the cyclocondensation of  glycine ethyl ester hydrochloride, 
t-butylmethyl ether (TBME), benzaldehyde was added followed by anhydrous 
Na2SO4 and triethylamine 
 
PhCHO Et3N
Na2SO4 TBME
HCl.
48hrs
NH2
COOEt
PhCHO Et3N
Na2SO4 TBME
HCl.
48hrs N COOEt
 
 
THERAPEUTIC IMPORTANCE 
 Literature survey reveals that various Schiff’s bases reported as potential 
drugs and are known to possess broadn spectrum of biological activites. 
1.  Antiviral244
2.  Antifungal245
3.  Antiparasitic246
4.  Antibacterial247
5.  Antipyretic248   
6.  Antiinflammatory249
7.  Antitubercular250
Smalders et. al.251 synthesized some new Schiff’s base as potential antitumor 
agents. Sharaf El-Din and Nabaweyal252 have synthesized some Schiff’s base 
derivatives (I) having good antibacterial activity. Chohan et. al.253 have synthesized 
Schiff’s bases, which have been screened and compared for their antibacterial action 
against bacterial  species Escherichia coli, Pesudomonas aeruginose and Klebisella  
pneumoniase.  
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N
OH
OH
OH
O
R=3,4-OH,  3,4-NO2
N
OH
OH
OH
O
R=3,4-OH,  3,4-NO2
( I )
 
Schiff’s bases exhibit a wide range of pharmacological activities like 
antifungal, antibacterial, antiviral, anti-inflammatory etc. R. H. Mehta et al.254 have 
synthesized coummarin schiff’s base derivatives (II) and examined for their 
antibacterial activity. A. K. Khalafallah and M. E. Hassan.255 have prepared some 
styryl Schiff’s bases spiro derivatives as potential antibacterial and antifungal activity. 
 
(II)
O O
NH
( II )
 
     
Joydip Das et. al.256 have synthesized trans-N-refinylidene-n-butylamine (III) 
which found stabillized in liposomes of phophatidylcholine. The rate of formation of 
the Schiff’s base is found to decrease with increasing cholesteral concentration in the 
membrane. V. M. Patel et.al.257  have synthesized some new Schiff’s bases having 
good antibacterial activity. 
 
N
But
Me Me MeMe
(III)
 
M. D. Deshmukh. and A. G. Doshi 258 prepared some new Schiff’s bases show 
good antimicrobial activity against test organism S. aureus, E. coli, Saigella 
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dysenteridse and Salmonella typhi. Wang Yangang et. al.259 have synthesized 
diazomethines having plant hormone activity. Das Arima et. al.260 have prepared 
Schiff’s bases of aminohydroxy guanidine (SB-AHG5) and tested for antiviral activity 
against Herpes Simplex virus (HSV-1) and adenovirus (Ad-5) along with 11 other 
heterocyclic SB-AHG5. 
S. Castellano et. al.261 have prepared azomethine derivatives and evaluated in 
vitro against several pathogenic fungi responsible for human disease. Holla B. 
Shivarama et. al.262 have documented antibacterial, antifungal and herbicidal activity 
of Schiff’s base derivatives. Wang Yangsng and co-workers263 have screened some 
Schiff’s bases having good plant hormone activity. Pascal Rothelst et. al.264 have 
reported some new Schiff’s bases as antiparasitic agents. 
 J. R. Dimmock et. al.265 have reported Schiff’s bases as Cytotoxic agents. A. 
Adnan et. al.266 have synthesized Schiff’s bases possessing significant antibacterial 
and antifungal activity. 
C. Alexandru et. al.267 have synthesized Schiff’s bases, which have good 
analgesic and antipyretic properties. S. N. Pandeya et. al.268 have synthesized Schiff’s 
bases showed good activity against Vibrio cholerae non-o., Shigella boydii, 
Enterococcus faecalis and Edwaredsiella torla with MIC in the rang of 10-25 μg/ml. 
Some compounds were found to be active against Salmonellal typhi and Vibro 
cholerae-0, (MIC 25-150 μg/ml). 
R. V. Chambhare et al.269 have prepared some Schiff’s bases and tested for 
their antimicrobial activity. Holla B. Shivarama et. al.270 have synthesized Schiff’s 
bases of (IV) having antibacterial and anti-inflammatory activity. 
R
R=2-NO2,4-NO2,4-Br......etc.
(IV)
N
S
NH
N
O
Cl
Cl
Cl
R
R=2-NO2,4-NO2,4-Br......etc.
(IV)  
Ram Tilak et. al.271 have synthesized some Schiff’s bases, thiazolidinones 4- 
triazolines, and formazones of 2-chloro phenothiazines and screened against 
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carrageenininduced edema in albino rats. The thiazolidinones showed promising anti-
inflammatory activity. 
Perumal Panneerselvam et al.272 have been synthesized some novel Schiff’s 
bases by condensation of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones with 
different aromatic aldehydes via cyclized intermediate 6,8-dibromo-2-phenyl 
benzoxazin-4-one. The synthesized compounds 3-(benzylideneamino)-6,8-dibromo-2-
phenylquinazolin-4(3H)-one(V) were screened for anti-bacterial and anti-fungal 
activity by paper disc diffusion technique.  
 
N
N
Br
Br
O
C6H5
N=CH-R
R=Aryl ( V )
 
 
S. J. Wadher et. al.273 have been synthesized Schiff’s bases of (VI) having 
antibacterial and anti-fungal activity.  
 
           
R=Aryl
CHR
N SO2 N
CH R
( VI )
 
 
Looking to the interesting properties of Schiff’s bases, we have synthesized 
some new Schiff’s bases, which have been described as under. 
 
SECTION-I :  SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N- 
   ARYLIDENEAMINO-4-[(4',4"-DIFLUORODIPHENYL)- 
   METHYL]-PIPERAZINES.  
SECTION-II : SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-  
    ARYLMETHYLAMINO-4-[(4',4"-DIFLUORODIPHENYL)- 
    METHYL]-PIPERAZINES.  
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SECTION-I 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYLIDENE 
AMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES.  
 
Schiff’s base derivatives represent one of the modest classes of biological 
active agent which have been deeply studies during search on new potential drugs, 
these have been reported to be active as antimicrobial, antitubercular, anthelmintics 
etc. In view of getting to synthesized 1-N-arylideneamino-4-[(4',4"-difluorodiphenyl)-
methyl]-piperazines of Type (VII) have been synthesized by the condensation of 1-
amino - 4 - [(4',4"- difluorodiphenyl) - methyl] - piperazine  with  different  aromatic 
aldehydes in order to study their biodynamic behavior.  
 
Type-VII R=Aryl
F
N N
F
N
R
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR SPECTRAL STUDY OF 1-N-[(4'''-METHOXYBENZYLIDENE)-AMINO]-
4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
 
 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
 
Frequency in cm-1Type Vibration 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2948 2990-2850 474 
C-H str. (sym.) 2881 2880-2860 " 
C-H def. (asym). 1450 1470-1435 " Alkane 
C-H def. (sym.) 1369 1390-1370 " 
C-H  str. 3024 3090-3030 475 
C=C str 1487 1600-1450 " Aromatic 
C-H i.p. (def.) 1130 1300-1100 " 
Halide C-F str. 757 800-600 " 
Piperazine C-N str. 1323 1360-1310 " 
Ether C-O-C str. 1265 1280-1200 " 
C-N str. 1089 1220-1020 " Schiff’s base 
C=N str. 1598 1612-1593 " 
 
                                                                                                                                    115 
 
                                                                                                   Studies on Schiff’s Bases
                                                                                                                                    116 
NMR   SPECTRAL   STUDY   OF   1 - N - [(4'''- METHOXYBENZYLIDENE) - 
AMINO]- 4 - [(4',4" -DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.50-2.59 4H doublet     C-H (ff’) 
2 2.73-2.77 4H doublet      C-H (ee’) 
3 3.75 3H singlet     Ar-OCH3 (a) 
4 5.20 1H singlet     C-H (g) 
5 6.89-6.89 4H doublet     Ar-H (hh’, kk’) 
6 7.08-7.10 2H doublet     Ar-H (bb’) 
7 7.14-7.28 4H triplet     Ar-H (ii’, jj’) 
8 7.37-7.44 2H doublet     Ar-H (cc’) 
9 8.11 1H singlet     C-H (d) 
 
F
F
N
N
N
O
CH3a
b b'
c c'
d
e
e'
f
f'g
h
h'
i
i'
j j'
k k'
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MASS SPECTRAL STUDY OF 1-N-[(4'''-METHOXYBENZYLIDENE)-AMINO]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
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MASS FRAGEMENT STUDY OF 1-N-[(4'''-METHOXYBENZYLIDENE)-AMINO]-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
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REACTION SCHEME 
 
 
Type - VII                                                                                 R = Aryl 
F
N NH
F
NaNO2 
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N N N
F
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N N NH2
F
0-5 0C
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N N N
F
R
F
 
                                                                                                                                    119 
 
 
                                                                                               
                                                                                                 Studies on Schiff’s Bases 
                                                                                                                                    120 
[A] Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYLIDENE 
AMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
(C25H25ON3F2; Required: C: 71.24; H: 5.98; N: 9.97; Found: C: 71.20; H: 5.95; N: 
9.94%). 
 
 
 
 
 
 
Biological Screening was carried out as described in Part-I, Section-I, Page 
no-40. The zone of inhibition of the test solution are recorded in Graphical Chart No-
7. 
[D]          Biological Screening of 1-N-arylidieneamino-4-[(4',4"-difluoro   
 diphenyl) -methyl]-piperazines: 
Similarly, other Schiff’s bases were prepared. The physical constants are 
recorded in Table No-7. 
         A mixture of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine (3.03gm, 
0.01M) and 4-methoxybenzaldehyde (1.36 gm, 0.01M) dissolved in ethanol (20 ml) in 
presence of catalytic amount of concentrated sulphuric acid (0.2 ml).The reaction 
mixture was refluxed for 8 hrs. The contents were cooled and poured in crushed ice 
product  was  isolated  and  re-crystallized  from  ethanol. Yield: 76.54%, M.P. 146oC. 
[C]        Synthesis of 1-N-[(4'''-methoxybenzylidene)-amino]-4-[(4',4"-difluoro 
       diphenyl)-methyl]-piperazine(7e): 
 
 See, Part-I, Section-II (B), on page no-52 
[B]       Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 
 See, Part-I, Section-II (A), on page no-52 
 
EXPERIMENTAL 
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TABLE NO - 7 : PHYSICAL  CONSTANTS  OF 1-N-ARYLIDENEAMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-  
       PIPERAZINES. 
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
7a C6H5 - C24H23N3F2 391 214 62.21 10.73 10.70 
7b 2-OH-C6H4- C24H23ON3F2 407 187 66.00 10.31 10.27 
7c 4-OH-C6H4 - C24H23ON3F2 407 139 76.29 10.31 10.27 
7d 2-OCH3-C6H4 - C25H25ON3F2 421 165 75.87 9.97 9.94 
7e 4-OCH3-C6H4 - C25H25ON3F2 421 146 76.54 9.97 9.94 
7f 2-Cl-C6H4  - C24H22N3F2Cl 425 132 60.47 9.87 9.85 
7g 4-F-C6H4  - C24H22N3F3 409 178 55.74 10.26 10.22 
7h 2-NO2-C6H4 - C24H22O2N4F2 436 187 59.25 12.84 12.80 
7i 3-NO2-C6H4 - C24H22O2N4F2 436 196 60.12 12.84 12.80 
7j C4H3O - C22H21ON3F2 381 193 65.00 11.02 10.97 
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GRAPHICAL CHART NO -7 :  BIOLOGICAL  SCREENING  OF  1-N-ARYLIDENEAMINO-4-[(4',4"-DIFLUORODIPHENYL)-                                
           METHYL]-PIPERAZINES. 
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PART-IV 
 
SECTION - I : BIOLOGICAL SCREENING STUDY OF 1-N-ARYLIDENEAMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]- 
    PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS. 
 
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                        
                                                         7b-(22)               7b-(20)                      7b-(20)                 7c-(20) 7c-(21) 
  7d-(23) 7c-(22)                      7d-(22) 7e-(19) 7e-(23) 
  7f-(24) 7e-(23) 7f-(23) 7f-(21) 7g-(21) 
  7h-(20) 7g-(22) 7i-(21) 7i-(20) 7i-(22) 
  7i-(24) 7i-(22) 7j-(22) 
  7j-(23) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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SECTION-II 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYLMETHYL 
AMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES.  
 
Piperazine derivatives are associated with wide therapeutic activities like 
antimicrobial, antitubercular, anthelmintics, anticancer etc. These finding prompted 
us to synthesize 1-N-aryl methylamino - 4 - [(4', 4"- difluorodiphenyl) - methyl] - 
piperazines of Type (VIII) bearing piperazine moiety obtained by selective 
reduction of (imine group) Schiff’s bases of 1 - N - arylideneamino - 4 - [(4', 4"- 
difluorodiphenyl) - methyl] -piperazines of Type (VII) with sodium borohydride 
(NaBH4).  
 
Type-VIII R=Aryl
F
N N
F
NH
R
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR  SPECTRAL  STUDY  OF  1 - N - [(4''' - METHOXYPHENYL) - METHYL 
AMINO)-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
F
F
N N NH
O
CH3
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
Frequency in cm-1Type Vibration 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2910 2990-2850 474 
C-H str. (sym.) 2837 2880-2860 " 
C-H def. (asym). 1454 1470-1435 " Alkane 
C-H def. (sym.) 1396 1390-1370 " 
Alkene -CH2 str. 2655 2850-1790 " 
C-H  str. 3033 3090-3030 475 
C=C str. 1496 1600-1450 " Aromatic 
C-H i.p. (def.) 1197 1300-1100 " 
Halide C-F str. 759 800-600 " 
Piperazine C-N str. 1361 1360-1310 " 
Ether C-O-C str. 1250 1280-1200 " 
C-N str. 1606 1650-1550 " Schiff’s base 
N-H bend. 1522 1650-1510 " 
Sec. amine N-H str. 3330 3500-3100 " 
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NMR   SPECTRAL   STUDY   OF   1-N-[(4'''-METHOXYPHENYL)-METHYL 
AMINO)-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE. 
 
 Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.30-2.38 4H doublet     C-H (gg’) 
2 2.61-2.67 4H doublet      C-H (ff’) 
3 3.70 3H singlet     Ar-OCH3 (a) 
4 4.01 2H singlet     C-H (d) 
5 5.10 1H singlet      C-H (h) 
6 6.93-6.96 2H doublet     Ar-H (bb’) 
7 7.04-7.06 4H triplet     Ar-H (ii’, ll’) 
8 7.18-7.27 2H doublet     Ar-H (cc’) 
9 7.39-7.48 4H triplet     Ar-H (jj’, kk’)  
10 8.10 1H singlet     N-H (e) 
F
F
NN NH
O
CH
a
b
b'
c
c'
d
e
f
f'
g
g'
h
i
i'
j
j'
k
k'l
l'
3
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MASS SPECTRAL STUDY OF 1-N-[(4'''-METHOXYPHENYL)-METHYLAMINO)-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE. 
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MASS  FRAGEMENT  STUDY  OF  1 - N - [(4'''- METHOXYPHENYL) - METHYLAMINO) - 4 - [(4', 4"- DIFLUORODIPHENYL) -
METHYL]-PIPERAZINE. 
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REACTION SCHEME 
 
 
 
F
N NH
F
NaNO2 
F
N N N
F
O
LiAlH4
F
N N NH2
F
F
N N N
F
R
0-5 0C
+ HCl
R-CHO
Con.H2SO4
F
N N NH
F
R
NaBH4
                                                                               Type - VIII           R = Aryl 
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[A] Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYLMETHYL 
AMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]-PIPERAZINES. 
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Biological Screening was carried out as described in Part-I, Section-I, Page 
no-40. The zone of inhibition of the test solution are recorded in Graphical Chart No-
8. 
[E]            Biological  Screening  of  1 - N - arylmethylamino - 4 - [(4',4"-difluoro
 diphenyl)- methyl]-piperazines: 
Similarly, other methylamino derivatives were prepared. The physical 
constants are recorded in Table No-8. 
(C25H27ON3F2; Required: C: 70.90; H: 6.43; N: 9.92; Found: C: 70.87; H: 6.39; N: 
9.89 %). 
Sodium borohydride (0.57gm, 0.015M) was added to a methanolic solution of 
1 - N - [(4'''- methoxybenzylidene) - amino] - 4 - [(4',4"- difluorodiphenyl) - methyl] -
piperazine (4.21gm, 0.01M) over a period of 30 minutes at temperature 5-10oC with 
constant stirring. The reaction mixture was kept over night at room temp with 
constant stirring. The excess sodium borohydride was neutralized by adding water 
and the product was extracted with ether. The ether layer was washed with water 
untill become neutral, then dried over anhydrous Na2SO4 and finally the ether 
was evaporated to give aminomethyl derivatives. Yield: 82.00%, M.P. 175°C. 
[D]        Synthesis of 1 - N - [(4'''-methoxyphenyl) - methylamino] - 4 - [(4',4"-
       difluorodiphenyl)-methyl]-piperazine: 
                  See, Part-IV, Section-I (C), on page no-120 
[C]        Synthesis of 1-N-[(4'''-methoxybenzylidene)-amino]-4-[(4',4"-difluoro 
       diphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (B), on page no-52 
[B]       Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (A), on page no-52 
 
EXPERIMENTAL 
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TABLE NO - 8 :  PHYSICAL  CONSTANTS  OF  1-N-ARYLMETHYLAMINO-4-[(4',4"-DIFLUORODIPHENYL)-METHYL]- 
    PIPERAZINES. 
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
8a C6H5 - C24H25N3F2 393 186 72.28 9.66 9.62 
8b 2-OH-C6H4- C24H25ON3F2 409 171 69.40 10.26 10.22 
8c 4-OH-C6H4 - C24H25ON3F2 409 179 73.49 10.26 10.22 
8d 2-OCH3-C6H4 - C25H27ON3F2 423 157 65.38 9.92 9.89 
8e 4-OCH3-C6H4 - C25H27ON3F2 423 175 82.00 9.92 9.89 
8f 2-Cl-C6H4  - C24H24N3F2Cl 427 127 80.47 9.82 9.85 
8g 4-F-C6H4  - C24H24N3F3 411 108 85.11 10.21 10.19 
8h 2-NO2-C6H4 - C24H24O2N4F2 438 161 69.87 12.78 12.75 
8i 3-NO2-C6H4 - C24H24O2N4F2 438 117 74.12 12.78 12.75 
8j C4H3O - C22H23ON3F2 383 172 78.00 10.96 10.94 
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GRAPHICAL CHART NO - 8 : BIOLOGICAL  SCREENING  OF  1-N-ARYLMETHYLAMINO-4-[(4',4"-DIFLUORODIPHENYL)-
            METHYL]-PIPERAZINES.. 
0
5
10
15
20
25
30
Z
O
N
E
 
O
F
 
I
N
H
I
B
I
T
I
O
N
 
I
N
 
m
m
B.subtillis 15 22 18 23 17 21 19 14 24 23 23 22 24 0
B.cerus 14 22 16 21 15 20 16 23 13 20 22 23 21 0
E .coli 19 23 15 22 16 20 15 15 17 21 21 21 23 0
E .aerogen 17 20 14 19 16 22 15 21 18 22 19 20 22 0
A.niger 19 22 16 23 15 17 17 21 18 21 0 0 0 23
8a 8b 8c 8d 8e 8f 8g 8h 8i 8j Ampicillin Chloramp
henicol
Norfloxaci
n
Greseoful
vin
 
 
                                                                                                                                                   132 
 
 
 
 
                                                                                                                                                                                                                                Studies on Schiff’s Bases 
 
PART-IV 
 
SECTION - II :  BIOLOGICAL  SCREENING  STUDY  OF  1 - N - ARYLMETHYLAMINO - 4 - [(4', 4"- DIFLUORODIPHENYL) -
       METHYL]-PIPERAZINES COMPARE WITH KNOWN STANDARD DRUGS. 
 
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                    
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger  
                                                                                                                                                                                        
                                                         8b-(22)                8b-(22)                      8b-(23)                8b-(20)                          8b-(22)  
 8d-(23) 8d-(21) 8d-(22) 8d-(19)                         8d-(23) 
 8f-(21) 8f-(20) 8f-(20) 8f-(22)                          8h-(21) 
 8i-(24) 8h-(23) 8j-(21) 8h-(21)                         8j-(21)  
 8j-(23) 8j-(20) 8i-(18) 
 8j-(22) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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STUDIES ON 4-THIAZOLIDINONES  
 
INTRODUCTION 
Thiazolidinones, which belong to an important group of heterocyclic 
compounds, have been extensively explored for their application in the field of 
medicine. Thiazolidinones, with a carbonyl group at position 2-(I), 4-(II), on 5-(III) have 
been subjects of extensive study in the field of 4-Thiazolidinones. Numerous reports 
have appeared in the literature which high light their chemistry and use. 
 
1
N
H
S
O1
2
34
5
N
H
S
O
1
2
34
5
N
H
SO
1
2
34
5
( I ) ( II ) ( III )
 
 
 
4-Thiazolidinones derivatives of thiazolidinone with carbonyl group at 4- 
position(II) substituent in 2,3- and 5 position may be varied but the greatest different in 
structure and properties is exerted by the group attached to carbon atom at the 2-
possition and to N atom at the 3-position. V. H. Shah et. al.274 have been 
synthesized 4-thiazolidinones derivatives in thymol nucleus. The cyclic structure 
was assigned after recognisation of mercapto acetic acid as primary products of 
hydrolysis of 3-phenyl-2 -phenyl-amino-4-thiazolidinones.275
The chemistry of 4-thiazolidinones was reviewed in depth by F. C. Brown276 
in 1962 and G. R. Newkome and A. Nayak277 in 1977. 
 
MECHANISM 
The reaction mechanisms of the formation of 4-thiazolidinones are well 
studied by A. Verma et.al.278 The reaction proceeds by of the mercapto acetic acid 
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upon the C=N group, with the HS-CH2-COOH adding to the carbon atom followed 
by the capture of a proton by nitrogen and subsequent cyclization. 
 
R1 NH2
R2
R3
O Step-1
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In there reaction, the uncyclised intermidiate is formed in several cases. 
The uncyclised product has been isolated279, phosphorous pentoxide in dioxane was 
used for subsequent cyclisation of certain uncyclised products.280 In may instance 
4-thiazolidinones can conveniently be prepared by refluxing the mixture of the 
thioglycolic acid and schiffs bases in benzene281, dry ether282 or ethanol.283
The nucleophilic attach of mercapto acetic acid anion on carbon of 
azomethine, which has got possitive character while nitrogen has negative 
character is evidenced, simultaneously removal of water as it form in reaction, helps, 
in condensation and determination of the reaction time. 
 
SYNTHETIC ASPECT 
4-Thiazolidinones are synthesized either by cyclization of acyclic compounds 
or by interconversion among appropriately substituted thiazolidinone derivatives. 
α-Mercapto alkanoic acids have been extensively used for the synthesis of 
4-thiazolidinones. 
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R1 = Aryl or Heterocyclic
R2 = H or Alkyl
R3 = H or Alkyl
R2,R3 = Arylidene
 
 
The substituted α-mercapto alkanoic acid reacts conveniently with schiffs 
bases to give a variety of 2-substituted-4-thiazolidinones.284-286  
THERAPEUTIC IMPORTANCE 
The 4-Thiazolidinones' subsituted at 2- and 3-position showed a wide variety of 
biologically activity. The frequent ocurrence of group - NH - CS - NH - or its 
tautomer in compounds possess and evaluated in vitro tuberculostatic activity by 
E. Frolich et al.287
1.   Analgesic288 
2.  Antibacterial2 89 ,2 90 
3.   Antidiabetic291 
4.  An t i funga l 2 9 2 - 2 9 4  
5.   Anti HIV and anti cancer295 
6.   Anti microbial2 96 , 297 
7.   Ant iulcer2 9 8 , 2 9 9  
8.   Anti tumor300 
9.   Anti tubuercular301 ,302 
10.  Anti viral303 
11.  Anthelmintics304,305 
12.  Cardiovascular306 
13.  Herbicidal307 
14.  Hypnotic308-310 
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15.  Insectidal311 
16.  Mosquito repellent312 
17.  Local anaesthetic313
K. Mogliaiah and Co-workers314,315 isolated some 4-thiazolidinones 
derivativies and tested their antibacterial activity. H. Y. Hassan et. al.316 has 
prepared 2-amino-4-thiazolidinones which have been found to possess 
antimicrobial activity. G. S. Gadaginamath et.al.317 also prepared thiazolidinones 
derivatives, as antimicrobial agent.  
R. S. Lodhi and co-workers3 18 have been synthesized and studied 
antimicrobial, anti-inflammatory and analgesic activity of 4-thiazolidinone and 
arylidene derivatives (IV). 
 
N
N
O
NH N
S
O
Z
R1
R = (Un) Substituted aryl
Z = H2
Z = CH2R2
R1 = Substituted aryl
( IV )
 
 
G. Bhawana et.  al.3 19 have been synthesized thiazolidinone 
derivatives and compared their anti-inflammatory potency, ulcerogenic liability, 
cardiovascular and CNS effect. R. P. Pawar and co-workers320 reported synthesis and 
in vitro antibacterial activity of some 4-thiazolidinone derivatives. In 
other study, some thiazolidinone derivatives have been found to be promising 
antibacterial agent.321 A. J. Baxi et. al.322 have been synthesized 4-thiazolidinone 
derivatives and also evaluated antimicrobial activity. 
Morever, Albuquerque and co-workers323 have prepared 4-thiazolidinones 
which show antidiabetic and antiinflammatory activity. Tagami and co-worker324 have 
synthesized 4-thiazolidinone derivatives as allergy inhibitor. M. Siddique et. al.325 
have prepared substituted thiazolidinones and reported their antibacterial, 
antifungal, antithyroid and amoebicidal properties(V). 
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H. H. Parekh and et. al.326 have been synthesized some new thiazolidinones as 
antimicrobial agent (VI). 
NCH3 Cl
N
S
CH3
O
R
( VI ) R=Aryl
 
 
H. S. Joshi et. al.327 have synthesis microwave assited 4-thiazolidinones 
and reported as biological active agent.  
K. R. Desai et.al.328 have been synthesized some new 4-thiazolidinones as 
antimicrobial agent (VII). 
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( VII ) R= Aryl
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R. K. Rawal et al.329 have reported a series of compounds bearing isothiourea 
or thiourea functional group and have shown high anti-HIV-1 activity. Furthermore, a 
series of  2-aryl-3-heteroaryl-1,3-thiazolidine-4-ones  was  also  reported  by  this 
group( IX ).  
+
S
N
NH2
+
CHO
R
SHCH2COOH
Toluene, Reflux
N
S
N S
O
R
( IX )R=Aryl
 
 
C. J. Hobbs et. al.330 have synthesized some new N-type (Cav2.2) calcium 
channel blockers derived from the ‘hit’ structures 2-(3-bromo-4-fluorophenyl)-3-(2-
pyridin-2-ylethyl)thiazolidin-4-one and its 2-[4-(4-bromophenyl) pyridin-3-yl]-3-
isobutyl analogues( X ). 
 
N
OR Br
SHCH2COOH
Isobutylamine,
C6H6, 70 °C
N
BrN S
O
CH3
CH3
( X )
 
 
Zhong-Zheng Zhou et. al.331 have prepared a one-pot liquid-phase 
combinatorial synthesis of 2-(4-oxo-4H-1-benzopyran-3-yl)-4-thiazolidinones bearing 
diverse substituents at the 3-position under microwave irradiation using 3-formyl 
chromone, primary amine, and mercaptoacetic acid as reactants( XI ). 
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++
O
O O
H
NH2
R
Na2SO4, PTSA
MW
O
O
N
S
O
R
R=Aryl ( XI )  
 
S. V. Bhandari et .al.3 32  have been synthesized thiazolidinone 
derivatives and tested for electrocardiographic, antiarrhythmic, 
vasorelaxing and antihypertensive activity as well as for in-vitro nitric 
oxide (NO) releasing ability (VIII).  
 
N
S
N
O
R
OH
NH
CONHNHCOCH2ONO2
( VIII ) R= Substituted phenyl
 
 
In view of getting better therapeutic activities showed by 4-thiazolidinones, to 
prompted us to synthesize included piperazine molecule in 4-thiazolidinones moiety, 
which have been described as under. 
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SECTION-I : SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2 -ARYL        
-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE-1'-YL}-5-H-4-THIAZOLIDINONES.   
 
SECTION-II : SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2-ARYL 
                                -3-N-{4'-[(4'',4"'-DIFLUORODIPHENYL)-METHYL]-       
   PIPERAZINE-1'-YL}-5-METHYL-4-THIAZOLIDINONES.   
 
SECTION-III : SYNTHESIS  AND  BIOLOGICAL  SCREENING OF 2-ARYL-
3-N-{4'-[(4'',4"'-DIFLUORODIPHENYL)-METHYL]-
PIPERAZINE-1'-YL}-5-CARBOXYMETHYL-4-
THIAZOLIDINONES.   
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SECTION - I 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-
[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-H-4-
THIAZOLIDINONES.   
4-Thiazolidinone derivatives represent one of the most active classes of 
compounds possessing a wide spectrum of biological activities, such as significant in 
vitro activity against DNA and RNA viruses including polio viruses, hypnotic, 
sedative, analgesic, diuretic, antitubercular, anticonvulsant, antifungal, antibacterial, 
activity etc. These valid observations led us to synthesize some new 4-thiazolidinone 
derivatives.  2 - Aryl - 3 - N - {4'-[(4", 4'''- difluorodiphenyl) - methyl] - piperazine-1'-
yl}-5-H -4-thiazolidinones of Type (IX) have been synthesized by the 
heterocyclization of Schiff’s bases of 1-N-arylideneamino-4-[(4',4"-difluoro 
diphenyl)-methyl]-piperazines of  Type (VII) with thioglycolic acid. 
 
 
 
Type-IX R=Aryl
N
F
F
N N
S
O
R
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR   SPECTRAL  STUDY  OF  2 -(4''''- METHOXYPHENYL)-3-N-{4'-[(4",4'''-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-H-4-
THIAZOLIDINONE.   
 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
Frequency in cm-1Type Vibretion 
 
mode 
Observed Reported 
Ref. 
C-H str.(asym.) 2947 2990-2850 474 
C-H str. (sym.) 2885 2880-2860 " 
C-H def. (asym. 1446 1470-1430 " Alkane 
C-H def. (sym.) 1377 1395-1370 " 
Alkene -CH2 str. 2812 2850-1790 " 
C-H  str. 3045 3090-3030 " 
C=C str 1519 1600-1450 " Aromatic 
C-H i.p. (def.) 1197 1300-1100 " 
Halide C-F str. 779 800-600 475 
Piperazine C-N str. 1327 1360-1310 " 
Ether C-O-C str. 1274 1280-1200 " 
C-N str. 1047 1220-1020 " 
C=O str. 1677 1710-1650 " Thiazolidinone 
C-S-C str. 713 750-600 " 
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Internal Standard: TMS; Solvent: CDCl
 
NMR  SPECTRAL STUDY OF  2 -(4''''-METHOXYPHENYL)-3-N-{4'-[(4",4'''-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-H-4-
THIAZOLIDINONE.   
 
3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.49-2.57 4H doublet     C-H (gg’) 
2 2.61-2.66 4H doublet     C-H (ff’) 
3 2.85-2.95 1H quartet     Ar-H (e’) 
4 3.26-3.44 1H quartet     Ar-H (e) 
5 3.82 3H singlet     Ar-OCH3 (a) 
6 5.00 1H singlet     C-H (h) 
7 5.90 1H singlet     Ar-H (d) 
8 6.85-6.87 2H doublet     Ar-H (bb’) 
9 7.00-7.10 4H ddoublet     Ar-H (ii’, ll’) 
10 7.26-7.28 2H doublet     Ar-H (cc’) 
11 7.47-7.53 4H ddoublet     Ar-H (jj’, kk’) 
N
F
F
N N
S
O
H
H
OCH3
a
b
b'
c
c'
d
e
e'
f
f'
g
g'
h
i
i'
j
j'
k
k'l
l'
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MASS  SPECTRAL  STUDY OF  2 -(4''''-METHOXYPHENYL)-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-
1'-YL}-5-H-4-THIAZOLIDINONE.   
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MASS   FRAGEMENT   STUDY   OF   2 - (4''''- METHOXYPHENYL) - 3 - N - {4' - [(4", 4'''- DIFLUORODIPHENYL) - METHYL] -
PIPERAZINE-1'-YL}-5-H-4-THIAZOLIDINONE.   
 
O
C H 3
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m/z = 495
m/z = 303
m/z = 288
m/z = 137
m/z = 275
m/z = 86
m/z = 96
m/z = 204
m/z = 194 m/z = 103
m/z = 187
m/z = 401
m/z = 459
m/z = 317
m/z = 219
m/z = 329m/z = 280
m/z = 108
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REACTION SCHEME
 
 
F
N NH
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NaNO2 
F
N N N
F
O
LiAlH4
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N N NH2
F
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N N N
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0-5 0C
+ HCl
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Con.H2SO4
N
F
F
N N
S
O
R
HSCH2COOH
                                                                              Type - IX           R = Aryl 
                                                                                                                                    147 
                                                                                  
                                                                                                               Studies on 4-Thiazolidinones  
                                                                                                                                    148 
EXPERIMENTAL 
-METHYL]-PIPERAZINE-1'-YL}-5-H-4-
HIAZOLIDINONES.   
A] iphenyl)-methyl]-piperazine: 
]      iphenyl)-methyl]-piperazine: 
ylidene)-amino]-4-[(4',4"-difluoro 
    
]      
 
 dried and recrystallized from absolute 
l
N3F2S; Required: C: 65.44; H: 5.95; N: 8.48; Found : C:65.40; H: 5.92; N: 
45 %). 
  
-thiazolidinones were prepared. The physical constants are 
recorde  in Table No-9. 
]  uorodiphenyl)-   
 
 
no-40. The zones of inhibition of test solution are recorded in Graphical Chart No-9.  
 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-
[(4",4'''-DIFLUORODIPHENYL)
T
 
[ Synthesis of 1-nitroso-4-[(4',4"-difluorod
 See, Part-I, Section-II (A), on page no-52 
[B  Synthesis of 1-amino-4-[(4',4"-difluorod
 See, Part-I, Section-II (B), on page no-52 
[C]  Synthesis of 1-N-[(4'''-methoxybenz
 diphenyl)-methyl]-piperazine: 
              See, Part-IV, Section-I (C), on page no-120 
[D       Synthesis of 2 -(4''''-methoxyphenyl)-3-N-{4'-[(4",4'''-difluoro  
      diphenyl)-methyl]-piperazine-1'-yl}-5-H-4-thiazolidinone(9e):   
A mixture of  1 - N -[(4'''- methoxybenzylidene)- amino] - 4 - [(4',4"- difluoro 
diphenyl)-methyl]-piperazine (4.21gm, 0.01M) in benzene (25 ml) was taken, Dean 
stark apparatus was attached to it and  thioglycolic acid (0.92 gm, 0.01M) in benzene 
was added slowly. Then it was refluxed for 15 hrs, during the course of the reaction 
the water was removed continuously. The benzene was distilled off to get the 
thiazolidinones. The solid product was filtered,
alcoho . Yield: 82 %, M.P.176oC.  
(C27H27O2
8.
Similarly, other 4
d
 
[E      Biological Screening of 2 -aryl-3-N-{4'-[(4",4'''-difl
     methyl]-piperazine-1'-yl}-5-H-4-thiazolidinones:   
Biological Screening were carried out as described in Part-I, Section-1 page
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TABLE NO - 9 :  PHYSICAL  CONSTANTS  OF   2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-     
        YL}-5-H-4-THIAZOLIDINONES.   
 
%of Nitrogen 
 M.P. Yield Molecular Formula Sr. No. R M.W. 0C % 
Calcd. Found. 
9a C H6 5 - C26H25ON F S 465 142 65.15 9.03 9.00 3 2
9b 2-OH-C H - C6 4 26H25O N F S 481 117 69.47 8.73 8.69 2 3 2
9c 4-OH-C H - C6 4 26H25O N F S 481 179 61.32 8.73 8.69 2 3 2
9d 2-OCH -C H3 6 4 - C27H27O N F S 495 135 70.25 8.48 8.45 2 3 2
9e 4-OCH -C H3 6 4 - C27H27O N F S 495 176 82.00 8.48 8.45 2 3 2
9f 2-Cl-C6H - C4  26H24ON F SCl 500 162 72.85 8.40 8.36 3 2
9g 4-F-C6H - C4  26H24ON F S 483 108 64.36 8.69 8.66 3 3
9h 2-NO -C H2 6 4 - C26H24O N F S 510 127 78.88 10.97 10.95 3 4 2
9i 3-NO -C H2 6 4 - C26H24O N F S 510 134 76.48 10.97 10.95 3 4 2
9j C H O4 3  - C24H23O N F S 455 182 69.51 9.22 9.18 2 3 2
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GRAPHICAL CHART NO - 9 : BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL] -
            PIPERAZINE-1'-YL}-5-H-4-THIAZOLIDINONES.   
0
5
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m
m
B.subtillis 21 15 20 23 17 24 14 22 17 23 23 22 24 0
B.cerus 16 22 14 21 14 23 20 15 22 17 22 23 21 0
E .coli 18 21 16 23 19 17 20 19 22 16 21 21 23 0
E .aerogen 19 13 18 15 20 16 22 14 21 15 19 20 22 0
A.niger 17 22 18 20 23 19 15 18 22 21 0 0 0 23
9a 9b 9c 9d 9e 9f 9g 9h 9i 9j Ampicillin Chloramp
henicol
Norfloxaci
n
Greseoful
vin
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Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
 
PART-V 
 
SECTION - I :  BIOLOGICAL  SCREENING  STUDY  OF   2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]- 
     PIPERAZINE-1'-YL}-5-H-4-THIAZOLIDINONES COMPARE WITH KNOWN STANDARD DRUGS. 
 
                                                                                              Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                        
                                                        9a-(21)                 9b-(22)                      9b-(21)                 9a-(19)    9b-(22)  
 9c-(20)                 9d-(21) 9d-(23)      9c-(18)                          9e-(23) 
 9d-(23) 9f-(23) 9g-(20)  9e-(20)     9i-(22) 
 9f-(24) 9g-(20) 9i-(22)  9g-(22)     9j-(21) 
 9h-(22) 9i(22)  9i-(21) 
 9j-(23) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
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SECTION - II 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-
[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-
METHYL-4-THIAZOLIDINONES.   
4-Thiazolidinone derivatives represent one of the most active classes of 
compounds possessing a wide spectrum of biological activities, such as significant in 
vitro activity against DNA and RNA viruses including polio viruses, hypnotic, 
sedative, analgesic, diuretic, antitubercular, anticonvulsant, antifungal, antibacterial, 
activity etc. These valid observations led us to synthesize some new 4-thiazolidinone 
derivatives. 2-Aryl-3-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]- piperazine-1'-yl}-5-
methyl - 4 -thiazolidinones of Type (X) have been synthesized by the 
heterocyclization of Schiff’s bases of 1-N-arylideneamino-4-[(4',4"-
difluorodiphenyl)-methyl]-piperazines of  Type (VII) with thiolactic acid. 
 
 
 
Type-X R=Aryl
N
F
F
N N
S
O
R
CH3
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR   SPECTRAL  STUDY OF  2 -(4''''-METHOXYPHENYL)-3-N-{4'-[(4",4'''-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-METHYL-4-
THIAZOLIDINONE.   
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
-1Frequency in cmType Vibretion Ref. 
 
mode 
Observed Reported 
C-H str.(asym.) 2910 2990-2850 474 
C-H str. (sym.) 2879 2880-2860 " 
Alkane 
C-H def. (asym. 1442 1470-1430 " 
C-H def. (sym.) 1386 1395-1370 " 
C-H  str. 3072 3090-3030 " 
C=C str 1506 1600-1450 " 
Aromatic 
C-H i.p. (def.) 1272 1300-1100 " 
Halide C-F str. 808 800-600 475 
Piperazine C-N str. 1323 1360-1310 " 
Ether C-O-C str. 1226 1280-1200 " 
C-N str. 1155 1220-1020 " 
C=O str. 1652 1710-1650 " Thiazolidinone 
C-S-C str. 701 750-600 " 
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Internal Standard: TMS; Solvent: CDCl
NMR SPECTRAL STUDY OF  2 -(4''''-METHOXYPHENYL)-3-N-{4'-[(4",4'''-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-METHYL-4-
THIAZOLIDINONE.   
3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 1.36-1.38 3H doublet     Ar-CH3 (f) 
2 2.48-2.53 4H doublet     C-H (hh’) 
3 2.57-2.60 4H doublet     C-H (gg’) 
4 3.51-3.60 1H quartet     Ar-H (e) 
5 3.80 3H singlet     Ar-OCH3 (a) 
6 5.19 1H singlet     C-H (i) 
7 5.93 1H singlet     Ar-H (d) 
8 7.02-7.05 2H doublet     Ar-H (bb’) 
9 7.37-7.41 4H doublet     Ar-H (jj’, mm’) 
10 7.51-7.54 2H doublet     Ar-H (cc’) 
11 7.85-7.89 4H triplet     Ar-H (kk’, ll’) 
F
F
N N N
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MASS  SPECTRAL  STUDY OF  2 -(4''''-METHOXYPHENYL)-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-
1'-YL}-5-METHYL-4-THIAZOLIDINONE.   
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MASS  FRAGEMENT  STUDY  OF   2 - (4''''- METHOXYPHENYL) - 3 - N - {4' - [(4", 4'''- DIFLUORODIPHENYL) - METHYL] -
PIPERAZINE-1'-YL}-5-METHYL-4-THIAZOLIDINONE.   
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REACTION SCHEME 
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EXPERIMENTAL 
THYL]-PIPERAZINE-1'-YL}-5-
ETHYL-4-THIAZOLIDINONES.   
A] iphenyl)-methyl]-piperazine: 
]      iphenyl)-methyl]-piperazine: 
ylidene)-amino]-4-[(4',4"-difluoro 
    
] 
 
 dried and recrystallized from absolute 
l
N3F2S; Required: C: 65.99; H: 5.74; N: 8.25; Found : C:65.97; H: 5.71; N: 
23 %). 
  
thiazolidinones were prepared. The physical constants are 
recorde  in Table No-10. 
]  iphenyl)-   
 
 
no-40. The zones of inhibition of test solution are recorded in Graphical Chart No-10.  
 
[E      Biological Screening of 2 -aryl-3-N-{4'-[(4",4'''-difluorod
8.
alcoho . Yield: 78.03 %, M.P.116
 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-
[(4",4'''-DIFLUORODIPHENYL)-ME
M
 
[ Synthesis of 1-nitroso-4-[(4',4"-difluorod
 See, Part-I, Section-II (A), on page no-52 
[B  Synthesis of 1-amino-4-[(4',4"-difluorod
 See, Part-I, Section-II (B), on page no-52 
[C]  Synthesis of 1-N-[(4'''-methoxybenz
 diphenyl)-methyl]-piperazine: 
              See, Part-IV, Section-I (C), on page no-120 
[D       Synthesis of 2 -(4''''-methoxyphenyl)-3-N-{4'-[(4",4'''-difluoro       
      diphenyl)-methyl]-piperazine-1'-yl}-5-methyl-4-thiazolidinone(10e):   
A  mixture  of  1- N - [(4'''- methoxybenzylidene)- amino]- 4 -[(4',4"-difluoro 
diphenyl)-methyl]-piperazine (4.21gm, 0.01M) in benzene (25 ml) was taken, Dean 
stark apparatus was attached to it and  thiolactic acid (1.06 gm, 0.01M) in benzene 
was added slowly. Then it was refluxed for 15-16 hrs, during the course of the 
reaction the water was removed continuously. The benzene was distilled off to get the 
thiazolidinones. The solid product was filtered,
oC.  
(C28H29
d
     methyl]-piperazine-1'-yl}-5-methyl-4-thiazolidinones:   
Biological Screening were carried out as described in Part-I, Section-1 page
Similarly, other 4-
O2
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TABLE NO -10 : PHYSICAL  CONSTANTS  OF  2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE - 1' -
        YL}-5-METHYL-4-THIAZOLIDINONES.   
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
10a C6H5 - C27H27ON3F2S 479 122 69.54 8.76 8.74 
10b 2-OH-C6H4- C27H27O2N3F2S 495 96 70.71 8.48 8.45 
10c 4-OH-C6H4 - C27H27O2N3F2S 495 129 64.00 8.48 8.45 
10d 2-OCH3-C6H4 - C28H29O2N3F2S 509 145 77.29 8.25 8.23 
10e 4-OCH3-C6H4 - C28H29O2N3F2S 509 116 78.03 8.25 8.23 
10f 2-Cl-C6H4  - C27H26ON3F2SCl 514 132 82.85 8.17 8.13 
10g 4-F-C6H4  - C27H26ON3F3S 497 158 74.69 8.44 8.40 
10h 2-NO2-C6H4 - C27H26O3N4F2S 524 141 71.52 10.68 10.65 
10i 3-NO2-C6H4 - C27H26O3N4F2S 524 134 74.35 10.68 10.65 
10j C4H3O - C25H25O2N3F2S 469 122 67.43 8.95 8.92 
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GRAPHICAL CHART NO - 10 : BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL] -        
  PIPERAZINE-1'-YL}-5-METHYL-4-THIAZOLIDINONES.   
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PART-V 
 
SECTION - II : BIOLOGICAL  SCREENING  STUDY OF  2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL] - 
      PIPERAZINE-1'-YL}-5-METHYL-4-THIAZOLIDINONE COMPARE WITH KNOWN STANDARD DRUGS.  
  
 
 
 
 
 
  10f-(22) 10e-(20) 10e-(23) 10d-(19) 10h-(21) 
 10e-(21) 10d-(23)  10d-(23) 10c-(20) 10e-(23) 
 
 
  10j-(22) 10j-(19) 
 
 
 
 
 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
                                                                                              Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                        
                                                       10b-(22)                10b-(22)                   10a-(21)              10b-(19)         10b-(22) 
 10h-(23) 10f-(22) 10g-(20) 10f-(22) 
 10i-(22) 10h-(21) 10i-(22) 10h-(20) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
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SECTION - III 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-
[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-
CARBOXYMETHYL-4-THIAZOLIDINONES.   
4-Thiazolidinone derivatives represent one of the most active classes of 
compounds possessing a wide spectrum of biological activities, such as significant in 
vitro activity against DNA and RNA viruses including polio viruses, hypnotic, 
sedative, analgesic, diuretic, antitubercular, anticonvulsant, antifungal, antibacterial, 
activity etc. These valid observations led us to synthesize some new 4-thiazolidinone 
derivatives. 2 - Aryl - 3 -N-{4'-[(4",4'''- difluorodiphenyl)- methyl]- piperazine-1'-yl}-
5-carboxy methyl-4-thiazolidinones of Type (XI) have been synthesized by the 
heterocyclization of  Schiff’s  bases of  1 - N - arylideneamino - 4 -[(4', 4"- 
difluorodiphenyl)- methyl] -piperazines of  Type (VII) with thiomalic acid. 
 
 
 
Type-XI R=ArylType-XI R=Aryl
N
F
F
N N
S
O
R
COOH
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR   SPECTRAL  STUDY  OF  2 -(4''''- METHOXYPHENYL)-3-N-{4'-[(4", 4'''-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-CARBOXY 
METHYL-4-THIAZOLIDINONE.  
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
-1Frequency in cmType Vibretion Ref. 
 
mode 
Observed Reported 
C-H str.(asym.) 2910 2990-2850 474 
C-H str. (sym.) 2857 2880-2860 " 
C-H def. (asym. 1454 1470-1430 " Alkane 
C-H def. (sym.) 1396 1395-1370 " 
Alkene -CH  str. 2522 2850-1790 " 2
C-H  str. 3085 3090-3030 " 
C=C str 1496 1600-1450 " Aromatic 
C-H i.p. (def.) 1161 1300-1100 " 
Halide C-F str. 759 800-600 475 
Piperazine C-N str. 1361 1360-1310 " 
Ether C-O-C str. 1197 1280-1200 " 
C-N str. 1080 1220-1020 " 
C=O str. 1705 1710-1650 " Thiazolidinone 
C-S-C str. 702 750-600 " 
Carboxylic acid O-H (brod) 3330 3400-3200 " 
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NMR SPECTRAL STUDY OF  2 -(4''''-METHOXYPHENYL)-3-N-{4'-[(4", 4'''-
DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-5-CARBOXY 
METHYL-4-THIAZOLIDINONE.   
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
 
Signal 
No. 
Signal Position
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.44-2.51 8H ddoublet     C-H (h) 
2 2.61-2.64 1H triplet     C-H (f) 
3 2.99-3.12 1H triplet     C-H (f’) 
4 3.72 3H singlet     Ar-OCH3 (a) 
5 3.90-4.10 1H quartet     Ar-H (e) 
6 5.06 1H singlet     C-H (i) 
7 5.85 1H singlet     Ar-H (d) 
8 6.95-6.99 2H doublet     Ar-H (bb’) 
9 7.05-7.24 4H doublet     Ar-H (jj’, mm’) 
10 7.27-7.29 2H doublet     Ar-H (cc’) 
11 7.35-7.46 4H doublet     Ar-H (kk’, ll’) 
12 11.10 1H singlet     -COOH (g) 
F
F
N N N
S
O
OCH3
COOHH
H
a
b
b'
c
c'
d
f
f' g
h
h
h
h
i
j
j'
k
k'
l
l'm
m'
e
        
 
 
 
 
                                                                                                                                                                                                                        Studies on 4-Thiazolidinones 
MASS  SPECTRAL  STUDY  OF  2-(4''''-METHOXYPHENYL)-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-
1'-YL}-5-CARBOXYMETHYL-4-THIAZOLIDINONE.   
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MASS   FRAGEMENT   STUDY   OF   2 - (4'''' - METHOXYPHENYL) - 3 - N - {4' - [(4", 4'''- DIFLUORODIPHENYL) - METHYL] -
PIPERAZINE-1'-YL}-5-CARBOXYMETHYL-4-THIAZOLIDINONE.   
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REACTION SCHEME 
F
N NH
F
NaNO2 
F
N N N
F
O
LiAlH4
F
N N NH2
F
F
N N N
F
R
0-5 0C
+ HCl
R-CHO
Con.H2SO4
SH CH COOH
H2C COOH N
F
F
N N
S
O
R
HOOC
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EXPERIMENTAL 
NE-1'-YL}-5-
ARBOXYMETHYL-4-THIAZOLIDINONES.   
A] iphenyl)-methyl]-piperazine: 
]      iphenyl)-methyl]-piperazine: 
ylidene)-amino]-4-[(4',4"-difluoro 
    
]   
ine-1'-yl}-5-carboxymethyl-4-                
 
 dried and recrystallized from absolute 
N3F2S; Required: C: 62.92; H: 5.28; N: 7.59; Found : C:62.89; H: 5.25; N: 
56 %). 
  
thiazolidinones were prepared. The physical constants are 
recorde  in Table No-11. 
]   
 
 
no-40. The zones of inhibition of test solution are recorded in Graphical Chart No-11.  
 
[E      Biological Screening of 2 -aryl-3-N-{4'-[(4",4'''-difluorodiphenyl)-  
7.
alcohol. Yield: 84.50 %, M.P.137
 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-
[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZI
C
 
[ Synthesis of 1-nitroso-4-[(4',4"-difluorod
 See, Part-I, Section-II (A), on page no-52 
[B  Synthesis of 1-amino-4-[(4',4"-difluorod
 See, Part-I, Section-II (B), on page no-52 
[C]  Synthesis of 1-N-[(4'''-methoxybenz
 diphenyl)-methyl]-piperazine: 
              See, Part-IV, Section-I (C), on page no-120 
[D       Synthesis of 2 -(4''''-methoxyphenyl)-3-N-{4'-[(4",4'''-difluoro     
       diphenyl)-methyl]-piperaz
      thiazolidinone(11e):   
A  mixture  of  1- N -[(4'''- methoxybenzylidene)- amino]- 4 -[(4', 4"- difluoro 
diphenyl)-methyl]-piperazine (4.21gm, 0.01M) in benzene (25 ml) was taken, Dean 
stark apparatus was attached to it and  thiomalic acid (1.50 gm, 0.01M) in benzene 
was added slowly. Then it was refluxed for 15-16 hrs, during the course of the 
reaction the water was removed continuously. The benzene was distilled off to get the 
thiazolidinones. The solid product was filtered,
oC.  
(C29H29
d
     methyl]-piperazine-1'-yl}-5-carboxymethyl-4-thiazolidinones:   
Biological Screening were carried out as described in Part-I, Section-1 page
Similarly, other 4-
O4
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TABLE NO - 11 : PHYSICAL  CONSTANTS  OF  2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE - 1' -
         YL}-5-CARBOXYMETHYL-4-THIAZOLIDINONES.   
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
11a C6H5 - C28H27O3N3F2S 523 114 67.42 8.03 8.00 
11b 2-OH-C6H4- C28H27O4N3F2S 539 127 74.63 7.79 7.76 
11c 4-OH-C6H4 - C28H27O4N3F2S 539 148 68.10 7.79 7.76 
11d 2-OCH3-C6H4 - C29H29O4N3F2S 553 175 74.00 7.59 7.56 
11e 4-OCH3-C6H4 - C29H29O4N3F2S 553 137 84.50 7.59 7.56 
11f 2-Cl-C6H4  - C28H26O3N3F2SCl 558 161 72.89 7.53 7.50 
11g 4-F-C6H4  - C28H26O3N3F3S 541 192 69.71 7.76 7.72 
11h 2-NO2-C6H4 - C28H26O5N4F2S 568 187 75.32 9.85 9.81 
11i 3-NO2-C6H4 - C28H26O5N4F2S 568 153 72.87 9.85 9.81 
11j C4H3O - C26H25O4N3F2S 513 136 68.23 8.18 8.15 
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GRAPHICAL CHART NO - 11 : BIOLOGICAL  SCREENING  OF  2 -ARYL-3-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL] -
              PIPERAZINE-1'-YL}-5-CARBOXYMETHYL-4-THIAZOLIDINONES.   
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PART-V 
 
SECTION - III :  BIOLOGICAL  SCREENING  STUDY  OF  2 - ARYL - 3 - N -{4'-[(4", 4'''- DIFLUORODIPHENYL) - METHYL] -
        PIPERAZINE-1'-YL}-5-CARBOXYMETHYL-4-THIAZOLIDINONES.   
 
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
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    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger  
                                                                                                                                                                                         
                                                        11b-(22)              11b-(22)                      11a-(20)               11b-(19)           11c-(22) 
  11d-(21) 11d-(21)   11c-(23) 11d-(20) 11e-(23)  
  11f-(24) 11f-(22)  11f-(22) 11f-(22) 11f-(21) 
  11h-(23) 11h-(23)  11g-(20) 11h-(18) 11h-(22) 
 
 11i-(22) 11i-(20)   11j-(22) 11j-(19) 11i-(21)  
  
 Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   --  
 Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23   
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STUDIES ON 2-AZETIDINONES  
 
INTRODUCTION  
Azetidin-2-one, also called β-Lactam, is a four member cyclic amide which 
was first synthesized by Staudinger in 1907.333 Because of the discovery of penicillin 
in 1928 by Fleming and its structural confirmation by X-ray crystallography,334 the 
bioactivity of β-lactam compounds has been investigated intensively.335 Before 1970, 
penicillin and cephalosporins were the antibiotics that attracted most synthetic effort. 
The four membered β-lactam (2-azetidinone) ring systems (I) has for many years 
been of great practical significance as the centre of reactivity of penicillins (II) and 
Cephalosporin (III). 
 
NH
O
R
O
NH
N
S
O
CH3CH3
COOK
O
NH
O
R
COOH
OCH3( I ) ( II ) ( III )  
 
 
P. G. Summes336 have been synthesized of simple β-lactams for testing as 
antibiotics, anti-depressants, sedatives etc. J. C. Sheeham et. al.337 have been synthesis 
and extensively studied of 2-azitidinone derivatives. 2-azetidinone derivatives have 
been synthesis by different methods cited in literature.338-347 A.J. Baxi et. al.348 have 
been synthesized 2-azetidinone derivatives and also evaluted antimicrobial 
screening. 
 
MECHANISM 
Synthesis of β-lactam of the addition of  C - N and C = O component to form 
a ring substituted acetyl chloride with electron withdrawing substituents and atleast 
one hydrogen at α-carbon add to imines in the presence of amine bases.349 The 
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mechanism take place by non-concerted cycloaddition reaction as depicted in following 
scheme (IV). 
( IV )
 
The reaction may be experimented in many cases by treating a mixture of 
the  imine  and  dichloroacete ac id  wi th  P O C l 3  o r  P O B r 3 .350,351 I t  has  
been  observed that the acid chloride is formed as an intermediate through the 
phosphorus halide participate as an electrophillic catalyst as shown in following scheme 
(V). 
( V )
 
Cyclo addition of diphenylketone to a performed imine352 also forms 
β-lactam. 
 
THERAPEUTIC IMPORTANCE 
β-Lactam drugs are still the most widely described antibiotics in medicine.353 
2-Azetidinone derivatives possess wide therapeutic activity viz. sedative, 
hypnotics, anticonvulsant,354 herbicidal and antibacterial.355 They are also 
effective on the central nervous system.356 A large number of 3-chloro monocyclic β-
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lactams have been prepared by cyclo addition of β,β-disubstituted enamines with aryl 
isothiocyanates which possess a powerful antibacterial activity.357 
 J. Goto et. al.358 have been synthesized a series of 7-β-(2-amino pyrimidinyl)-
2-oxyimino acetamido-cephalosporins as useful antibiotics. Penicillins of type (VI) 
and there corresponding penicillins gave antibacterial activity. 
 
 
N
NH
O
R
O
S CH3
CH3
COONa
( VI )
 
 
Several alkyl, alkenyl, alkonyl, 2-azetidinones359 and 3-alkyl-4-halomethyl/ 
arylmethyl-2-azetidinones useful as intermediates for antibioties360 have been 
reported 4-(trifluoromethyl)-2-azetidinone derivatives361,362 were prepared as 
intermediates for antibiotics. 
M. Sendai and co-workers363 have prepared 2-azetidinones of type (VII) to 
prove the antibacterial activity of sulfazecins out of them when R =-CH3,    
-CH2COOH and R1 = -CONH2 showed potent antibacterial activity comparable 
against Gram positive and Gram negative bacteria. 
 
 
R= -CH3, -CH2COOH
R1= -CONH2, -CONHNH2
( VII )
S
N
NH2
NO
R
O
NH
N
O SO3H
R1
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2 -Azetidinone derivatives have been reported as antiparkinson, antibacterial 
and antifungal,3 6 4 - 3 7 1  antiinflammatory,3 7 2 - 3 7 4  hypochloresterolimic3 7 5  
and antimicrobial agents.376
 
V. Jayamma and co-workers377 have prepared some new derivatives of 2- 
azetidinones and tested their antimicrobial activity. S. Giri et. al.378 have 
synthesized some 1-[5'-aryl-1',3',4'-thiadiazol-2'-yl]-3-chloro-4-substituted 2 - 
azetidinones as potential fungicides. 
 
Morever, Saito et. al.379 have synthesized some new 2-azetidinones as a 
carbapenem antibiotics. V. H. Shah et. al.380 have reported 2-azetidinones 
derivatives as antimicrobial and antitubercular agents. A. K. Khalafallah et.al.381 
have assessed some new azetidinone derivatives for their antimicrobial activity. Several 
co-workers have prepared some new 2-azetidinones and reported their anti-
inflammatory activity.382
 
R. H. Udupi et. al.383 synthesized 2-azetidinones which shows good 
antiinflammatory, antitubercular, bactericidal and fungicidal activity. Wayne D. 
Vaccaro and Co-workers384 prepared some novel azetidinone derivatives as 
cholesterol absorption inhibitors, Brain A. Mckittrick and co-workers385 have 
prepared some new azetidinones display potent cholestorl absorption inhibitory activity. 
 
Ishwar K. Bhat et. al.386 have been synthesized some 2-azetidinones as 
antibacterial and antifungal agent (VIII). 
 
                  
H3CO
NH
CH2
C
O
NH
N
O
Cl
R
R=Substituted phenyl ( VIII )  
 
K. H. Patel and A. G. Mehta387 have been synthesized some novel 2-
azetidinones as antibacterial activity (IX). 
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S
N N
O
Cl
R
R=Substituted phenyl ( IX )
 
 
S. J. Wadher et. al.388 have been synthesized some  2-azetidinones display 
potent as antibacterial and antifungal activity (X). 
 
N
O
Cl
R
S
O
O
N
O
Cl
R
R= Substituted phenyl ( X )
 
 
S. Jubie et. al.389 have been synthesized some  2-azetidinone derivatives showed 
potent antibacterial activity comparable against Gram positive and Gram negative 
bacteria and antifungal activity (XI). 
 
                        
H3CO N
O
Cl
R
R= Substituted phenyl ( XI )
 
 
Sudhir Kumar Bhati and Ashok Kumar390 have been synthesized some new 2-
azetidinones evaluated for their anti-inflammatory, analgesic, ulcerogenic activities and 
toxicity studies (XII). 
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C
N N
C
S
N
N N
S
NH
CH2
N
O
Cl
R
R= Aryl ( XII )
 
 
Ivan Plantan et. al.391 have been synthesized as a stereoselective compounds of 
(1'S, 3R, 4R)-4-acetoxy-3-(2'-fluoro-1'-trimethylsilyloxyethyl)-2-azetidinone as a new 
fluorine-containing intermediate towards β-lactams is described (XIII). 
     
                          
NH
F
O
HTMSO OAC
( XIII )
. 
 
 Thus, in search of a more potential therapeutic agent by incorporating 
azetidinone moiety in piperazine nucleus, it was contemplated to synthesis β-lactam 
of type (XII) by the condensation of chloro acetyl chloride with Schiff's bases in 
presence of triethyl amine which has been described as under.    
 
SECTION-I : SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  1-N-{4'-
[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-
YL}-4-ARYL-3-CHLORO-2-AZETIDINONES.   
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SECTION - I 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  1 - N - {4' - [(4", 4''' -
DIFLUORODIPHENYL) - METHYL] - PIPERAZINE -1'-YL} - 4 - ARYL - 3 -
CHLORO - 2 - AZETIDINONES.   
2-Azetidinone derivatives represent one of the most active classes of 
compounds possessing a wide spectrum of biological activity such as powerful 
antibiotic activity shown by monocyclic β-lactams, antidepressants, sedative, 
hypnotics, anticonvulsant, antiviral etc. In view of getting to synthesized 2-
azetidinone derivatives of 1-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]-piperazine-1'-
yl}-4-aryl-3-chloro-2-azetidinones of Type (XII) have been under taken by the chemo 
selective cyclization of Schiff's bases of 1-N-arylideneamino-4-[(4',4"-difluoro 
diphenyl)-methyl]-piperazines of Type (VII) with chloro acetyl chloride in the 
presence of triethyl amine as a basic catalyst. 
 
 
 
Type-XII R=Aryl
N
F
F
N N
O
Cl
R
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR   SPECTRAL  STUDY  OF   1 - N - {4' - [(4", 4'''- DIFLUORODIPHENYL) - 
METHYL]-PIPERAZINE-1'-YL}-4-(4''''-METHOXYPHENYL)-3-CHLORO-2-
AZETIDINONE.   
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
Frequency in cm-1Type Vibretion 
 
mode 
Observed Reported 
Ref. 
C-H str.(asym.) 2979 2990-2850 474 
C-H str. (sym.) 2889 2880-2860 " 
C-H def. (asym. 1444 1470-1430 " Alkane 
C-H def. (sym.) 1371 1395-1370 " 
C-H  str. 3051 3090-3030 " 
C=C str 1568 1600-1450 " Aromatic 
C-H i.p. (def.) 1282 1300-1100 " 
Halide C-F str. 773 800-600 475 
Piperazine C-N str. 1359 1360-1310 " 
Ether C-O-C str. 1265 1280-1200 " 
C-N str. 1172 1220-1020 " 
Azetidinone C=O str. 1633 1710-1650 " 
Halide C-Cl str. 742 800-600 " 
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Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
NMR  SPECTRAL  STUDY  OF  1 - N - {4' -[(4", 4'''- DIFLUORODIPHENYL)- 
METHYL]-PIPERAZINE-1'-YL} - 4 -(4''''-METHOXYPHENYL)-3-CHLORO-
2-AZETIDINONE.   
Signal 
No. 
Signal Position
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.49-2.55 4H doublet     C-H (gg’) 
2 2.56-2.58 4H doublet     C-H (ff’) 
3 3.71 3H singlet     Ar-OCH3 (a) 
4 4.89-4.91 1H doublet     Ar-H (e) 
5 5.02 1H singlet     C-H (h) 
6 5.34-5.37 1H doublet     Ar-H (d) 
7 6.47-6.49 2H doublet     Ar-H (bb') 
8 6.77-6.86 2H triplet     Ar-H (ii’) 
9 6.90 2H singlet     Ar-H (ll’) 
10 6.99-7.03 2H doublet     Ar-H (jj’) 
11 7.26-7.28 2H doublet     Ar-H (kk’) 
12 7.29-7.33 2H doublet     Ar-H (cc’) 
F
F
N N N
O
C l
O
C H 3
a
b b'
c c'
d
e
f
f'
g
g'
h
i
i'
j
j'
k
k'l
l'
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MASS  SPECTRAL  STUDY  OF  1-N- {4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE -1'-YL} - 4 -(4''''-METHOXY 
PHENYL)-3-CHLORO-2-AZETIDINONE.  
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MASS  FRAGEMENT  STUDY  OF  1-N-{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-4-(4''''-METHOXY 
PHENYL)-3-CHLORO-2-AZETIDINONE.   
 
  
 
 
                                                                
                                                                                                                                                                                         
                                                                                                 Studies on 2-Azetidinones 
REACTION SCHEME
 
 
F
N NH
F
NaNO2 
F
N N N
F
O
LiAlH4
F
N N NH2
F
F
N N N
F
R
0-5 0C
+ HCl
R-CHO
Con.H2SO4
N
F
F
N N
O
Cl
R
Et3N
ClCOCH2Cl
                                                                              Type - XII           R = Aryl 
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Biological Screening were carried out as described in Part-I, Section-1 page 
no-40. The zones of inhibition of test solution are recorded in Graphical Chart No-12.  
[E]       Biological Screening of 1-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]-       
      piperazine-1'-yl}-4-aryl-3-chloro-2-azetidinones:   
Similarly, other 2-azetidinones were prepared. The physical constants are 
recorded in Table No-12. 
  
(C27H26O2N3F2Cl; Required: C: 65.12; H: 5.26; N: 8.44; Found : C:65.10; H: 5.23; N: 
8.41 %). 
A  mixture  of  1 - N -[(4'''- methoxybenzylidene)- amino]- 4 -[(4', 4"- difluoro 
diphenyl)-methyl]- piperazine (4.21gm, 0.01M) in dry dioxane (25 ml) was added to a 
well stirred mixture of chloacetylchloride (1.90 ml, 0.02M) and triethylamine (3.35 
ml, 0.024M) in dry dioxane at 0°C. The reaction mixture was then stirred for 10-15 
hrs and kept for 2 days at room temperature. The reaction mixture was then poured 
into crushed ice, filtered and washed with water. The solid product was dried and re-
crystallized from ethanol and water. Yield: 74.60 %, M.P.135oC.  
[D]       Synthesis of 1-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]-piperazine-1'-
       yl}-4-(4''''-methoxyphenyl)-3-chloro-2-azetidinone(12e):   
                  See, Part-IV, Section-I (C), on page no-120 
[C]  Synthesis of 1-N-[(4'''-methoxybenzylidene)-amino]-4-[(4',4"-difluoro 
 diphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (B), on page no-52 
[B]       Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (A), on page no-52 
[A] Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 
SYNTHESIS  AND  BIOLOGICAL  SCREENING  OF  1-N-{4'-[(4",4'''-DIFLU 
ORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-4-ARYL-3-CHLORO- 2 -
AZETIDINONES.   
 
 
EXPERIMENTALS 
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TABLE NO - 12 : PHYSICAL  CONSTANTS  OF  1 - N -{4'-[(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL} - 4 -
         ARYL-3-CHLORO- 2 -AZETIDINONES.   
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
12a C6H5 - C26H24ON3F2Cl 467 202 68.17 8.98 8.95 
12b 2-OH-C6H4- C26H24O2N3F2Cl 483 163 70.24 8.68 8.66 
12c 4-OH-C6H4 - C26H24O2N3F2Cl 483 147 63.72 8.68 8.66 
12d 2-OCH3-C6H4 - C27H26O2N3F2Cl 497 159 64.65 8.44 8.41 
12e 4-OCH3-C6H4 - C27H26O2N3F2Cl 497 135 74.60 8.44 8.41 
12f 2-Cl-C6H4  - C26H23ON3F2Cl2 502 178 73.42 8.36 8.32 
12g 4-F-C6H4  - C26H23ON3F3Cl 485 149 67.38 8.65 8.62 
12h 2-NO2-C6H4 - C26H23O3N4F2Cl 512 127 76.54 10.92 10.90 
12i 3-NO2-C6H4 - C26H23O3N4F2Cl 512 187 69.60 10.92 10.90 
12j C4H3O - C24H22O2N3F2Cl 457 169 70.00 9.18 9.15 
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GRAPHICAL CHART NO - 12 :  BIOLOGICAL  SCREENING  OF  1 - N - {4'- [(4", 4'''- DIFLUORODIPHENYL) - METHYL] - 
               PIPERAZINE-1'-YL}-4-ARYL-3-CHLORO-2-AZETIDINONES.   
0
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B.subtillis 21 14 22 17 23 12 19 24 21 20 23 22 24 0
B.cerus 14 22 19 23 15 20 16 13 21 22 22 23 21 0
E .coli 18 21 17 20 13 23 16 19 20 22 21 21 23 0
E .aerogen 20 15 18 20 16 21 14 22 15 19 19 20 22 0
A.niger 17 22 20 19 20 16 23 21 19 22 0 0 0 23
12a 12b 12c 12d 12e 12f 12g 12h 12i 12j Ampicillin Chloramp
henicol
Norfloxaci
n
Greseoful
vin
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PART-VI 
 
SECTION - I : BIOLOGICAL  SCREENING  STUDY  OF  1-N-{4'-[(4", 4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-
    YL}-4-ARYL-3-CHLORO-2-AZETIDINONES COMPARE WITH KNOWN STANDARD DRUGS.   
 
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
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                                                      12a-(21)                 12b-(22)                 12b-(21)                  12a-(20)    12b-(22) 
 
 
 12c-(22) 12d-(23) 12d-(20) 12c-(18) 12g-(23) 
 12e-(23) 12f-(20) 12f-(23) 12d-(20) 12h-(21) 
  12h-(24) 12i-(21) 12i-(20) 12f-(21) 12j-(22) 
  12i-(21) 12j-(22) 12j-(22) 12h-(22) 
 12j-(20) 12j-(19)  
Ampicillin            (50 µg)                 23                         22                              21                          19                                   --  
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   --  
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                         
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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STUDIES ON 5-OXO-IMIDAZOLINES  
 
INTRODUCTION 
The five membered heterocyclic ring system 5-oxo-imidazolines have two 
nitrogen atom at 1- and 3-positions and a carbonyl group at 5-position. 
 
NH
N
O
 (I)          
 
 
The discovery of the 2-substituted-5-imidazolines dates back to the year 1888, 
when A. W. Hoffman392 for the first time discovered 5-oxo-imidazoline by heating N-
diacetylethylene diamine in a stream of dry hydrogen chloride. Moreover, some 
compounds were prepared by A. Ladenburg393 by the fusion of two equivalents of 
sodium acetate with one equivalent of ethylene diamine dihydrochloride. 
SYNTHETIC ASPECT 
Various methods have been reported for the synthesis of imidazolinones in 
Literature.394 Aminolysis of oxazolone with amine leads to the formation of 
imidazolinones which has been reported in literature.395
1. Feng-Jun-Cai et. al.396 have been synthesized 5-imidazolinone derivatives by 
 micro-waves irradiation. 
2. A. Saxena et. al.397 have been synthesized new imidazolinones.  
 
N
O
N Ar
-
O
Cl
O
NH
NH2
Ar-
N
N
O
NH
O
Cl
 
 
3. H. A. Allimony et. al.398 have  been synthesized  new imidazolinone 
 derivatives by  conventional method. 
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MECHANISM 
In present study aromatic aldehyde were condensed with benzoyl glycine in 
presence of anhydrous sodium acetate and acetic anhydride to get azlactones / 
oxazolinones.399 
 
+R-CHO NH
O
OH
O
R'
N
O
OH
OH
R'
(CH3CO)2O
CH3COONa
N
O
R'
R
O
R = Aryl
R' = -C6H5 , -4-OCH3-C6H4
 
 
Azalactone reacts with variety of compounds such as water, alcohols, amines 
and hydrogen halides. Amides of α-acylamino acryclic acids obtained from the 
condensation of azalactone and primary amine can be converted to imidazolinones as 
shown in reaction. 
 
N
O
R
O
X
NH
O
X
R
O
NH R1
N
N
R
R1X
O
R1 NH2 POCl3
(a) (b) (c)
R' -NH2 ,Dry C5H5N / Abs.C2H5OH,K2CO3
 
 
The ring closer can be effected under a variety of conditions. Substituted 
anilides have been converted to imidazolinone derivatives by the action of POCl3. In 
order of get variety of useful pharmacological important compounds, reaction of 
azalactones have been extensively investigated with different type of compounds such 
as aromatic amines,400,401 hydrazine hydrate,402 aromatic amino acids, phenyl 
hyrdazine403 and  ammonia.     
                                                                                                                                    189 
 
                                                                                         Studies on 5-Oxo-Imidazolines 
THERAPEUTIC IMPORTANCE 
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various 
imidazolinone derivatives which have been used as adrenergic stimulants and 
tolazoline and phenotolamine as adrenergic blocking agents. Various imidazolinones 
are known to exhibit a broad spectrum of biological activities such as,   
1. Antitubercular404
2. Potent CNS depressant405,406
3. Insecticidal407
4. Antiviral408
5. Hypertensive409
6. Antiinflammatory410-412
7. Glucagon antagonists413
8. Antimicrobial414
9. Thrombin inhibitor415
10. Anticonvulsant416,417
11. Sedative and hypnotics418
12. Bactericidal419,420
13. Fungicidal421,422
14. Antiparkinson423,424
15. Anthelmintic425
16. Antihistaminic426
17. Anticancer427,428
18. Antidiabatic429 
F. C. Geoffrey et. al 430 and B. L. Pilkington et. al.431 have been synthesized 
and studied antifungal activity of imidazolinones. L. J. Peter and Co-worker432 have 
been prepared substituted imidazolinones which inhibited the abnormal cell growth in 
human body. S. Lauter and Co-worker433 have been isolated imidazoline from 
different methods and tested for the treatment of cytokine release. Imidazoline 
derivatives have been prepared by D. Erick and co-worker434 showing anti-HIV 
activity. Ding Ming-Wu et. al.435 have been  prepared  new imidazolines  and  
reported  their  antifungal  activity. 
V. Kolhe et. al.436 has reported anti-AIDS, antibacterial and fungicidal activity 
of 5-oxo-imidazolines. B. R. Shah and co-worker437 have been prepared some new 
imidazolines and reported anticancer and anti HIV activity. 
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V. Akyoshi et. al.438 have been prepared some new imidazolinone derivatives 
(II) and reported their herbicidal activity. Agrochemical activity of imidazolinones 
has been reported by J. P. Bascou and co-workers.439
R. Sharma and co-workers440 have been reported antimicrobial activity of 5-
oxo-imidazolines (III). 
 
N
O
N
N
H
NH
CH3
CH3
O
CH3
CH3
N
N
O
R1
NH
N
N
N
R3
R2 ( III )( II )
 
 
K. K. Awasthi et. al.441 (IV) have been synthesized some new imidazolinone 
derivatives and reported their antimicrobial activity. 
 
N N
R O
NH
NH
S
CH3
CH3
( IV )
 
 
CONTRIBUTION  FROM  OUR  LABORATORY 
A. R. Parikh et. al.442 have been synthesized imidazolinones bearing thiazole 
as moderately active bactericidal and fungicidal. H. H. Parekh et. al.443 have 
elaborated better activity for some imidazolinones with activated benzylidene group at 
5-position. 
D. M. Purohit et. al.444 have been synthesized 5-oxo-imidazoline (V) 
derivatives in “Fluchloralin” moiety. D. M. Purohit et. al.445,446  have been synthesized 
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5-oxo-imidazolines (VI) in “dichlorine” nucleus. D. M. Purohit et. al.447 have been  
synthesized 5-oxo-imidazolines (VII) in 2, 4-Dichloro derivatives.  
 
F3C
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R
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( VI )
 
 
V. N. Patoliya et. al.448,449 have been synthesized 5-oxo-imidazolines (VIII,IX) 
evaluated its antimicrobial activity. 
 
N
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CH3
N
N
O
N
O
N
R
( VIII ) ( IX )
 
 
A. R. Parikh et. al. have been synthesized imidazolinones bearing 
phthalazine,450 2-base of chloramphenicol451 moiety at one position which were 
evaluated for their antimicrobial activity. A. R. Parikh et. al.452 have been reported 4-
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(4'-Arylidine-2'- phenyl-5'-oxo-imidazolin-1-yl) benzophenones which were screened 
for their antimicrobial activity. Biplab De et. al.453 have been reported some new 5-
oxoimidazoline as antimicrobial agents. Imidazolinones have been reported to possess 
antioxidant activity. 
Moreover, A. R. Parikh, H. H. Parekh and co-workers have been synthesized 
the newer 5-oxo-imidazolines with different variety of activities described as under. 
1) 1-p-(4'-Acetamidobenzenesulphonamido) phenyl-2-phenyl-4 -substituted 
 benzal-5-oxoimidazolines.454 
2) Synthesis of biologically active 5-oxo-imidazolines.455-457  
3) Preparation and antimicrobial activity of 1-N-Aryl-2-methyl-4'-(8-hydroxy 
 quinolin-7'-yl)-methine-5-oxoimidazolines.458 
4) Synthesis of some 5-imidazolinones as novel bioactive compounds derived from 
 benzimidazole.459 
5) Synthesis and biological screening of 2-Chloro-8-methylquinolin-3-yl-N-(2'-
 phenyl-4'-arylidine-5'-oxo-imidazolin-1'-yl)-azomethines.460 
Moreover, Yoneda Naoto et. al.461 have been synthesized imidazolinones as 
antihypertensive agent. R. C. Dage et. al.462 have been synthesized cardiotonic 
imidazolones. Armando Rossello et. al.463 have been synthesized imidazolones as 
antifungal agent. A. B. Cooper and co-workers464 have been found that imidazolones 
are inhibitors of farnesyl protein transferase. Machii Daisuke et. al.465 have been  
synthesized new imidazolones as a telomerase inhibitors and antitumor agents M. R. 
Jean et. al.466 have been synthesized imidazolones and tested as antileishmanial agent. 
Chafiq Hamdouchi et. al.467 have been synthesized imidazolinones and screened for 
their potent and broad spectrum activity. M. L.  Irene et. al.468 have been synthesized 
imidazolinones and tested as antiretroviral activity. Xu Zhi-Feng et. al.469 have been 
synthesized imidazolinones as biological agent.  
 
Tarik El-Sayed Ali et. al.470 have been synthesized some new imidazolinone 
derivatives and reported their antifungal activity (X). 
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O
O
Cl
N
N N
O
Ar
 Ar = Substituted Phenyl ( X )
 
 
N. C. Desai et. al.471 have been synthesized some new 5-imidazolinone 
derivatives and reported their antibacterial and antifungal activity.  
Murlidhar P. Wadekar et. al.472 have been synthesized some novel 5-oxo-
imidazolines containing  azo linkages and reported their antimicrobial activity against 
gram positive and gram negative(XI). 
 
              
NN
N N
O Ar
N
OH
R
R= -Cl, -Br, -CH3, -OCH3
Ar = Substituted Phenyl ( XI )
 
 
With a view to getting better therapeutic agent, it was contemplated to 
synthesized 5-imidazolinones to enhance the overall activity of resulting compounds 
which have been described as under.  
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SECTION - I : SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-{4'- 
               [(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-
    YL}-4-ARYLIDENE-2-PHENYL-5-OXO-IMIDAZOLINES.  
 
SECTION-II : SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-{4'- 
               [(4",4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-
    YL}-4-ARYLIDENE-2-(4""-METHOXYPHENYL)-5-OXO- 
    IMIDAZOLINES.  
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SECTION:-I 
SYNTHESIS AND BIOLOGICAL SCREENING 1-N-{4'-[(4",4'''-DIFLUORO 
DIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-4-ARYLIDENE-2-PHENYL-5-
OXO-IMIDAZOLINES.  
 
5-Imidazolinones represent one of the most active classes of compounds 
having a wide spectrum of biological activities with an aim to getting better 
therapeutic agent like anticonvulsant, potent CNS depressant, anti-inflammatory, 
antimicrobial, anticancer, sedative, hypnotics and mono amino oxidase (MOA) 
inhibitors etc. In view of getting to synthesized 5-oxo-imidazoline derivatives of  1-N-
{4'-[(4",4'''-difluorodiphenyl)- methyl]- piperazine -1'-yl}-4- arylidene-2-phenyl -5-
oxo-imidazolines of Type (XIII) have been under taken by the condensation of 1-
amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine with different oxazolones. 
 
Type-XIII R=Aryl
N
F
F
N N
N
O
R
 
 
 
 
 
 
 
 
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR  SPECTRAL  STUDY  OF  1 - N - {4' - [(4", 4'''- DIFLUORODIPHENYL) -
METHYL] - PIPERAZINE - 1' - YL} - 4 - (4""- METHOXYBENZYLIDENE) -
2-PHENYL-5-OXO-IMIDAZOLINE.  
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
Frequency in cm-1Type Vibretion 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2937 2990-2850 474 
C-H str. (sym.) 2875 2880-2860 " 
C-H def. (asym.) 1443 1470-1435 " Alkane 
C-H def. (sym.) 1374 1390-1370 " 
C-H  str. 3090 3090-3030 " 
C=C str 1523 1600-1450 " Aromatic 
C-H i.p. (def.) 1197 1300-1100 " 
Halide C-F str. 785 800-600 475 
Piperazine C-N str. 1323 1360-1310 " 
Ether C-O-C str. 1274 1280-1200 " 
C-N str. 1172 1220-1020 " 
C=N str. 1575 1612-1593 " Imidazoline 
C=O str. 1687 1710-1650 " 
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NMR  SPECTRAL  STUDY  OF  1 - N - {4'-[(4", 4'''- DIFLUORODIPHENYL) -
METHYL] - PIPERAZINE - 1' - YL} - 4 - (4""- METHOXYBENZYLIDENE) - 
2 -PHENYL-5-OXO-IMIDAZOLINE.  
 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons Multiplicity Inference 
1 2.43-2.44 8H doublet C-H (gg’, hh’) 
2 3.75 3H singlet Ar-OCH3 (a) 
3 5.10 1H singlet        C-H (i) 
4 7.28-7.30 2H doublet  Ar-H (bb’) 
5 7.42-7.49 4H ddoublet    Ar-H (jj’, mm’) 
6 7.61-7.64 2H doublet     Ar-H (cc’) 
7 7.71-7.74 4H doublet     Ar-H (kk’, ll’) 
8 7.81-7.84 3H doublet     Ar-H (f) 
9 7.95-8.10 3H doublet     Ar-H (ee’)     C-H (d) 
F
F
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Biological Screening was carried out as described in Part-I, Section-I, Page 
no-40.The zone of inhibition of the test solution are recorded in Graphical Chart No-
13. 
Similarly, other 5-oxo-imidazolines have been prepared. The physical 
constants are recorded in Table No.13.      
  
 A mixture of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine (3.03gm, 
0.01M) and 4-(4'-methoxybenzylidene)-2-phenyl-5-oxazolone (2.79 gm, 0.01 M) in 
dry pyridine (20 ml) was refluxed for 12 hrs. in oil bath. Resulting mass was poured 
into crushed ice and neutralized with dil. HCl, filtered and the product was 
recrystallized from 1,4-dioxan.Yield: 65.85%, M.P.142oC. (C34H30O2N4F2 ;  Required 
: C: 72.32; H: 5.36; N: 9.92; Found : C: 72.30; H: 5.34; N: 9.90 %). 
[D]            Synthesis of 1-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]-piperazine-1'-
      yl}- 4-(4""-methoxybenzylidene)-2-phenyl-5-oxo-imidazolines(13e): 
A mixture of (benzoylamino)-acetic acid, (hippuric acid) (5.19gm, 0.029M), 
acetic anhydride (3.26gm, 0.032M), sodium acetate (2.62gm, 0.032M) and 4-methoxy 
benzaldehyde (4.35gm, 0.032 mol) was heated on a water bath for 4 hrs. Resulting 
mass poured into ice cold water, filtered and crystallized from acetone and water. 
Yield: 86%, M.P. 155oC.  
[C]       Synthesis of 4-(4'-methoxybenzylidene)-2-phenyl-5-oxazolone.  
 See, Part-I, Section-II (B), on page no-52 
[B]       Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (A), on page no-52 
[A] Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
     
SYNTHESIS AND BIOLOGICAL SCREENING 1-N-{4'-[(4", 4'''-DIFLUORO 
DIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-4-ARYLIDENE-2-PHENYL-5-
OXO-IMIDAZOLINES.  
[E]     Biological Screening of 1-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]-
 piperazine-1'-yl}-4-arylidene-2-phenyl-5-oxo-imidazolines.  
Similarly, other oxazolones have been prepared by Erlen Meyer method.473
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TABLE NO - 13 : PHYSICAL  CONSTANTS  OF  1 - N - {4'-[(4", 4'''- DIFLUORODIPHENYL)- METHYL]- PIPERAZINE -1'-YL} - 
          4 - ARYLIDENE-2-PHENYL-5-OXO-IMIDAZOLINES.  
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
13a C6H5 - C33H28ON4F2 534 134 65.00 10.48 10.45 
13b 2-OH-C6H4- C33H28O2N4F2 550 114 67.54 10.18 10.15 
13c 4-OH-C6H4 - C33H28O2N4F2 550 104 72.32 10.18 10.15 
13d 2-OCH3-C6H4 - C34H30O2N4F2 564 137 75.51 9.92 9.90 
13e 4-OCH3-C6H4 - C34H30O2N4F2 564 142 65.85 9.92 9.90 
13f 2-Cl-C6H4  - C33H27ON4F2Cl 569 162 69.24 9.85 9.83 
13g 4-F-C6H4  - C33H27ON4F3 552 113 63.25 10.14 10.12 
13h 2-NO2-C6H4 - C33H27O3N5F2 579 154 59.63 12.08 12.05 
13i 3-NO2-C6H4 - C33H27O3N5F2 579 140 57.87 12.08 12.05 
13j C4H3O - C31H26O2N4F2 524 127 69.70 10.68 10.65 
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GRAPHICAL CHART NO - 13 :  BIOLOGICAL  SCREENING  OF  1 - N - {4'-[(4", 4'''- DIFLUORODIPHENYL) - METHYL] - 
              PIPERAZINE-1'-YL}-4-ARYLIDENE-2-PHENYL-5-OXO-IMIDAZOLINES. 
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PART-VII 
 
SECTION - I : BIOLOGICAL  SCREENING  STUDY  OF  1-N-{4'-[(4", 4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-
     YL}-4-ARYLIDENE-2-PHENYL-5-OXO-IMIDAZOLINES COMPARE WITH KNOWN STANDARD DRUGS .  
 
 
 
                                                                                              Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
                                                                   
    Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                        
                                                       13a-(22)              13b-(21)                    13b-(20)               13a-(18)            13b-(22) 
 13d-(21) 13d-(22) 13d-(21) 13c-(22)  13d-(21) 
 13f-(24) 13f-(20) 13f-(22) 13f-(20)  13h-(23) 
 13i-(21) 13h-(23) 13i-(23) 13h-(19)  13j-(23) 
 13j-(22) 13j-(21) 13i-(22) 
 13j-(18) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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SECTION:-II 
SYNTHESIS AND BIOLOGICAL SCREENING 1-N-{4'-[(4",4'''-DIFLUORO 
DIPHENYL)-METHYL] - PIPERAZINE - 1' -YL} - 4 - ARYLIDENE - 2 - (4""-
METHOXYPHENYL)-5-OXO-IMIDAZOLINES.  
 
5-Imidazolinones represent one of the most active classes of compounds 
having a wide spectrum of biological activities with an aim to getting better 
therapeutic agent like anticonvulsant, potent CNS depressant, anti-inflammatory, 
antimicrobial, anticancer, sedative, hypnotics and mono amino oxidase (MOA) 
inhibitors etc. In view of getting to synthesized 5-oxo-imidazoline derivatives of  1-N-
{4'-[(4", 4'''-difluorodiphenyl)- methyl]- piperazine-1'-yl}-4-arylidene-2-(4""-methoxy 
phenyl)-5-oxo-imidazolines of Type(XIV) have been under taken by the condensation 
of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine with different oxazolones. 
 
Type-XIV R=Aryl
N
F
F
N N
N
O
R
OCH3
 
 
 
 
 
 
 
 
 
 
The constitution of the synthesized compounds have been characterized by 
using elemental analysis, IR, 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by mass spectroscopy and TLC. 
 All the products have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The 
biological activities of the synthesized compounds were compared with standard 
drugs. The details have been cited in part-I, section-I, page no-42, Table no. A. 
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IR  SPECTRAL  STUDY  OF  1 - N - {4' - [(4", 4'''- DIFLUORODIPHENYL) -
METHYL] - PIPERAZINE - 1' - YL} - 4 - (4""'- METHOXYBENZYLIDENE) -
2-(4""-METHOXYPHENYL)-5-OXO-IMIDAZOLINE.  
 
F
F
NN N
N
O
OCH3
O
CH3
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
Frequency in cm-1Type Vibretion 
mode Observed Reported 
Ref. 
C-H str.(asym.) 2937 2990-2850 474 
C-H str. (sym.) 2866 2880-2860 " 
C-H def. (asym.) 1469 1470-1435 " Alkane 
C-H def. (sym.) 1377 1390-1370 " 
C-H  str. 3055 3090-3030 " 
C=C str 1579 1600-1450 475 Aromatic 
C-H i.p. (def.) 1259 1300-1100 " 
Halide C-F str. 761 800-600 " 
Piperazine C-N str. 1311 1360-1310 " 
Ether C-O-C str. 1228 1280-1200 " 
C-N str. 1099 1220-1020 " 
C=N str. 1608 1612-1593 " Imidazoline 
C=O str. 1633 1710-1650 " 
 
                                                                                                                                    207                         
 
                                                                                                            Studies on 5-Oxo-Imidazolines 
                                                                                                                                    208                         
NMR SPECTRAL STUDY OF  1 - N - {4' - [(4", 4'''- DIFLUORODIPHENYL) -
METHYL] - PIPERAZINE - 1' -YL} - 4 - (4""'- METHOXYBENZYLIDENE) -
2-(4""-METHOXYPHENYL)-5-OXO-IMIDAZOLINE. 
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer 
(300MHz)   
Signal 
No. 
Signal Position 
(δppm) 
Relative No. 
of protons Multiplicity Inference 
1 2.50-2.51 8H doublet C-H (gg’, hh’) 
2 3.73 6H singlet Ar-OCH3 (a) 
3 5.20 1H singlet        C-H (i) 
4 6.68-6.70 2H doublet   Ar-H (bb’) 
5 6.91-6.99 2H doublet   Ar-H (ff’) 
6 7.27-7.34 4H triplet      Ar-H (jj’, mm’) 
7 7.55-7.59 4H triplet      Ar-H (kk’, ll’) 
8 7.66-7.73 2H doublet      Ar-H (cc’) 
9 7.89-7.93 2H doublet      Ar-H (ee’) 
10 8.47 1H singlet      C-H (d) 
 
F
F
N N N
N
O
O
OCH3
CH3
b b'
c c'
d
e
e'f
g
g'
h
h'
i
j
j'
k
k'
l
l'm
m'
a
f'
a
 
 
 
 
                                                                                                                                                                                                                       Studies on 5-Oxo-Imidazolines 
MASS  SPECTRAL STUDY OF  1-N-{4'-[(4", 4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-4-(4""'-METHOXY 
BENZYLIDENE) -2-(4""-METHOXYPHENYL)-5-OXO-IMIDAZOLINE. 
                                                                                                                                                                                                                                  209                         
                                                                                                                                                                                                                                  210                         
                                                                                                                                                       Studies on 5-Oxo-Imidazolines 
MASS  FRAGEMENT  STUDY OF  1-N-{4'-[(4", 4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-4-(4""'-METHOXY 
BENZYLIDENE) -2-(4""-METHOXYPHENYL)-5-OXO-IMIDAZOLINE. 
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REACTION SCHEME 
 
Type - XIV                                                                     R = Aryl 
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Biological Screening was carried out as described in Part-I, Section-I, Page 
no-40.The zone of inhibition of the test solution are recorded in Graphical Chart No-
14. 
Similarly, other 5-oxo-imidazolines have been prepared. The physical 
constants are recorded in Table No.14.       
 A mixture of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine (3.03gm, 
0.01M) and 4-(4''-methoxybenzylidene)-2-(4'-methoxyphenyl)-5-oxazolone (3.09 gm, 
0.01 M) in dry pyridine (20 ml) was refluxed for 12 hrs. in oil bath. Resulting mass 
was poured into crushed ice and neutralized with dil. HCl, filtered and the product 
was recrystallized from 1,4-dioxan.Yield: 69.52 %, M.P.117oC. (C35H32O3N4F2 ;  
Required : C: 70.69; H: 5.42; N: 9.42; Found : C: 70.67; H: 5.39; N: 9.40 %). 
[D]            Synthesis of 1-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]-piperazine-1'-
      yl} - 4 -(4""'-methoxybenzylidene) - 2 - (4""-methoxyphenyl) - 5 - oxo -
      imidazolines(14e): 
A mixture of [(4-methoxybenzoyl)amino]-acetic acid (6.06gm, 0.029M), 
acetic anhydride (3.26gm, 0.032M), sodium acetate(2.62gm, 0.032M) and 4-methoxy 
benzaldehyde (4.35gm, 0.032 mol) was heated on a water bath for 4 hrs. Resulting 
mass poured into ice cold water, filtered and crystallized from acetone and water. 
Yield: 82%, M.P. 185oC.  
[C] Synthesis of 4 - (4''-methoxybenzylidene) - 2 - (4'-methoxyphenyl) -5 -                        
oxazolone. 
 See, Part-I, Section-II (B), on page no-52 
[B]       Synthesis of 1-amino-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
 See, Part-I, Section-II (A), on page no-52 
[A] Synthesis of 1-nitroso-4-[(4',4"-difluorodiphenyl)-methyl]-piperazine: 
SYNTHESIS AND BIOLOGICAL SCREENING 1-N-{4'-[(4", 4'''-DIFLUORO 
DIPHENYL)-METHYL] - PIPERAZINE - 1'-YL} - 4 - ARYLIDENE - 2 - (4""-
METHOXYPHENYL)-5-OXO-IMIDAZOLINES.  
[E]     Biological Screening of 1-N-{4'-[(4",4'''-difluorodiphenyl)-methyl]-
 piperazine -1'- yl} - 4 - arylidene - 2 - (4""-methoxyphenyl) - 5 - oxo -
 imidazolines.  
Similarly, other oxazolones have been prepared by Erlen Meyer method.473
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TABLE NO - 14 : PHYSICAL  CONSTANTS  OF  1-N-{4'-[(4", 4'''-DIFLUORODIPHENYL)-METHYL]-PIPERAZINE-1'-YL}-4 - 
         ARYLIDENE-2-(4""-METHOXYPHENYL)-5-OXO-IMIDAZOLINES.  
 
%of Nitrogen 
 Sr. No. R Molecular Formula M.W. M.P. 0C 
Yield 
% 
Calcd. Found. 
14a C6H5 - C34H30O2N4F2 564 164 64.22 9.92 9.90 
14b 2-OH-C6H4- C34H30O3N4F2 580 127 66.37 9.65 9.62 
14c 4-OH-C6H4 - C34H30O3N4F2 580 130 71.42 9.65 9.62 
14d 2-OCH3-C6H4 - C35H32O3N4F2 594 152 70.65 9.42 9.40 
14e 4-OCH3-C6H4 - C35H32O3N4F2 594 117 69.52 9.42 9.40 
14f 2-Cl-C6H4  - C34H29O2N4F2Cl 599 154 64.43 9.35 9.32 
14g 4-F-C6H4  - C34H29O2N4F3 582 172 65.75 9.62 9.60 
14h 2-NO2-C6H4 - C34H29O4N5F2 609 168 59.00 11.49 11.46 
14i 3-NO2-C6H4 - C34H29O4N5F2 609 145 60.45 11.49 11.46 
14j C4H3O - C32H28O3N4F2 554 135 68.71 10.10 10.08 
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GRAPHICAL CHART NO - 14 :  BIOLOGICAL  SCREENING  OF  1 - N -{4'-[(4", 4'''- DIFLUORODIPHENYL)- METHYL] - 
              PIPERAZINE-1'-YL}-4-ARYLIDENE-2-(4""-METHOXYPHENYL)-5-OXO-IMIDAZOLINES. 
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PART-VII 
 
SECTION - II : BIOLOGICAL  SCREENING  STUDY  OF  1-N-{4'-[(4", 4'''-DIFLUORODIPHENYL)- METHYL]- PIPERAZINE-1'-
      YL} - 4 - ARYLIDENE- 2 - (4""- METHOXYPHENYL)- 5 - OXO - IMIDAZOLINES  COMPARE  WITH  KNOWN 
      STANDARD DRUGS.  
                                                                                               Antibacterial activity                                                Antifungal activity 
                                                                                        Zone of inhibition in m. m.                                     Zone of inhibition in m. m.   
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     Drugs                                       B. subtillis             B. cerus                      E. coli               E. aerogen                      A. niger 
                                                                                                                                                                                         
                                                    14b-(22)                14c-(20)                     14b-(22)                14a-(22)            14b-(21) 
 14d-(20) 14e-(22)                    14d-(20) 14b-(18) 14d-(22) 
 14f-(21) 14g-(23)                    14f-(23) 14e-(20) 14g-(23)  
 14h-(24) 14j-(22)                     14g-(20) 14g-(22) 14i-(21) 
 14i-(23)                              14i-(22)     14i-(21) 
                               14j-(20) 
Ampicillin            (50 µg)                 23                         22                              21                          19                                   -- 
Chloramphenicol(50 µg)                 22                         23                              21                          20                                   -- 
Norfloxacin         (50 µg)                  24                         21                              23                          22                                   --                          
Greseofulvin       (50 µg)                  --                           --                               --                           --                                    23 
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